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A B S T R A C T
Background
Obstetric cholestasis has been linked to adverse maternal and fetal/neonatal outcomes. As the pathophysiology is poorly understood,
therapies have been empiric. The first version of this review, published in 2001, and including nine randomised controlled trials
involving 227 women, concluded that there was insufficient evidence to recommend any of the interventions alone or in combination.
This is the first update.
Objectives
To evaluate the effectiveness and safety of therapeutic and delivery interventions in women with cholestasis of pregnancy.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (20 February 2013) and reference lists of identified studies.
Selection criteria
Randomised controlled trials that compared two intervention strategies for women with a clinical diagnosis of obstetric cholestasis.
Data collection and analysis
The review authors independently assessed trials for eligibility and risk of bias. We independently extracted data and checked these for
accuracy.
Main results
We included 21 trials with a total of 1197 women. They were mostly at moderate to high risk of bias. They assessed 11 different
interventions resulting in 15 different comparisons.
Compared with placebo, ursodeoxycholic acid (UDCA) showed improvement in pruritus in five (228 women) out of seven trials.
There were no significant differences in instances of fetal distress in the UDCA groups compared with placebo (average risk ratio
(RR) 0.67; 95% confidence interval (CI) 0.22 to 2.02; five trials, 304 women; random-effects analysis: T² = 0.74; I² = 48%). There
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were significantly fewer total preterm births with UDCA (RR 0.46; 95% CI 0.28 to 0.73; two trials, 179 women). The difference for
spontaneous preterm births was not significant (RR 0.99; 95% CI 0.41 to 2.36, two trials, 109 women).
Two trials (48 women) reported lower (better) pruritus scores for S-adenosylmethionine (SAMe) compared with placebo, while two
other trials of 34 women reported no significant differences between groups.
UDCAwas more effective in improving pruritus than either SAMe (four trials; 133 women) or cholestyramine (one trial; 84 women), as
was combined UDCA+SAMe when compared with placebo (one trial; 16 women) and SAMe alone (two trials; 68 women). However,
combined UDCA+SAMe was no more effective than UDCA alone in regard to pruritus improvement (one trial; 53 women) and two
trials (80 women) reported data were insufficient to draw any conclusions from. In one trial comparing UDCA and dexamethasone (83
women), a significant improvement with UDCA was seen only in a subgroup of women with severe obstetric cholestasis (23 women).
Danxiaoling significantly improved pruritus in comparison to Yiganling. No significant differences were seen in pruritus improvement
with other interventions.
Eight trials reported fetal or neonatal deaths, with two deaths reported overall (both in the placebo groups).
Women receiving UDCA and cholestyramine experienced nausea, vomiting and diarrhoea. Guar gum caused mild abdominal distress,
diarrhoea and flatulence during the first days of treatment. Women found charcoal suspension unpleasant to swallow. Dexamethasone
caused nausea, dizziness and stomach pain in one woman.
One trial (62 women) looked at the timing of delivery intervention. There were no stillbirths or neonatal deaths in ’early delivery’
or the ’await spontaneous labour’ group. There were no significant differences in the rates of caesarean section, meconium passage or
admission to neonatal intensive care unit between the two groups.
Authors’ conclusions
Different approaches to assessing and reporting pruritus precluded pooling of trials comparing the effects of UDCA versus placebo
on pruritus, but examination of individual trials suggests that UDCA significantly improves pruritus, albeit by a small amount. Fewer
instances of fetal distress/asphyxial events were seen in the UDCA groups when compared with placebo but the difference was not
statistically significant. Large trials of UDCA to determine fetal benefits or risks are needed.
A single trial was too small to rule in or out a clinically important effect of early term delivery on caesarean section.
There is insufficient evidence to indicate that SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, Salvia, Yinchenghao
decoction (YCHD), Danxioling and Yiganling, or Yiganling alone or in combination are effective in treating women with cholestasis
of pregnancy.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating cholestasis in pregnancy
Obstetric cholestasis is a liver disorder in pregnancy that appears most often in the third trimester of pregnancy. The main symptom of
this condition is itching (pruritus), which can be quite distressful to the pregnant woman. Bile acids accumulate within the liver and
the blood level of bile acids are raised. The signs and symptoms spontaneously clear within the first few days after birth, or within two
to three weeks. This condition is associated with preterm birth and is thought to be associated with complications in the unborn babies,
including stillbirth. Most clinicians deliver babies early to reduce the risk of stillbirth. Therapies such as ursodeoxycholic acid (UDCA)
and S-adenosylmethionine (SAMe) seek to detoxify bile acids, or to change how they dissolve. Some agents (activated charcoal, guar
gum, cholestyramine) have been used to bind bile acids in the intestine and thus get rid of them. Some of these agents have potential
adverse effects for mothers due to the depletion of vitamin K, required for blood clotting.
We included 21 randomised controlled trials involving 1197 participants in this review. The trials were mostly at moderate to high
risk of bias. Compared with placebo, UDCA showed improvement in itching in five trials (228 women), no benefit was observed in
one trial (16 women) and one trial reported improvement only in women with severe disease (94 women). Distress in the unborn
baby or symptoms of asphyxia were reported in five trials (304 women) and although there were fewer instances of fetal distress in
the UDCA groups compared with placebo, the difference was not significant. The results from the four trials comparing SAMe and
placebo were conflicting. Two trials (48 women) reported better pruritus scores for SAMe compared with placebo and two trials (34
women) reported no significant differences between groups for the disappearance of their pruritus.
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Comparisons of guar gum, activated charcoal, dexamethasone, cholestyramine, Salvia, Yinchenghao decoction, Danxioling or Yiganling
(used in Chinese medicine for their liver-protective properties) with placebo or one with another was based on data from one trial.
Further trials are required before any firm conclusions might be made about their effectiveness.
One trial (63 women) compared early delivery versus expectant management. There were no stillbirths or neonatal deaths in either
group. No significant differences in caesarean section, passage of meconium-stained liquor or admission to neonatal intensive care unit
were observed.
B A C K G R O U N D
Description of the condition
Introduction and definition
Obstetric cholestasis (also known as intrahepatic cholestasis of
pregnancy (ICP)) is an obstetric liver condition appearing most
often in the third trimester of pregnancy. It is a relatively benign
but often significantly distressing condition maternally, and may
adversely affect fetal outcome as seen by associations with preterm
labour, fetal distress and stillbirths. Significant features needed for
a diagnosis of obstetric cholestasis are pruritus (itching), which
classically affects palms and soles but may become generalised but
without a rash apart from excoriations, together with increased
concentrations of serumbile acids (fasting values usually at least 10
µmol/L) and/or increased concentrations of serum transaminases
(e.g. alanine aminotransferase (ALT) greater than 50 U/L). Clini-
cal pruritus may precede the development of abnormal biochem-
istry (Kenyon 2001). Following birth, there is usually spontaneous
relief of signs and symptoms within the first few days, although oc-
casionally resolution may take two to three weeks (Beuers 2006).
Ongoing clinical symptoms and abnormal liver biochemical val-
ues within a month after birth is not consistent with a diagnosis
of obstetric cholestasis. Histopathology of the liver of those af-
fected by obstetric cholestasis shows non-specific mild intrahep-
atic cholestasis with accumulation of bile pigments in hepatocytes
and bile duct swelling (Heikkinen 1981). Accumulation of bile
acids within the liver increases bile acid levels which may cause
pruritus, perhaps due to increased availability of brain opiate re-
ceptors (Jones 1990), although the fact that pruritus may precede
abnormal chemistry, including changes in bile acids, suggests that
other mechanisms may be at work.
Epidemiology
The incidence of obstetric cholestasis varies across ethnic groups.
It is observed in less than 1% of pregnancies in areas of Central
and Western Europe and North America, and 1% to 2% in Scan-
dinavia and the Baltic states, but can be as high as 5% to 15% in
Araucanian Indians in Chile and Bolivia (Lammert 2000).
Pathophysiology
The exact pathophysiology of obstetric cholestasis is unknown but
genetic, endocrine and environmental factors have been impli-
cated. The role of genetics remains unsubstantiated but in high
prevalence areas a strong family history is oftenpresent (Berg 1986;
Eloranta 2001; Qui 1983; Reyes 1976; Shaw 1982). It is thought
that mutations of bile acid transporter genes may impair maternal
excretion and affect transplacental passage of bile acids (Milkiewicz
2002). Familial disorders such as progressive familial intrahepatic
cholestasis and benign recurrent intrahepatic cholestasis may be
linked to obstetric cholestasis via alterations in the binding do-
mains of liver receptors for DNA and oestrogens (Leevy 1997). A
higher than anticipated incidence of obstetric cholestasis has been
found inmothers of patients with these two familial liver disorders
(de Swiet 2002).
The precise role of oestrogens is unknown but their causal role is
suggested by the appearance of obstetric cholestasis in the third
trimester (when oestrogen concentrations are highest), the in-
creased frequency of obstetric cholestasis in pregnancies with high
oestrogen concentrations (e.g. multiple pregnancies) (Gonzalez
1989), and the resolution of symptoms following the cessation
of pregnancy (Germain 2002). Women who develop obstetric
cholestasis are at a higher risk of developing cholestasis with com-
bined oral contraceptive pill use. This also suggests that oestrogen
may be an aetiological factor (de Swiet 2002).
Similarly, the role of progesterone in obstetric cholestasis is unclear.
While the total serumprogesterone levels and the amount excreted
in urine are similar to normal pregnancies, large amounts of sul-
phated progesterone have been detected in the plasma and urine
of women with obstetric cholestasis (Meng 1997). In-vitro animal
studies suggest that high levels of progesterone metabolites induce
trans-inhibition of the bile salt export pump (BSEP), and conse-
quently interfere with bile acid secretion into bile. This leads to
intracellular accumulation of bile acids, which disrupts mitochon-
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drial function andmay explain the role of progesteronemetabolites
in the aetiopathogenesis of obstetric cholestasis (Vallejo 2006).
Seasonal variation in the prevalence of obstetric cholestasis indi-
cates that environmental factors may have a role (Reyes 1997). It
was also observed that only 60% of Chilean women who develop
obstetric cholestasis have it in a subsequent pregnancy (Ribalta
1995). Pollutants in pesticides, erucic acid (a constituent of rape-
seed oil) and dietary deficiency of selenium have been suggested
as possible environmental factors (Ribalta 1995).
Clinical features
Women present with pruritus without rash characteristically after
30 weeks’ gestation (Kenyon 2002; Reyes 1992). Pruritus often
worsens as the pregnancy progresses. Steatorrhoea and dark urine
may occur. Jaundice is a rare symptom (de Swiet 2002). Increased
rates of postpartum haemorrhage have been postulated to be due
to vitamin K deficiency (Johnston 1979; Reid 1976; Reyes 1992).
One study reported a higher rate of postpartum haemorrhage in
women who had not taken vitamin K compared to those who had
(Kenyon 2002). Gallstones may be present more often in these
women (Kirkinen 1984; Ropponen 2006). Women with hepati-
tis C infection have a higher incidence of obstetric cholestasis
(Locatelli 1999; Paternoster 2002).
Investigations
The most specific laboratory test for obstetric cholestasis is mea-
surement of plasma or serum concentration of bile acids, such as
cholic or chenodeoxycholic acid: values may be 10 to 100 times
those found in healthy pregnant women (Bacq 1997; Heikkinen
1981). Increases of serum transaminases are also common (Reyes
1997).Unlike in other cholestatic diseases, increases of gammaglu-
tamyl transferase (GGT) are less common (Walker 2002). Upper
abdominal ultrasound should be performed to exclude gallblad-
der disease, duct dilatation and other liver pathology. Serology for
hepatitis A, B, C, Epstein Barr virus (EBV) and cytomegalovirus
(CMV) will help to exclude viral pathology, while an autoim-
mune screen including anti-smooth muscle, liver-kidney microso-
mal (LKM) and antimitochondrial antibodies will help to identify
women with chronic active hepatitis or primary biliary cirrhosis
(Bacq 1997; Heinonen 1999; Kenyon 2005).
Fetal effects
The implications of excess maternal serum bile acids on the fe-
tus is not completely understood. Increased rates of fetal com-
plications, perinatal mortality rates, stillbirths, low birthweight,
preterm labour and birth, and fetal distress in labour have been
linked with the condition (Alsulyman 1996; Davies 1995; Fisk
1988; Gaudet 2000; Jiang 1986; Johnston 1979; Laatikainen
1975; Reid 1976; Rioseco 1994; Roszkowski 1968; Williamson
2004; Wilson 1979; Ylostalo 1975). There is evidence to sug-
gest an increased incidence of meconium-stained liquor in women
with obstetric cholestasis (RCOG 2011) and it is more common
in those with serum bile acid levels over 40 µmol/L (Lee 2008).
No specific fetal monitoring such as cardiotocography (CTG), ul-
trasound or amniocentesis for meconium presence has found to
be beneficial or accurate in predicting an adverse outcome in ob-
stetric cholestasis (RCOG 2011). Possible mechanisms that have
been suggested include a toxic effect of bile acids on the fetal my-
ocardium, leading to cardiac dysrhythmia and acute anoxia, as
demonstrated in neonatal rat cardiomyocytes (Williamson 2001).
It has been hypothesised that high bile acid concentration in the
mother may cause bile acid pneumonia in the newborn (Zecca
2006; Zecca 2008).
Description of the intervention
Early delivery (e.g. around 37 weeks of pregnancy as discussed by
RCOG) is widely practiced across the world on the assumption
that it might pre-empt stillbirths (Roncaglia 2002; RCOG 2011).
Topical emollients may provide temporary relief of pruritus for
somewomen and antihistamines are also used to provide symptom
relief. These are widely used (RCOG 2011). Chlorpheniramine
is sometimes prescribed in obstetric cholestasis, although its role
in reducing itching in obstetric cholestasis has not been substan-
tiated. Other treatments aimed to decrease bile production (dex-
amethasone and phenobarbitone) are rarely used in UK practice.
In the United States, hydroxyzine and diphenhydramine are com-
monly used as first-line agents to treat pruritus in women with
cholestasis.
Some agents have been used that bind bile acids in the intestine,
facilitating their elimination and preventing enterohepatic recir-
culation (activated charcoal, guar gum, cholestyramine). Agents
binding bile acids have potential adverse effects for mothers due
to the depletion of vitamin K (Briggs 2001).
Other therapies such as ursodeoxycholic acid (UDCA) and S-
adenosylmethionine (SAMe) may detoxify bile acids, or change
their solubility, thereby allowing increased choleresis and poten-
tially reducing their adverse cellular effects.
Yinchenghao decoction (YCHD), and Danxioling and Yiganling
are used in Chinese medicine for their hepato-protective proper-
ties. There is little information available on these products.
Potential side effects for mother and fetus exist for dexametha-
sone, phenobarbitone, SAMe and UDCA since they all cross the
placenta.
How the intervention might work
Early delivery pre-empts stillbirth but can increase caesarean sec-
tion rate and respiratory distress syndrome in neonates.
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The efficacy of topical emollients has not been tested in clinical
trials but they seem to provide temporary relief from pruritus in
some women and are safe in pregnancy (RCOG 2011). Calamine
lotion contains zinc oxide (ZnO) and 0.5% iron oxide (Fe2O3)
and has antipruritic and antiseptic properties. One to two per cent
menthol in aqueous cream affects A delta sensory nerve fibres and
suppresses histamine-induced itching (Bernhard 1994; Bromma
1995). Diprobase contains liquid paraffin, white soft paraffin, ce-
tomacrogol and cetostearyl alcohol. The principle behind its use is
to provide symptomatic relief from itching due to its moisturising
properties. BalneumPlus cream contains urea and lauromacrogols;
the hydrophilic properties of urea hydrate the skin and the local
anaesthetic properties of lauromacrogols cause a soothing effect.
Chlorpheniramine is a first-generation alkylamine antihistamine.
Its use in obstetric cholestasis has not been tested in a clinical trial
but it seems to provide symptomatic relief from itching in some
women. It can cause sedation but is otherwise safe in pregnancy.
Dexamethasone decreases the synthesis of fetal and maternal
adrenocorticotrophin hormone (ACTH). It also reduces produc-
tion and secretion of oestrogen precursors dehydroepiandros-
terone (DHEA) andDHEA sulphate fromboth maternal and fetal
adrenal glands (Kauppila 1979; Simmer 1975). More than 50%
of oestrogen in the maternal circulation is derived from the fetor-
placental unit. Reduction of maternal oestrogen levels may be the
possible mechanism by which it may improve cholestasis (Diac
2006).
The role of phenobarbitone in cholestasis was first demonstrated
by Cunningham in 1968 (Cunningham 1968). Animal mod-
els suggest that phenobarbitone increases the excretion of bile
salts into the biliary tree and enhances bile flow (Klaasen 1970;
Robinson 1971).
Activated charcoal is a highly porous carbon compound. It is
widely used to treat acute poisoning following oral ingestion,
where it binds to the toxin and prevents its absorption from the
stomach and intestine. It can effectively adsorb bile salts in vitro
(Krasopoulos 1980).
Guar gum is a viscous polysaccharide obtained from guar beans.
It helps to hold plant cells together. Its main use is in the food
industry where it is used to thicken or add texture to foods and
drinks (Insel 2010). It is also used to add thickness in lotions and
creams, to bind ingredients together in tablets and was widely used
as an appetite suppresser in weight loss formulations in the past.
Guar gums binds the bile acids to the intestinal contents, which
are then expelled from the body (Morgan 1993).
Cholestyramine is a resin that binds to bile acids in the intestine
and prevents their reabsorption. Consequently, it may interfere
with the absorption of fat-soluble vitamins, including vitamin K,
which is essential for blood coagulation. This may increase the
risk of postpartum haemorrhage in the mother and intracranial
haemorrhage in the fetus (Sadler 1995).
S-adenosylmethionine is produced from methionine and adeno-
sine triphosphate (ATP) in all mammalian cells. Liver is the prin-
cipal site where it is produced and metabolised (Cantoni 1952).
It is an important methyl group donor and plays a crucial role in
the biosynthesis of phospholipids, which are important for main-
taining the fluidity of hepatic cell membranes and excretion of
oestrogen metabolites (Boelsterli 1983). Interference with hepatic
SAMe biosynthesis may cause and predispose hepatocytes to in-
jury. Experiments on rat models indicate that SAMe can reverse
cholestasis (Stramentinoli 1981). The exact mechanism of action
remains unclear.
Ursodeoxycholic acid is a naturally occurring hydrophilic bile
acid. Studies suggest that UDCA displaces endogenous hydropho-
bic, detergent-like, toxic bile acids in cholestatic disorders with-
out disrupting the bile acid pool (Stiehl 1999). UDCA has
been attributed with cytoprotective and anti-apoptotic properties
(Mitsuyoshi 1999; Rodrigues 1998). Animal studies have shown
that UDCA improves hepatocellular and cholangiocellular biliary
secretion in cholestatic disorders by post-transcriptional regula-
tion of the apical transporters, BSEP andmultidrug resistance pro-
tein 2 (MRP2) (Beuers 2001). Women with obstetric cholestasis
treated with UDCA have reduced levels of cord blood bile acid
levels. This may be due to up regulation of the expression of pla-
cental MRP2 (Azzaroli 2007).
Yinchenghao decoction (YCHD) is extracted from three different
herbs:Artemisia capillaries, Gardenia jasminoides Ellis and Rheum
officinaleBaill. It was invented 2000 years ago and has been used in
Chinesemedicine to treat awide range of liver disorders.Downreg-
ulation of the production of pro-inflammatory cytokine tumour
necrosis factor (TNF) by inhibition of NF-kappaB activation (Cai
2006), an antifibrotic action, in part due to the inhibitory action
on extracellular matrix (ECM) gene expression (Lee 2009), and
decreased tumour growth factor 1 (TGF-1)mRNA expression and
inhibition of lipid peroxidation with reduced hepatic collagen ac-
cumulation (Lee 2007) have all been postulated as possible mech-
anisms for its hepato-protective properties.
Why it is important to do this review
This is an update of a Cochrane review first published in 2001
(Burrows 2001), which concluded that there was insufficient ev-
idence for any of the treatments for obstetric cholestasis so far
evaluated in randomised controlled trials. None were found to be
consistently effective in resolving maternal pruritus. It is therefore
important to update this review to incorporate new evidence gen-
erated since 2001.
O B J E C T I V E S
To assess the effects of interventions to treat women with cholesta-
sis of pregnancy, on maternal, fetal and neonatal outcomes.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials.
Types of participants
Women stated to have a diagnosis of intrahepatic cholestasis of
pregnancy.
Types of interventions
Interventions used to treat obstetric cholestasis and its symptoms,
compared with placebo, no treatment or another intervention.
Types of outcome measures
Primary outcomes
Maternal
• Pruritus (scores, change in score, improvement)
Fetal/neonatal
• Stillbirths and or neonatal deaths
• Fetal distress/asphyxial events
Secondary outcomes
Maternal
• Liver function as measured by bile acid and ALT
• Caesarean section
• Postpartum haemorrhage
• Adverse effects of medication
Fetal/neonatal
• Meconium-stained liquor
• Mean gestational age at birth
• Spontaneous birth at less than 37 weeks
• Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
• Admission to neonatal intensive care unit
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
Trials Register by contacting the Trials Search Co-ordinator (20
February 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
EMBASE, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the Register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of identified studies.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Appendix 1. For this update we
used the following methods when assessing the trials identified by
the updated search.
Selection of studies
Two review authors (Vinita Gurung (VG), Michael Stokes (MS))
independently assessed for inclusion all the potential studies iden-
tified as a result of the search strategy. There were no disagree-
ments. Studies presented only as abstracts were considered for in-
clusion on the same basis as studies published in full.
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Data extraction and management
MS designed a form to extract data. For eligible studies, VG and
MS extracted the data using the agreed form.We resolved discrep-
ancies through discussion or, by consulting the other authors of
the review (PhilippaMiddleton (PM),WilliamHague (WH), Jim
Thornton (JT)). VG entered data into Review Manager software
(RevMan 2012) and JT checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
VG and PM independently assessed risk of bias for each study us-
ing the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We resolved any disagree-
ment by discussion or by consulting the other assessors.
(1) Random sequence generation (checking for possible
selection bias)
We describe for each included study whether the method used to
generate the allocation sequence was described in sufficient detail
to allow an assessment of whether it produced comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We describe for each included study whether the method used to
conceal the allocation sequence and determine whether interven-
tion allocation could have been foreseen in advance of, or during
recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We describe for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be
at low risk of bias if they were blinded, or if we judged that the
lack of blinding could not have affected the results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We describe for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We describe for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We state whether attrition and
exclusions were reported. We also mention the numbers included
in the analysis at each stage (compared with the total randomised
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information was reported,
or could be supplied by the trial authors, we re-included missing
data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated” analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting bias
We describe for each included study how we investigated the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
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• unclear risk of bias.
(6) Other sources of bias
We describe for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book (Higgins 2011). With reference to (1) to (6) above, we as-
sessed the likely magnitude and direction of the bias and whether
they were likely to impact on the findings. We explored the impact
of the level of bias through undertaking sensitivity analyses - see
Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials. We planned to use
the standardised mean difference to combine trials that measured
the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
If cluster-randomised trials had been available they would have
been included. We planned to adjust their sample sizes using the
methods described in theCochrane Handbook Section 16.3.4 using
an estimate of the intra-cluster correlation co-efficient (ICC) de-
rived from the trial (if possible), from a similar trial or from a study
of a similar population. If we had used ICCs from other sources,
we would have reported this and conducted sensitivity analyses to
investigate the effect of variation in the ICC. If we had identified
both cluster-randomised trials and individually-randomised tri-
als, we planned to synthesise the relevant information. We would
have considered it reasonable to combine the results from both if
there was little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit was considered to be unlikely.
We also planned to acknowledge heterogeneity in the randomisa-
tion unit and to perform a sensitivity analysis to investigate the
effects of the randomisation unit (Higgins 2011)
Cross-over trials
This is not an appropriate study design for the topic of this review.
Dealing with missing data
For included studies we noted levels of attrition. We explored the
impact of included studies with high levels of missing data in the
overall assessment of treatment effect by sensitivity analysis.
For all outcomes, we analysed the data, as far as possible, on an
intention-to-treat (ITT) basis, i.e. we made an attempt to include
all participants randomised to each group in the analyses, and
all participants were analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial was
the number randomised minus any participants whose outcomes
were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the T² is greater than zero and either I² is greater than
30% or there is a low P value (less than 0.10) in the Chi² test for
heterogeneity.
Assessment of reporting biases
If there were 10 or more studies for any outcome in the meta-
analysis, we had planned to investigate reporting biases (such as
publication bias) using funnel plots. We planned to assess funnel
plot asymmetry visually. If asymmetry was suggested by a visual
assessment, we planned to perform exploratory analyses to inves-
tigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2012).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment ef-
fects differed between trials, or if substantial statistical heterogene-
ity was detected, we used random-effects meta-analysis to produce
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an overall summary if an average treatment effect across trials was
considered clinically meaningful. We treated the random-effects
summary as the average of the range of possible treatment effects
and we discussed the clinical implications of treatment effects dif-
fering between trials. If the average treatment effect was not clin-
ically meaningful, we did not combine trials.
Where we used random-effects analyses, we presented the results
as the average treatment effect with its 95% confidence interval,
and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we had identified substantial heterogeneity, we planned to in-
vestigate it using subgroup analyses and sensitivity analyses. We
planned to consider whether an overall summary was meaningful,
and if it was, use random-effects analysis to produce it.
We carried out the following subgroup analyses.
1. Bile acids levels ≥ 40 µmol/L versus bile acid levels less than
40 µmol/L.
We used primary outcomes only for the subgroup analysis.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2012). We reported the results of sub-
group analyses quoting the χ2 statistic and P value, and the inter-
action test I² value.
Sensitivity analysis
When appropriate, in future updates, we will carry out sensitivity
analysis to explore the effect of trial quality based on concealment
of allocation, by excluding studies with unclear or high risk of bias
for allocation concealment.
R E S U L T S
Description of studies
SeeCharacteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We included21 trials, and excluded two studies.Wewere unable to
trace one study published in Chinese. It is classified under studies
awaiting classification.
Included studies
The original review included nine randomised controlled trials
(Diaferia 1996; Floreani 1996; Frezza 1984; Frezza 1990; Kaaja
1994; Nicastri 1998; Palma 1997; Ribalta 1991; Riikonen 2000).
The updated search identified 11 new studies and all were judged
to be eligible for inclusion (Binder 2006; Fang 2009; Glantz 2005;
Huang 2004; Kondrackiene 2005; Liu 2006; Luo 2008; PITCH
2012; Roncaglia 2004; Shi 2002; Zhang 2012). In addition, one
study (Leino 1998) was a conference abstract and excluded from
the original review (Burrows 2001). This has also been included
in the update.
Thus 21 trials involving 1197 women are now included in this
review. For a full description of the characteristics of included
studies, see table of Characteristics of included studies.
Participants
All women had a diagnosis of obstetric cholestasis based on the
presence of pruritus in pregnancy and abnormalities of liver func-
tion. The onset of pruritus varied among the studies, occurring
before week 19 (Frezza 1984), week 28 (Nicastri 1998), week 29
(Diaferia 1996), week 32 (Ribalta 1991), week 33 (Palma 1997),
week 35 (Zhang 2012), in the second half of pregnancy (Huang
2004), the last trimester (Floreani 1996) or the second or third
trimester (Binder 2006; Kondrackiene 2005; Roncaglia 2004). In
one study (PITCH 2012), women were randomised after week
24, irrespective of the time of onset of gestational pruritus. Nine
studies did not specify a time for onset of pruritus (Frezza 1990;
Fang 2009; Glantz 2005; Kaaja 1994; Leino 1998; Liu 2006; Luo
2008; Riikonen 2000; Shi 2002). Generally the inclusion crite-
ria stipulated the severity and duration of pruritus, elevated lev-
els of bile acids/salts and/or other liver function assays, consent
to remain in hospital until the birth or undergo extensive fetal
monitoring and the exclusion criteria stipulated absence of skin
disease, chronic liver disease or other abnormalities unrelated to
pregnancy. One study (Riikonen 2000) reported that one woman
was in the study twice, during successive pregnancies.
Interventions
Eleven different interventions were compared with placebo, no
treatment or another intervention in the included trials. One
trial compared the timing of delivery in obstetric cholestasis. We
grouped them into the following 15 comparisons (with some trials
appearing in more than one comparison):
• UDCA versus placebo - seven studies (Diaferia 1996;
Glantz 2005; Leino 1998; Liu 2006; Nicastri 1998; Palma 1997;
PITCH 2012)
• SAMe versus placebo - four studies (Frezza 1984; Frezza
1990; Nicastri 1998; Ribalta 1991)
• Guar gum versus placebo - one study (Riikonen 2000)
• Activated charcoal versus no treatment - one study (Kaaja
1994)
• Dexamethasone versus placebo - one study (Glantz 2005)
• UDCA versus SAMe - five studies (Binder 2006; Floreani
1996; Nicastri 1998; Roncaglia 2004; Zhang 2012)
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• UDCA versus dexamethasone - one study (Glantz 2005)
• UDCA versus cholestyramine - one study (Kondrackiene
2005)
• UDCA+SAMe versus placebo - one study (Nicastri 1998)
• UDCA+SAMe versus SAMe - three studies (Binder 2006;
Nicastri 1998; Zhang 2012)
• UDCA+SAMe versus UDCA - four studies (Binder 2006;
Luo 2008; Nicastri 1998; Zhang 2012)
• UDCA+Salvia versus UDCA - one study (Fang 2009)
• Yinchenghao decoction (YCHD) versus SAMe - one study
(Huang 2004)
• Danxiaoling Pill (DXLP) versus Yiganling - one study (Shi
2002)
• Early term delivery versus expectant management - one
study (PITCH 2012)
Ursodeoxycholic acid (UDCA) versus placebo (Diaferia
1996; Glantz 2005; Leino 1996; Liu 2006; Nicastri 1998;
Palma 1997, PITCH 2012)
Participants in Leino 1998 received UDCA 450 mg/day in two
doses for 14 days.The treatment and control interventions were
identical in two studies (Diaferia 1996 and relevant arms of
Nicastri 1998): 600 mg/day UDCA, or placebo (vitamin) given
in two oral doses for 20 days (given after 30 weeks’ gestation in
Diaferia 1996). Participants in Glantz 2005 and Palma 1997 re-
ceived a higher dose of UDCA or placebo over a longer period of
time. UDCA 1000 mg/day or placebo was given as a single daily
dose for three weeks in Glantz 2005 and as three divided doses
or placebo (starch) in Palma 1997. In Liu 2006, women received
UDCA (18 mg/kg body weight) three times a day for two weeks.
The control group received a combination of 10% glucose, vita-
min C and Inosine for two weeks. It is unclear whether the inter-
ventions were administered orally or by parenteral route. Partici-
pants in PITCH 2012 received UDCA 1 g daily increased in in-
crements of 500 mg daily every three to 14 days up to a maximum
UDCA dose 2 g/day if no biochemical or clinical improvement
was observed.
S-adenosylmethionine (SAMe) versus placebo (Frezza 1984;
Frezza 1990; Nicastri 1998; Ribalta 1991)
In these studies 800 mg/day of SAMe dissolved in a 500 mL so-
lution of saline (Frezza 1984), 5% dextrose (Frezza 1990; Nicastri
1998) or 5% glucose (Ribalta 1991) were administered intra-
venously (IV) over the course of three (Ribalta 1991) or four hours
(Frezza 1984). The duration of administration was not reported in
two studies (Frezza 1990; Nicastri 1998). A lower dose of SAMe
200 mg/day with placebo was also compared (Frezza 1984). The
intervention was administered up to the day of delivery (Frezza
1984; Frezza 1990) or for a maximum of 20 days (Nicastri 1998;
Ribalta 1991). Placebo treatment was either 5% dextrose solu-
tion (Frezza 1990), mannitol (800 mg) in a 5% glucose solution
(Ribalta 1991), saline solution (Frezza 1984) or a vitamin solution
(Nicastri 1998).
Guar gum versus placebo (Riikonen 2000)
Guar gum or placebo (wheat flour) at doses from 5 to 15 g/day
(increases in dosage occurring at three-day intervals) were given
in three intermittent doses up until delivery. For the participants
to be included in the intervention analysis, they had to take guar-
gum or placebo for at least 10 days.
Activated charcoal versus no treatment (Kaaja 1994)
Activated charcoal as a water suspension was given in a dose of 50
g three times a day for eight days.
Dexamethasone versus placebo (Glantz 2005)
Dexamethasone 12 mg/day was administered as a single daily oral
dose for a week, followed by placebo for two weeks. Women in
the control group took a single dose of placebo every day for three
weeks.
Ursodeoxycholic acid (UDCA) versus S-adenosylmethionine
(SAMe) (Binder 2006; Floreani 1996; Nicastri 1998;
Roncaglia 2004; Zhang 2012)
These studies differed with regards to dose, administration and
duration of intervention. Binder 2006 used the highest dose of
UDCA (750 mg/day) and this was administered orally three times
a day until birth. In Nicastri 1998 and Roncaglia 2004, 600 mg/
day of UDCAwas administered as two oral daily doses for 20 days
or until delivery respectively whereas in Floreani 1996, UDCA
was given as a single oral dose of 450 mg/day until delivery.
Binder 2006, Floreani 1996,and Roncaglia 2004 administered
1000 mg/day of SAMe but the routes of administration and du-
ration of intervention were different. In Binder 2006, SAMe 500
mg was administered IV twice daily for 12 days and subsequently
as 500 mg twice daily oral dose until delivery. In Floreani 1996,
SAMe was administered as a single intramuscular (IM) injection
daily until birth whereas in Roncaglia 2004, it was given in two
doses by oral route until delivery. In Nicastri 1998, 800 mg/day of
SAMe was administered daily in two doses as IV infusions. These
were given for a maximum of 20 days.
In Zhang 2012 UDCA (250 mg given orally four times per day)
was compared with SAMe (1000 mg IV four times daily) alone.
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Ursodeoxycholic acid (UDCA) versus dexamethasone (Glantz
2005)
In Glantz 2005, UDCA 1000 mg was administered as a daily
single daily oral dose for three weeks. This was compared with
dexamethasone 12 mg/day given as a single oral dose for one week
and placebo during weeks two and three.
Ursodeoxycholic acid (UDCA) versus cholestyramine
(Kondrackiene 2005)
UDCA (8 to 10 mg/kg body weight per day) was compared with
cholestyramine (8 g/day). They were administered orally for two
weeks.
Yinchenghao decoction (YCHD) versus S-
adenosylmethionine (SAMe) (Huang 2004)
YCHD given twice daily orally for three weeks was compared with
SAMe IV infusion of 2 x 500 mg daily for three weeks.
Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus placebo (Nicastri 1998)
UDCA (600 mg/day, in two oral doses) plus SAMe (800 mg sul-
phate-P-toluenesulphatonate diluted in 500 mL 5% dextrose, in
two IV infusions) were compared with placebo (vitamin) admin-
istered for a maximum of 20 days.
Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus S-adenosylmethionine (SAMe)
(Binder 2006; Nicastri 1998; Zhang 2012)
In Nicastri 1998, UDCA (600 mg/day, in two oral doses) plus
SAMe (800 mg sulphate-P-toluenesulphatonate diluted in 500
mL 5% dextrose, in two IV infusions) were compared with SAMe
800 mg/day administered for a maximum of 20 days. In Binder
2006, UDCA (3 X 250 mg/day oral doses until delivery) plus
SAMe (2 X 500 mg/day given by slow infusion for 14 days) was
compared with SAMe (2 X 500 mg/day given by slow infusion
for 14 days) alone. In Zhang 2012 UDCA plus SAMEe (dose not
stated) was compared with SAMe (1000 mg IV four times daily)
alone.
Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus Ursodeoxycholic acid (UDCA)
(Binder 2006; Luo 2008; Nicastri 1998; Zhang 2012)
In Binder 2006, UDCA (3 X 250 mg/day oral doses until deliv-
ery) plus SAMe (2 X 500 mg/day given by slow infusion for 14
days) was compared with UDCA (3 X 250mg/day oral doses until
delivery) alone. In Zhang 2012, UDCA plus SAMEe (dose not
stated) was compared with UDCA (250mg given orally four times
daily) alone. In Nicastri 1998, UDCA (600 mg/day, in two oral
doses) plus SAMe (800 mg sulphate-P-toluenesulphatonate di-
luted in 500 mL 5% dextrose, in two IV infusions) was compared
with UDCA (600 mg/day, in two oral doses) alone administered
for a maximum of 20 days. In Luo 2008, SAMe (Transmetil 1 g
added to 250 mL 5% glucose administered as an IV infusion once
daily) plus UDCA (250 mg oral pill twice daily) were compared
with UDCA pill alone (250 mg oral pill twice daily) for 10 days.
Participants in both groups received dexamethasone (10 mg once
a day orally) for three days before commencing the study drugs.
Ursodeoxycholic acid (UDCA)+Salvia versus
Ursodeoxycholic acid (UDCA) (Fang 2009)
Salvia (10 mL in 10% 500 mL dextrose IV injection) and ur-
sodeoxycholic acid (15 mg/kg/day divided into three oral doses
per day) was compared with UDCA (same dose as above) only.
Both were used for 14 days.
Danxiaoling Pill (DXLP) versus Yiganling (Shi 2002)
DXLP 9 g/day given three times a day orally for seven days was
compared with Yiganling tablets given as four tablets three times
a day for seven days.
Excluded studies
Two studies were excluded as they are not randomised controlled
trials. For further details, see Characteristics of excluded studies.
Risk of bias in included studies
A summary of the risk of bias for the included studies is provided
in the following figures: Figure 1; Figure 2.
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Apart from two studies (Fang 2009; Shi 2002), which were
quasi-randomised controlled trials, all other studies were ran-
domised controlled trials. Eight trials reported adequate meth-
ods for sequence generation (Glantz 2005; Huang 2004; Nicastri
1998; Palma 1997; PITCH 2012; Ribalta 1991; Riikonen 2000;
Roncaglia 2004). Shi 2002 used alternation according to hospital
admission for to generate random sequence. In Fang 2009, pa-
tients were divided into two groups based on the date of hospital
admission. Floreani 1996 and Luo 2008 mentioned that the study
participants were ’randomly assigned’ to the two interventions, but
it is unclear how this random sequence was generated. In Frezza
1990, participants were randomised according to a pre-established
code, but it is unclear how this code was derived. It is unclear
whether the remaining studies had used a random sequence for
intervention allocation.
Allocation concealment was adequate for four trials (Glantz 2005;
Palma 1997; PITCH 2012; Ribalta 1991). There was a high risk
of possible selection bias in two (Fang 2009; Shi 2002) and it was
unclear in the remaining trials.
Blinding
Blinding of both participants and/or investigators was reported
in seven studies (Diaferia 1996; Glantz 2005; Leino 1998; Palma
1997; PITCH 2012; Ribalta 1991; Riikonen 2000). Two stud-
ies were single blinded where only the investigators were in-
formed of which treatment participants were receiving (Frezza
1984; Frezza 1990), and in nine studies no blinding occurred
(Binder 2006; Fang 2009; Floreani 1996; Huang 2004; Kaaja
1994; Kondrackiene 2005; Luo 2008; Nicastri 1998; Roncaglia
2004). In the three remaining studies it is unclear whether the
participants and/or investigators were blinded to trial allocation
(Liu 2006; Shi 2002; Zhang 2012).
Incomplete outcome data
Fourteen of the 20 studies either experienced no dropouts or did
not report losses to follow-up and therefore we presume all women
were included in the analysis (Binder 2006; Diaferia 1996; Fang
2009; Floreani 1996; Frezza 1984; Frezza 1990; Glantz 2005;
Huang 2004; Kaaja 1994; Kondrackiene 2005; Luo 2008;Nicastri
1998; PITCH 2012; Roncaglia 2004). In Shi 2002 outcomes
were reported for 25 (86%) participants for ALT and aspartate
transaminase (AST), 27 (93%) for ALP and for 21 (72%) women
for bilirubin levels out of 29 participants receiving Danxiaoling
and for 16 of 29 (55%) participants for bilirubin in theYiganling
group. In studies in which patients withdrew, no ITT analysis was
conducted. Outcomes were reported in 15 of 25 (63%) partici-
pants randomised in Palma 1997, 39 of 48 (81%) in Riikonen
2000, and 18 of 20 (90%) in Ribalta 1991. The number of par-
ticipants analysed in the results was unclear in one study (Leino
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1998). In one study (Zhang 2012), 20 cases were reported to have
been eliminated and not included in the analysis. However, It was
unclear how many of these from each randomised group were lost
to follow-up (Zhang 2012), as only the total number of cases elim-
inated from the analysis was reported.
Palma 1997 excluded nine women who delivered before comple-
tion of two weeks of treatment from the analysis.
Selective reporting
While most trials reported maternal pruritus after treatment, vari-
able and incomplete reporting precluded pooling of data for this
outcome.
The other primary outcomes of perinatal mortality were not re-
ported in all of the trials. In addition, several trials reported some
outcomes only in graphical form.
Other potential sources of bias
Most trials appeared to have no other potential sources of bias,
except Huang 2004 where there was an imbalance in numbers of
women randomised to each group.
Effects of interventions
1. Ursodeoxycholic acid (UDCA) versus placebo
Seven trials (Diaferia 1996; Glantz 2005; Leino 1998; Liu 2006;
Nicastri 1998; Palma 1997; PITCH 2012) involving 338 women
looked at this comparison.
Primary outcomes (maternal)
Pruritus
All seven trials (338 women) comparing UDCA and placebo re-
ported this outcome. Two studies (205 women) used a 100 mm
visual analogue scale (VAS), four studies (105 women) evaluated
itching on a 0-4 categorical scale and one study (18 women) did
not elaborate on the methods used to assess pruritus. Studies that
used a 0-4 scale (0 = absence of pruritus, 1 = occasional pruritus, 2
= discontinuous pruritus every day, with prevailing asymptomatic
lapses, 3 = discontinuous pruritus with prevailing symptomatic
lapses and, 4 = constant pruritus) analysed the data as a continuous
outcome, which is not ideal as the assumption of normality on a
short scale will not be met. We therefore planned to dichotomise
data by classifying a pruritus score of 0-2 as mild pruritus, and
3-4 as severe pruritus. We also planned to dichotomise pruritus
outcome after the end of intervention as “improvers” and “non-
improvers”. Only Palma 1997 allowed dichotomisation of data.
We could not pool results from any of these trials due to the dif-
fering methods of measuring and reporting pruritus.
Four studies (158 women) reported a significant improvement in
the pruritus score with both UDCA and placebo. Of these, two
studies (127 women) reported a statistically significant reduction
in pruritus score with UDCA compared with placebo (Diaferia
1996; PITCH 2012). One study (70 women) reported significant
improvements in pruritus score with UDCA only and one study
reported no difference in pruritus score on ITT analysis but signif-
icant improvement with UDCAwas seen in a subgroup of women
with bile acids ≥ 40 µmol/L.
• In Diaferia 1996, pruritus was assessed before treatment
(day 0) and at five-day intervals thereafter, on a 0-4 scale.
Pruritus score was reported as mean and standard deviation (SD)
at day 0 and day 20. The difference in pruritus score was
statistically significant both in UDCA (reported P value < 0.001)
and placebo (reported P value < 0.01), but favoured UDCA over
placebo.
• In Glantz 2005, no significant difference in pruritus score
(100 mm VAS) was seen between the UDCA and placebo groups
after three weeks treatment (94 women; no P value reported).
However, in the 23 women with severe cholestasis (at least 40
µmol/L bile acids), the pruritus score fell to a mean of about 15
in the UDCA group compared with a mean of about 52 in the
placebo group (reported P value 0.001). These data are not
reported graphically in this review.
• Leino 1998 reported a significant improvement in pruritus
scores within two weeks in the UDCA group. However, they did
not report numerical or graphical data.
• In Liu 2006, pruritus was evaluated on a 0-4 scale. Results
were reported as mean and SD at trial entry and two weeks later.
After 14 days treatment, a significant reduction in the pruritus
scores was observed in the UDCA group (reported P value <
0.05) compared with the placebo group (reported P value >
0.05).
• In Nicastri 1998, pruritus was evaluated by the participant
every three days up to 24 hours after delivery using the 0-4
scoring system. The change in pruritus score after 20 days
treatment was analysed as a continuous outcome and reported as
mean and SD. A significant reduction in pruritus score was
observed with both UDCA (reported P value < 0.01; 8 women)
and placebo (reported P value < 0.01; 8 women).
• In Palma 1997, a weekly assessment of pruritus was
performed in all the study participants by the same clinician
using the 0-4 scoring system. They reported a significant
improvement in pruritus score after two weeks (P < 0.01; 15
women) and three weeks (P = 0.02; 15 women) treatment with
UDCA compared with placebo. Data for improvement in
pruritus score were presented as a graph. Similar numbers of
women (seven of the eight women in the UDCA group and five
of the seven women in the placebo group) showed a reduction in
pruritus score after three weeks (risk ratio (RR) 1.23; 95%
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confidence interval (CI) 0.72 to 2.10 (Analysis 1.1)); all seven
’improvers’ in the UDCA group had low scores (under 1.5)
compared with two of the five ’improvers’ in the placebo group,
which was also a non-significant difference.
• PITCH 2012 prespecified in their trial protocol, published
before data unblinding, that their primary outcome was to be the
mean of all worst itching scores in the preceding 24 hours (100
mm VAS) measured between randomisation and delivery. The
authors of this trial surveyed patients and obstetricians who
indicated that the average minimum worthwhile improvement
was 30 mm. The results (Analysis 1.2; Analysis 1.3) showed a
statistically significant reduction but the 95% CI around the
effect was only 22 mm, i.e. smaller than the minimum
worthwhile treatment effect for most women and doctors.
Primary outcomes (fetal/neonatal)
Stillbirth
Two out of the three studies reported one stillbirth each, both in
the placebo group (RR 0.31; 95% CI 0.03 to 2.84; 233 women
(Analysis 1.4). In Glantz 2005, a woman on clomipramine for
long-term depressive disorder experienced itching from 33 weeks’
gestation. After going into spontaneous labour at week 38, in-
trauterine death was diagnosed. Her serum bile acid concentra-
tions were 16 µmol/L at trial inclusion and at two weeks later.
In Palma 1997, the woman with a stillbirth had received placebo
for two weeks and fetal death occurred after minor signs of fetal
distress were noted.
No neonatal deaths were reported.
Fetal distress/asphyxial events
Five of the seven trials comparing UDCA with placebo reported
fetal distress and/or asphyxial events in some form but the dif-
ference was not statistically significant (average RR 0.67 95% CI
0.22 to 2.02; random-effects analysis: T² = 0.74; I² = 48%) 304
women (Analysis 1.5)).
In Diaferia 1996 and Palma 1997, this outcome included women
who had operative births for fetal distress and in Liu 2006 it was
defined as abnormal results of antepartum testing prompting de-
livery. Glantz 2005 defined asphyxial events as all operative births
due to asphyxia, umbilical arterial pH less than 7.05 or Apgar
score less than seven at five minutes. In Liu 2006 one baby from
the UDCA group and seven babies from the placebo group were
reported to have asphyxia neonatorum (which was not clearly de-
fined in the paper). PITCH 2012 reported asphyxial events de-
fined as induction or caesarean section for fetal compromise.
Subgroup analysis (bile acid levels ≥ 40 µmol/L versus bile
acid levels < 40 µmol/L)
One study presented data for the subgroups of bile acid levels ≥
40 µmol/L (RR 0.31 95% CI 0.01 to 6.85; 23 women) versus bile
acids < 40 µmol/L (RR 1.03 95% CI 0.15 to 6.90; 71 women)
for one of the review’s primary outcomes (asphyxial events). There
were no differences between these subgroups (Analysis 1.6), (test
for subgroup differences: Chi² = 0.42, df = 1 (P = 0.52), I² = 0%).
Secondary outcomes (maternal)
Liver function
Bile acid concentrations appeared significantly lower after treat-
ment with UDCA compared with placebo (three trials). However,
due to extreme heterogeneity and large differences in SDs, we have
not presented the data for analysis.
In Nicastri 1998, a significant reduction in bile acids after treat-
ment with UDCA compared with placebo was reported (mean
difference (MD) 30.40 µmol/L lower; 95% CI 23.32 to 37.48,
16 women (Analysis 1.7)).
In two trials, alanine aminotransferase (ALT) concentrations were
significantly lower after treatment with UDCA compared with
placebo (average MD -111.0 IU/L; 95% CI -182.48 to -39.51;
random-effects analysis: T² = 1726.45; I² = 48%; 83 women (
Analysis 1.8)). In one trial, ALT concentrations were significantly
lower after treatment with UDCA compared with placebo (MD -
50.88 IU/L; 95% CI -75.14 to -26.62, 16 women (Analysis 1.9)).
In one trial a significant reduction in ALT after treatment with
UDCA compared with placebowas seen (MD121.00 IU/L lower;
95% CI 100.93 to 141.07, 16 women (Analysis 1.10)). Analysis
1.10 is presented as change data.
In Glantz 2005, liver function tests were reported only graphically
as medians and P values. The final bile acid concentrations were
significantly lower after treatment in the UDCA group compared
with the placebo group (P = 0.001). For ALT, there was a signifi-
cantly greater reduction in the UDCA group compared with the
placebo group overall (P = 0.01). Leino 1998 reported a reduction
of ALT and bile acid levels to the upper limit of normal pregnancy
values in the UDCA group but did not report numerical or graph-
ical data by randomisation group.
Caesarean section (and mode of birth)
In four trials, no significant differences were seen between UDCA
and placebo for rates of caesarean section (RR 1.00 95% CI 0.82
to 1.23; 210 women (Analysis 1.11)). Glantz 2005 did not report
caesarean births but did indicate that rates of elective birth (both
caesarean and vaginal) were not significantly different between the
two groups (32% for UDCA and 38% for placebo).
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Postpartum haemorrhage
There was no significant difference in the rates of postpartum
haemorrhage in the two trials (RR 0.77 95% CI 0.20 to 2.98; 127
women (Analysis 1.12)).
Adverse effects of medication
No adverse effects for mothers or babies in either group were re-
ported in three trials (Leino 1998; Liu 2006 and Nicastri 1998);
and Diaferia 1996 reported that there were no important adverse
effects in either the mothers or babies during or after the admin-
istration of UDCA.
In Glantz 2005, one participant in the UDCA group experienced
diarrhoea and one in the placebo group suffered a severe headache.
Palma 1997 reported that one woman in the UDCA group expe-
rienced transient morning nausea and mild vomiting, which re-
solved after changing the time of UDCA intake. PITCH 2012
reported 13 adverse events (seven mild, six moderate) in the treat-
ment group and 10 in placebo group (eight mild, two moderate).
The drug was stopped due to adverse events in one participant in
the treatment group and one in the placebo group. The difference
between the two groups was not significant (RR 1.32 95%CI 0.66
to 2.63; 220 women (Analysis 1.13)).
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
No statistically significant differences in meconium-stained liquor
were seen between the UDCA and placebo groups in three trials
(average RR 0.56 95% CI 0.24 to 1.30; random-effects analysis:
T² = 0.36; I² = 67% 274 women (Analysis 1.14)).
Mean gestational age at birth
In three trials there was a non-significant increase in gestational
age at birth in the UDCA group (averageMD 2.68 weeks 95%CI
-0.13 to 5.48; random-effects analysis: T² = 4.81; I² = 96%; 142
women (Analysis 1.15)). Leino 1998 reported a higher birthweight
in theUDCAgroup coincidingwith advanced gestation at birth in
this group, but did not report any numerical data by comparison
group.
Spontaneous birth at less than 37 weeks
In two trials, no significant differences in rates of spontaneous
preterm birth at less than 37 weeks were seen between the UDCA
and placebo groups (RR 0.99; 95% CI 0.41 to 2.36; 109 women
(Analysis 1.16)). Nicastri 1998 reported that two women in the
UDCA group had spontaneous preterm labour but did not report
this outcome for the women in the placebo group.
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
Two trials (different from the two reporting spontaneous preterm
birth above) reported the total number of preterm births at less
than 37 weeks of gestation. There were significantly fewer total
preterm births in the UDCA group compared with placebo (RR
0.46 95% CI 0.28 to 0.73; 179 women (Analysis 1.17)).
Admission to neonatal unit
One trial reported no significant difference in admission rates
to the neonatal intensive care unit between the UDCA and the
placebo groups (RR 0.48, 95% CI 0.18 to 1.31; 124 women
(Analysis 1.18)).
2. S-adenosylmethionine (SAMe) versus placebo
Four trials (Frezza 1984; Frezza 1990;Nicastri 1998;Ribalta 1991)
involving 82 women looked at this comparison.
Primary outcomes (maternal)
Pruritus
Four trials (82 women) reported this outcome. One trial (30
women) reported significant improvements in pruritus score with
SAMe, whereas another trial (18 women) reported reduction in
pruritus with 800 g daily dose of SAMe but not with 200 g daily
dose. Two studies (34 women) reported a significant improvement
in the pruritus score with both SAMe and placebo. None of these
studies performed a subgroup analysis for improvement in pruri-
tus in women with bile acids ≥ 40 µmol/L.
Three studies (52 women) evaluated itching on a 0-4 scale. Data
were reported as mean and SD. We planned to dichotomise and
re-analyse data but this was not possible because pruritus scores at
trial entry and after intervention were not reported.
• Frezza 1984 assessed pruritus on day 0 (before entering the
study), and at day 10 and day 20 of treatment. Pruritus was
graded from 0 to 4. The reductions in mean grade of pruritus
score after 10 and 20 days of treatment were analysed and
presented as a continuous outcome. A significant reduction in
pruritus grade was reported with 800 g daily dose of SAMe
(reported P value < 0.02 after day 10 and < 0.01 after day 20)
compared with placebo but not for the 200 g daily dose.
• In Frezza 1990, pruritus was assessed on a 10 cm analogue
scale every three days up to 24 hours after delivery. The authors
reported the mean pruritus scores after treatment as significantly
lower (better) in the SAMe group compared with the placebo
group (reported P value < 0.01; 30 women), but gave no
numerical data.
• Nicastri 1998 evaluated pruritus on a 0-4 scale every three
days. The mean changes in pruritus score in the two groups were
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reported as a continuous outcome. A significant reduction in
mean pruritus score was observed both in the SAMe group
(reported P value < 0.01; 8 women) and the placebo group (P <
0.01; 8 women).
• Ribalta 1991 assessed the severity of pruritus on a 0-4 scale
immediately before treatment and every five days until delivery,
one to three days after delivery and one to three months
afterwards. They were analysed as a continuous outcome. The
severity of pruritus reduced in both groups. The mean pruritus
score decreased more in the placebo group but this difference was
not significant.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
One trial reported this outcome and there were no stillbirths or
neonatal deaths (Analysis 2.1).
Fetal distress/asphyxial events
In Frezza 1984, all the infants born to women in the SAMe group
hadApgar scores of seven or above at fiveminutes. They did not re-
port these figures for the placebo group. Comparisons were there-
fore not possible. In Ribalta 1991, all the newborns had Apgar
scores of seven or above in both the groups. In Ribalta 1991, cae-
sarean sections were performed for various indications, including
fetal distress, but the actual number of caesarean sections for this
indication was not specified.
Secondary outcomes (maternal)
Liver function
In one trial (16 women), reductions in bile acid, and ALT were
significantly greater in the SAMe group compared with placebo
(Analysis 2.2; Analysis 2.3).
InFrezza 1984, the final values of serum transaminases, conjugated
bilirubin and total bile acids were reported to be lower in women
treated with 800 mg per day SAMe than women who received
placebo (total of 12 women for this comparison). In Frezza 1990
(30 women), after a mean 18 days of treatment with SAMe, total
bile acids, ALT and AST were all reported to be significantly lower
than for the placebo group (P = 0.01 for all four comparisons).
Ribalta 1991 (18 women) reported no significant differences in
results of the various liver function tests, but these were only pre-
sented in graphical form.
Caesarean section
In one trial, no significant differences were seen between the SAMe
and placebo groups for caesarean section (RR 1.14; 95% CI 0.75
to 1.74; 18 women (Analysis 2.4)).
Adverse effects
Frezza 1984 reported that SAMe was well tolerated by women and
no adverse effects were seen and in Frezza 1990 no adverse effects
were recorded for women or their children. Ribalta 1991 reported
that one woman experienced problems in peripheral veins due to
prolonged daily IV infusions.
Secondary outcomes (fetal/neonatal)
Spontaneous labour/birth at less than 37 weeks
In one trial, two women in the SAMe group and five in the placebo
group had preterm labour before 37 weeks (RR 0.40; 95% CI
0.09 to 1.75; 30 women (Analysis 2.5)). Nicastri 1998 reported
three preterm births in the SAMe group but did not state how
many there were in the placebo group. Ribalta 1991 reported the
total preterm births (see below) but did not specify the number of
spontaneous preterm births.
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
In one study, six women in the SAMe group versus eight in the
placebo group had preterm births (RR 0.75; 95%CI 0.45 to 1.26;
18 women (Analysis 2.6)).
The following secondary outcomes were not reported for this
comparison: postpartum haemorrhage, meconium-stained liquor,
mean gestational age at birth, or admission to neonatal unit.
3. Guar gum versus placebo
One trial (Riikonen 2000) involving 39 women studied this com-
parison.
Primary outcomes (maternal)
Pruritus
In one trial both investigators and participants assessed change
in pruritus following treatment. From the women’s perspective,
nine (48%) women receiving guar gum and five (25%) receiving
placebo experienced a reduction in pruritus (RR 1.89; 95% CI
0.77 to 4.64 (Analysis 3.1)). From the investigator’s perspective,
six (32%) women receiving guar gum and five (25%) receiving
placebo had a reduction in pruritus (RR 1.26; 95% CI 0.46 to
3.46 (Analysis 3.1)). The difference was not significant for either
group.
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Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
No neonatal or infant deaths were reported.
Fetal distress/asphyxial events
This outcome was not reported.
Secondary outcomes (maternal)
Liver function
In one trial, there were no significant differences seen between guar
gum and placebo in reducing the levels of bile acids (MD -7.40;
95% CI -24.22 to 9.42; 39 women (Analysis 3.2)) or ALT (MD
-37.50; 95% CI -137.33 to 62.33; 39 women (Analysis 3.3)).
Adverse effects of medication
Eight women (42%) in the guar gum group and six (30%) in the
placebo group reported mild abdominal distress, diarrhoea and
flatulence during the first days of treatment, showing no significant
difference overall (RR 1.40 95% CI 0.60 to 3.29) (Analysis 3.4)).
None of the participants discontinued the study.
Secondary outcomes (fetal/neonatal)
Mean gestational age at birth
The mean gestational age for women in the guar gum group was
38.40 weeks and 38.30 weeks for placebo (MD 0.10 weeks; 95%
CI -0.73 to 0.93 (Analysis 3.5).
The following secondary outcomeswere not reported for this com-
parison: caesarean section, postpartum haemorrhage, meconium-
stained liquor, spontaneous or total preterm birth, or admission
to neonatal unit.
4. Activated charcoal versus no treatment
One trial (Kaaja 1994) involving 20 women looked at this com-
parison.
Primary outcomes (maternal)
Pruritus
Participants maintained a daily written record of pruritus using
four-point scale. Four (40%) women taking activated charcoal
compared to none in the no treatment group reported relief of
itching after eight days follow-up. This difference was not signifi-
cant (RR 9.00; 95%CI 0.55 to 147.95; 20 women (Analysis 4.1)).
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
No details were provided.
Fetal distress/asphyxial events
Outcome not reported.
Secondary outcomes (maternal)
Liver function
After eight days treatment, seven (70%) women taking activated
charcoal compared with one (10%) woman in the no treatment
group had decreased bile acid concentrations. This was a signifi-
cant difference (MD -45.20 µmol/L; 95% CI -74.31 to -16.09;
20 women (Analysis 4.2)). However, there were no significant dif-
ferences between charcoal and no treatment in final ALT con-
centrations (MD 74.60; 95% CI -141.33 to 290.53; 20 women
(Analysis 4.3)).
Adverse effects of medication
Some participants reported that they found the charcoal suspen-
sion unpleasant to swallow; and some noted that their stools were
black.
Secondary outcomes (fetal/neonatal)
Mean gestational age at birth
There was no significant difference in mean gestation at birth
between the two groups (MD -1.00 week; 95% CI -2.77 to 0.77
(Analysis 4.4)).
The following secondary outcomeswere not reported for this com-
parison: caesarean section, postpartum haemorrhage, meconium-
stained liquor, spontaneous or total preterm birth, or admission
to neonatal unit.
5. Dexamethasone versus placebo
One trial (Glantz 2005) involving 83 women studied this com-
parison.
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Primary outcomes (maternal)
Pruritus
No significant difference in pruritus score (100-mmVAS)was seen
between the dexamethasone and placebo groups after three weeks
treatment (83 women; no P value reported).
Primary outcomes (fetal/neonatal)
Stillbirths
One stillbirth was reported in the placebo group and none in
the dexamethasone group (RR 0.43; 95% CI 0.02 to 10.31; 83
women (Analysis 5.1)).
Fetal distress/asphyxial events
Asphyxial events included operative birth due to asphyxia, arterial
umbilical pH less than 7.05 and Apgar score of less than seven at
five minutes. Four (11%) babies born to women receiving dex-
amethasone suffered asphyxial events compared with two (4%)
babies born to women who received placebo (RR 2.61; 95% CI
0.51 to 13.47; 83 women (Analysis 5.2)).
Subgroup analysis (bile acid levels ≥ 40 µmol/L versus bile
acid levels < 40 µmol/L)
Glantz 2005 presented data for the subgroups of bile acids ≥
40 µmol/L versus bile acids < 40 µmol/L for one of the review’s
primary outcomes (fetal distress/asphyxial events) (Analysis 5.3).
There were no differences between subgroups, (test for subgroup
differences: Chi² = 0.69, df = 1 (P = 0.40), I² = 0%).
Secondary outcomes (maternal)
Liver function
In one study, liver function tests were reported only graphically
as medians and P values. The final bile acid concentrations were
significantly reduced in the dexamethasone group compared with
placebo overall (P = 0.01); and also in the women with severe
cholestasis (P = 0.01). For ALT, therewas not a significantly greater
reduction in the dexamethasone group compared with the placebo
group overall.
Caesarean section
Glantz 2005 did not report caesarean births but did indicate that
rates of elective birth (both caesarean and vaginal) were not signif-
icantly different between the two groups (33% for dexamethasone
and 38% for placebo).
Adverse effects of medication
One woman on dexamethasone suffered nausea, dizziness and
stomach pain and one woman receiving placebo complained of
severe headache.
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
No significant differences for meconium-stained liquor were
found between dexamethasone and placebo (RR 1.00; 95% CI
0.56 to 1.78; 83 women (Analysis 5.4)). Similarly, the results were
not significant in the severe subgroup, with five out of 11 women
receiving dexamethasone having meconium-stained liquor com-
pared with six out of 11 women receiving placebo (RR 0.83; 95%
CI 0.36 to 1.94 (Analysis 5.4)).
Spontaneous birth at less than 37 weeks
No significant differences between dexamethasone and placebo
were seen for spontaneous preterm birth at less than 37 weeks’ ges-
tation (RR 1.52; 95% CI 0.21 to 10.90; random-effects analysis:
T² = 1.56; I² = 77%) 83 women (Analysis 5.5) or for the subgroup
of women with severe cholestasis (RR 0.60; 95% CI 0.19 to 1.92;
22 women (Analysis 5.5)). There was evidence of a difference be-
tween subgroups, (test for subgroup differences: Chi² = 4.10, df =
1 (P = 0.04), I² = 75.6%).
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
No statistically significant differences were found between dexam-
ethasone and placebo (RR 1.16; 95% CI 0.26 to 5.10; random-
effects analysis: T² = 0.88; I² = 77%: 83 women (Analysis 5.6)). 4/
11 women receiving dexamethasone versus 7/11 women receiving
placebo in the severe subgroup with bile acid levels ≥ 40µmol/
L had a preterm birth (RR 0.57; CI 0.23 to 1.41; 22 women
(Analysis 5.6). There was evidence of a difference between sub-
groups, (test for subgroup differences: Chi² = 4.11, df = 1 (P =
0.04), I² = 75.7%).
For this comparison the following secondary outcomes were not
reported: postpartum haemorrhage, mean gestational age at birth
or admission to neonatal unit.
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6. Ursodeoxycholic acid (UDCA) versus S-
adenosylmethionine (SAMe)
Five trials (Binder 2006; Floreani 1996; Nicastri 1998; Roncaglia
2004; Zhang 2012) involving 212 women compared these two
interventions.
Primary outcomes (maternal)
Pruritus
Nicastri 1998 reported a significantly greater fall in pruritus score
on a 0-4 scale with both interventions (reported P value < 0.01).
Results were analysed as a continuous outcome. Dichotomisation
of data for re-analysis was not possible because results were pre-
sented as mean and SD. Zhang 2012 reported improvements in
pruritus symptoms in both groups, but did not report the actual
scores and stated that the differences were not statistically signifi-
cant. The other three trials reported number of women with im-
proved pruritus after treatment - Binder 2006 on a 10-point scale,
and Floreani 1996 and Roncaglia 2004 on four-point scales. For
any improvement in pruritus, no significant difference was seen
between UDCA and SAMe (RR 1.20; 95% CI 0.89 to 1.61; three
trials, 117 women), but UDCA was significantly better in terms
of complete resolution or marked improvement in pruritus (RR
1.98; 95% CI 1.15 to 3.41; two trials, 71 women), though this
was unable to be formally assessed through subgroup interaction
testing. See Analysis 6.1.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
Binder 2006 reported zero stillbirths in either group and Zhang
2012 reported zero perinatal deaths in either group. Three trials
did not comment on this outcome.
Fetal distress/asphyxial events
For Binder 2006, we included those women who delivered by cae-
sarean section for fetal asphyxia to avoid duplication and overesti-
mation of rates of fetal distress. For Roncaglia 2004, we included
women with babies who had an Apgar score of less than seven at
five minutes in our analysis. Floreani 1996 reported that none of
the babies hadApgar scores less than seven at fiveminutes.Overall,
there were no significant differences in fetal distress between the
two groups (RR 0.94; 95% CI 0.25 to 3.58; 117 women (Analysis
6.2)).
Secondary outcomes (maternal)
Liver function
In one trial, women on UDCA had a greater fall in bile acid
concentrations compared with SAMe (MD 12.90 µmol/L; 95%
CI 4.36 to 21.44; 16 women (Analysis 6.3)). Another trial re-
ported a significantly lower bile acid concentration in the UDCA
group compared with the SAMe group after treatment (MD -
27.00 µmol/L; 95% CI -43.67 to -10.33; 51 women (Analysis
6.3)) while ALT concentrations were lower with SAMe (MD -
2.20 µkat/L; 95% CI -3.55 to -0.85; 51 women (Analysis 6.4)).
Roncaglia 2004 reported differences in laboratory variables as me-
dian and P values in relation to treatment. A significant reduction
was reported in bile acids (reported P value = 0.001), and ALT
(reported P value = 0.001) in the group receiving UDCA, whereas
the changes from baseline were not significant in the group receiv-
ing SAMe.
All liver function results in Floreani 1996 were presented graphi-
cally - after 15 days treatment; women in theUDCAgroup showed
significantly lower total bile acid concentrations compared with
women in the SAMe group (reported P value < 0.05) and there
were no significant differences seen for ALT concentrations after
15 days treatment with either UDCA or SAMe (20 women in
total).
Caesarean section
Three trials studies reported caesarean sections with no overall
difference seen between UDCA and SAMe (RR 0.90; 95% CI
0.52 to 1.58; 117 women (Analysis 6.5)).
Postpartum haemorrhage
Binder 2006 and Roncaglia 2004 reported estimated blood loss
(mL) at birth rather than the incidence of postpartum haemor-
rhage. The differences were not significant.
Adverse effects of medication
Binder 2006, Nicastri 1998, Roncaglia 2004 and Zhang 2012
noted no adverse effects on women or the fetuses with either ther-
apy. Floreani 1996 noted that both drugs were “well tolerated”.
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
Two trials compared meconium-stained liquor at birth, with no
significant difference seen between UDCA and SAMe (RR 0.47;
95% CI 0.17 to 1.27; 97 women (Analysis 6.6)).
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Mean gestational age at birth
No significant difference in gestational age at birth between
UDCA and SAMe was seen in two trials (MD -0.04 weeks; 95%
CI -0.84 to 0.76; 66 women (Analysis 6.7)).
Binder 2006 only reported ranges and not SD (no significant
differences were seen between UDCA and SAMe).
Spontaneous birth at less than 37 weeks
In two trials, no significant difference between UDCA and SAMe
was seen for spontaneous births less than 37 weeks (RR 0.59; 95%
0.22 to 1.59; 62 women (Analysis 6.8)).
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
Two other trials reported the total number of births at less than
37 weeks of gestation for the two groups, but did not specify how
many of them were spontaneous preterm births. There was no
significant difference between groups (RR 0.71, 95% CI 0.33 to
1.54; 71 women (Analysis 6.9)).
Admission to neonatal unit
Two trials reported the number of babies that were admitted to
the neonatal unit and the difference was not significant (RR 0.51;
95% CI 0.21 to 1.27; 97 babies (Analysis 6.10)).
7. Ursodeoxycholic acid (UDCA) versus
dexamethasone
One study (Glantz 2005) involving 83 women compared these
two interventions.
Primary outcomes (maternal)
Pruritus
Improvement in pruritus after three weeks of treatment was re-
ported graphically. No significant differences were seen overall, al-
though in the subgroup with severe obstetric cholestasis, UDCA
was significantly more effective than dexamethasone (P = 0.01).
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
There were no stillbirths or neonatal deaths in either group.
Fetal distress/asphyxial events
No statistically significant difference in asphyxial events results
were found between UDCA and dexamethasone (RR 0.34; 95%
CI 0.08 to 1.45; 83 women (Analysis 7.1)).
Subgroup analysis (bile acid levels ≥ 40 µmol/L versus bile
acid levels < 40 µmol/L)
Glantz 2005 presented data for the subgroups of bile acids ≥ 40
µmol/L versus bile acids < 40 µmol/L for fetal distress/asphyxial
events.
In the severe subgroup (bile acids ≥ 40 µmol/L), 0/12 in the
UDCAgroup and 1/11 in the dexamethasone groupwere reported
tohave asphyxial events (RR0.31; 95%CI0.01 to 6.85; 23women
(Analysis 7.1). There were no differences between subgroups (
Analysis 7.1), (test for subgroup differences: Chi² = 0.01, df = 1
(P = 0.93), I² = 0%).
Secondary outcomes (maternal)
Liver function
UDCA was significantly better than dexamethasone in reducing
serum bile acid concentrations (P = 0.001) and ALT (P = 0.01). In
the subgroup of women with severe cholestasis, these measures of
liver function showed significantly greater reductions for UDCA
compared with dexamethasone. These results were reported as
graphs and P values.
Caesarean section
Glantz 2005 did not report caesarean births but did indicate that
rates of elective birth (both caesarean and vaginal) were not sig-
nificantly different between the two groups (32% for UDCA and
33% for dexamethasone).
Adverse effects of medication
In one study, one woman on UDCA complained of diarrhoea
while one woman receiving dexamethasone suffered from nausea,
dizziness and stomach pain. This was a non-significant difference
(RR 0.77 95% CI 0.05 to 11.83; 83 women (Analysis 7.2)).
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
The differences between UDCA and dexamethasone for passage
of meconium-stained liquor was not statistically significant (RR
1.06; 95% CI 0.60 to 1.87; 83 women (Analysis 7.3)). In the
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severe subgroup, 6/12 women in the UDCA group and 5/11 in
the dexamethasone group had meconium-stained liquor.
Spontaneous birth at less than 37 weeks
The results for spontaneous preterm birth between UDCA and
dexamethasone were not significantly different (RR 0.68; 95% CI
0.29 to 1.59; 83 women (Analysis 7.4)). In the severe subgroup,
4/12 women in the UDCA group and 4/11 in the dexamethasone
group had a spontaneous preterm birth.
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
There were no significant differences seen between groups (RR
0.87; 95% CI 0.44 to 1.71; 83 women (Analysis 7.5)).
The following secondary outcomes were not reported: postpar-
tum haemorrhage, mean gestational age at birth or admission to
neonatal unit.
8. Ursodeoxycholic acid (UDCA) versus
cholestyramine
One trial (Kondrackiene 2005) involving 84 women compared
these two interventions.
Primary outcomes (maternal)
Pruritus
Self-assessment of pruritus was performed by participants on a 0-
4 scale. Pruritus was relieved after three to four days in the UDCA
group compared to seven to 10 days cholestyramine group.UDCA
was found to result in a lower mean pruritus score compared with
cholestyramine. After four days, the pruritus scorewas significantly
lower in the group receiving UDCA compared with the group
receiving cholestyramine (reported P value < 0.05 after four days;
P < 0.001 after 14 days). Results were presented as mean and SD
and dichotomization was not possible. Also, a significantly higher
number of women in the UDCA group reported a reduction of
pruritus score by more than 50% (RR 3.50; 95% CI 1.81 to 6.77;
84 women (Analysis 8.1).
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
In the only trial there were no stillbirths or neonatal deaths in
either group.
Fetal distress/asphyxial events
One out of 42 women in each group suffered morbidity associated
with fetal distress (RR 1.00; 95% CI 0.06 to 15.47; 84 women
(Analysis 8.2)).
Secondary outcomes (maternal)
Liver function
The trial did not observe significant differences in bile acid con-
centrations between the two groups after treatment (MD -1.80
µmol/L; 95% CI -13.10 to 9.50; 84 women (Analysis 8.3)). For
ALT, women in the UDCA group had much lower concentrations
after treatment than women in the cholestyramine group (MD -
144.20 U/L; 95% CI -186.63 to -101.77; 84 women (Analysis
8.4)).
Caesarean section
There were no statistically significant differences between the two
groups in rates of caesarean section (one trial; RR 2.33; 95% CI
0.65 to 8.42; 84 women (Analysis 8.5)). Reasons for the seven
caesareans in the UDCA group were three multiple pregnancies,
one placenta praevia, one cephalo-pelvic disproportion, one fetal
distress and one advanced maternal age. The three caesareans in
the cholestyramine group were performed for fetal distress, twin
pregnancy and cephalo-pelvic disproportion (one case each).
Adverse effects of medication
Cholestyramine use was found to have a greater number of ad-
verse effects with 12 out of 42 women suffering adverse effects
(11 women suffering nausea, five women suffering vomiting and
one woman suffering diarrhoea) compared with no adverse events
reported for women in the UDCA group (RR 0.04; 95% CI 0.00
to 0.65, (Analysis 8.6)).
Secondary outcomes (fetal/neonatal)
Mean gestational age at birth
Women receiving UDCA had a significantly shorter gestational
length thanwomen in the cholestyramine group (MD-1.30weeks;
95% CI -1.99 to -0.61: one trial; 84 women (Analysis 8.7)).
22Interventions for treating cholestasis in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Spontaneous birth at less than 37 weeks
The study did not report spontaneous preterm births separately
for the two interventions.
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
No significant difference was seen for preterm births between the
two groups ((RR 0.60; 95% CI 0.15 to 2.35; 84 women (Analysis
8.8)).
The following secondary outcomes were not reported: postpartum
haemorrhage, meconium-stained liquor or admission to neonatal
unit.
9. Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus placebo
One trial (16 women) contributed data to this comparison
(Nicastri 1998).
Primary outcomes (maternal)
Pruritus
Pruritus was assessed on a 0-4 scale and results were analysed as a
continuous outcome. Dichotomisation of data for reanalysis was
not possible because results were presented as mean and SD. Sig-
nificant change in pruritus score from the baseline was reported
after treatment in the two groups (reported P value < 0.01).
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
This outcome was not reported.
Fetal distress/asphyxial events
This outcome was not reported.
Secondary outcomes (maternal)
Liver function
Compared with women given placebo, women given UDCA +
SAMe had significantly greater decreases in bile acids (MD 41.70
µmol/L; 95% CI 35.57 to 47.83; 16 women (Analysis 9.1)).
Adverse effects of medication
No adverse effects were observed in the mother or the babies in
either group.
Secondary outcomes (fetal/neonatal)
Spontaneous birth at less than 37 weeks
One case of spontaneous preterm birth was reported in the UDCA
+ SAMe group but this outcome was not reported for the placebo
group in Nicastri 1998.
The following secondary outcomes were not reported: caesarean
section, postpartum haemorrhage, meconium-stained liquor,
mean gestational age at birth, total preterm birth or admission to
neonatal unit.
10. Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus S-adenosylmethionine (SAMe)
Three trials (147 women) contributed data to this comparison
(Binder 2006; Nicastri 1998; Zhang 2012).
Primary outcomes (maternal)
Pruritus
One study reportedno significant differences for any improvement
in pruritus on a 10-point scale between the two groups (RR 1.42;
95% CI 0.99 to 2.03; 52 women). However when restricted only
to women with marked improvement, significantly more in the
UDCA + SAMe group reported marked improvements in their
pruritus compared with those in the other SAMe alone group (RR
1.85; 95% CI 1.09 to 3.14; 52 women) Analysis 10.1.
Nicastri 1998 reported a significant reduction in pruritus after
treatment with UDCA + SAMe compared with SAMe alone.
They used 0-4 scale for assessing pruritus but analysed results as
a continuous outcome. Dichotomisation of data and reanalysis
was not possible because results were reported as mean and SD.
Zhang 2012 reported improvements in pruritus symptoms in both
groups, but did not report the actual scores and stated that the
differences were not statistically significant.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
There were no stillbirths or neonatal deaths in two trials (Analysis
10.2). This outcome was not reported in Nicastri 1998.
Fetal distress/asphyxial events
In one trial, one woman (4%) in the UDCA + SAMe group and
three (12%) in the SAMe group had an operative birth for fetal
asphyxia (RR 0.31 95% CI 0.03 to 2.78; 52 women (Analysis
10.3)).
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Secondary outcomes (maternal)
Liver function
The two trials reported contrasting results for improvement in bile
acid levels. In one trial bile acid after 3-4 weeks were significantly
lower in the UDCA + SAMe group compared with SAMe alone
(MD -25.00 µmol/L; 95% CI -40.16 to -9.84; 52 women) and in
the other trial, reduction in bile acid levels were significantly lower
in the SAMe only group compared to UDCA + SAMe group after
20 days (MD 24.20 µmol/L 95% CI 16.43 to 31.97; 16 women)
- Analysis 10.4.
Only one trial reported ALT concentrations after treatment - these
were significantly lower after treatment with UDCA + SAMe com-
pared with SAMe alone (MD -2.40 µkat/L; 95% CI -3.59 to -
1.21; 52 women (Analysis 10.5)).
Caesarean section
In one trial no significant difference was seen between the UDCA
+ SAMe group compared with the SAMe group for caesareans (RR
0.37; 95% CI 0.08 to 1.74, 52 women (Analysis 10.6)).
Postpartum haemorrhage
The three trials did not report the incidence of postpartum haem-
orrhage. Binder 2006 compared the estimated blood loss at de-
livery, which was 296 mL in the UDCA+SAMe group compared
with 295 mL in the SAMe only group (MD 1.00; 95% CI -76.75
to 78.75; 52 women (Analysis 10.7)).
Adverse effects of medication
No adverse effects were reported in two trials. Zhang 2012 re-
ported that no adverse drug reactions were observed.
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
In one trial there were no significant differences between the
UDCA + SAMe and SAMe only groups for passage of meconium-
stained liquor (RR0.46; 95%CI0.09 to 2.31; 52women (Analysis
10.8)).
Mean gestational age at birth
Binder 2006 indicated that this outcome did not differ signifi-
cantly between the UDCA + SAMe and SAMe only groups but
did not report mean gestational age at birth with SD.
Spontaneous birth at less than 37 weeks
One trial reported three cases of spontaneous preterm labour in
the SAMe group compared with one in the UDCA + SAMe group
(RR 0.33; 95% CI 0.04 to 2.56; 16 women (Analysis 10.9)).
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic) - not a pre-specified outcome
In Binder 2006, the rate of preterm birth at less than 36 weeks
was 28% (7/25) in the SAMe group compared with 15% in the
combined therapy group (4/27) for less than 36 weeks (RR 0.53;
95% CI 0.18 to 1.59; 52 women (Analysis 10.10)).
Admission to neonatal unit
No significant differences between UDCA + SAMe and SAMe
only group were seen for the outcome of admission to the neonatal
unit (RR 0.46; 95%CI 0.09 to 2.31; 52 women (Analysis 10.11)).
11. Ursodeoxycholic acid and S-adenosylmethionine
(UDCA+SAMe) versus Ursodeoxycholic acid (UDCA)
Four trials (215 women) contributed data to this comparison (
Binder 2006; Luo 2008; Nicastri 1998; Zhang 2012).
Primary outcomes (maternal)
Pruritus
One study reported the effect of treatment on pruritus as deterio-
ration, not affected,mild improvement andmarked improvement.
No significant differences were seen between UDCA + SAMe and
UDCA alone for improvement in pruritus, either for any improve-
ment (RR 1.05; 95% CI 0.83 to 1.35; 53 women) or marked
improvement (RR 1.07; 95% CI 0.76 to 1.50; 53 women) - see
Analysis 11.1.
Nicastri 1998 used a 0-4 scale for assessing pruritus and analysed
results as a continuous outcome, whichmay not be the appropriate
analysis. They found a significant reduction in pruritus score for
UDCA + SAMe compared with UDCA alone. Luo 2008 reported
mean itching score (0-4 scale) as mean and SD before and after
treatment andwewere therefore unable to include this in themeta-
analysis. The results reported were: UDCA+SAMe ’before treat-
ment’ 3.89 ± 1.52, ’after treatment’ 1.12 ± 0.63; UDCA ’before
treatment’ 3.90 ± 1.43, ’after treatment’ 2.78 ± 0.79. Zhang 2012
reported improvements in pruritus symptoms in both groups, but
did not report the actual scores and stated that the differences were
not statistically significant.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
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There were no stillbirths or neonatal deaths in two trials (Analysis
11.2). The other two trials did not report this outcome.
Fetal distress/asphyxial events
In one trial, two women in the UDCA group and one in the
UDCA+SAMe group had an operative birth for fetal asphyxia(RR
0.48; 95% CI 0.05 to 4.99; 53 women (Analysis 11.3)). Luo 2008
pre-specified an Apgar score of ≤ 7 as one of the fetal outcomes,
but these data were either not reported or not translated.
Secondary outcomes (maternal)
Liver function
One study found no significant differences between UDCA +
SAMe and UDCA alone for bile acid concentrations (MD 2.00
µmol/L; 95% CI -11.71 to 15.71; 53 women) after treatment,
whereas another study found a significant reduction in bile acid
concentrations with UDCA (MD 11.30 µmol/L; 95% CI 2.16 to
20.44; 16 women) (Analysis 11.4)).
Binder 2006 found significantly lower concentrations after treat-
ment with combined therapy (MD -2.40 µkat/L; 95% CI -3.59
to -1.21; 53 women (Analysis 11.5)) and Luo 2008 reported a
greater reduction with combined therapy (MD 1.28 IU/L; 95%
CI 1.15 to 1.41; 64 women) (Analysis 11.6)).
Caesarean section
Two trials reported this outcome. The rates of caesarean section
in the two groups were not statistically significant (RR 0.59; 95%
CI 0.35 to 1.02; 116 women) (Analysis 11.7)).
Postpartum haemorrhage
None of the three studies reported the incidence of postpartum
haemorrhage.
Adverse effects of medication
There were no adverse effects reported in the three studies. Luo
2008 did not report this outcome.
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
In one trial, no significant differences between UDCA + SAMe
andUDCA alone were seen for the outcome of meconium-stained
liquor (RR 0.64; 95 CI 0.12 to 3.54; 53 women (Analysis 11.8)).
Luo 2008 prespecified this outcome but data were not reported or
translated.
Mean gestational age at birth
Three trials did not report mean gestation at birth with SDs.
Binder 2006 indicated that this outcome did not differ signifi-
cantly between the two groups.
Spontaneous birth at less than 37 weeks
In one study, one woman who received UDCA + SAMe and two
women who received UDCA only went into spontaneous labour
at less than 37 weeks (RR 0.50; 95% CI 0.06 to 4.47; 16 women
(Analysis 11.9)).
Total preterm birth at less than 37 weeks (spontaneous and
iatrogenic)
In one study, no significant difference was noted for the outcome
of total preterm births at less than 37 weeks’ gestation in the two
groups (RR 0.69; 95% CI 0.29 to 1.62; 64 women) (Analysis
11.10)). In Binder 2006, the total preterm birth rate (< 36 weeks)
was 15% in both groups.
Admission to neonatal unit
One trial reported that two babies in the UDCA + SAMe group
were admitted to neonatal intensive care unit for moderate respira-
tory distress syndrome (RDS) and that three babies in the UDCA
group (severe prematurity in one baby and for RDS in two babies)
were admitted to the neonatal unit (RR 0.64; 95% CI 0.12 to
3.54; 53 babies (Analysis 11.11)).
12. Ursodeoxycholic acid (UDCA) and Salvia versus
UDCA (Ursodeoxycholic acid)
One trial (128 women) contributed data to this comparison (Fang
2009).
Primary outcomes (maternal)
Pruritus
Reduction in pruritus on a 0-4 scale frommoderate/severe to mild
pruritus (3.6 to 1.4) was reported in 58/72 (80.5%) women in
the UDCA + Salvia group compared with 43/56 (76.7%) in the
UDCA group. The difference was not significant (RR 1.05; 95%
CI 0.87 to 1.26; 128 women) (Analysis 12.1)). These effects were
seen within four to six days in Salvia + UDCA group and eight to
10 days in the UDCA group.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
The study did not report this outcome.
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Fetal distress/asphyxial events
Thirteen women in the combination group and 11 women in the
UDCA only group had caesarean births due to fetal distress. The
difference was not statistically significant(RR 0.92; 95% CI 0.45
to 1.89; 128 women (Analysis 12.2)).
Secondary outcomes (maternal)
Liver function
Fang 2009 found a significant reduction in the levels of ALT af-
ter treatment with UDCA + Salvia compared with UDCA alone
((MD -14.90 µmol/L; 95% CI -24.42 to -5.38; 128 women)
(Analysis 12.3)). Data on bile acids were not available.
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
No significant differences between UDCA + Salvia and UDCA
alone were seen for the outcome of meconium-stained liquor (RR
0.86; 95 CI 0.38 to 1.98; 128 women (Analysis 12.4)).
The following secondary outcomes were not reported: caesarean
section, postpartum haemorrhage, adverse effects of medication,
mean gestational age at birth, spontaneous preterm birth, total
preterm birth or admission to neonatal unit.
13. Yinchenghao decoction (YCHD) versus S-
adenosylmethionine (SAMe)
One trial (60women) contributed data to this comparison (Huang
2004).
Primary outcomes (maternal)
Pruritus
One trial demonstrated that there were no significant differences
between YCHD and SAMe in improving degree of pruritus after
treatment (RR 1.00; 95% CI 0.77 to 1.29; 60 women (Analysis
13.1)).
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
There were no stillbirths or neonatal deaths in either group.
Fetal distress/asphyxial events
No statistically significant difference in asphyxial events was found
between the two groups (RR 0.86; 95% CI 0.29 to 2.50; 60
women (Analysis 13.3)).
Secondary outcomes (maternal)
Liver function
There was no significant reduction in the levels of bile salt (CGA)
(MD -1.50; 95% CI -6.12 to 3.12; 60 women (Analysis 13.4)) or
ALT (MD 3.40; 95% CI -12.37 to 19.17; 60 women (Analysis
13.5)) when comparing the two intervention groups.
Caesarean section
No significant differences were seen between the YCHD and
SAMe group for caesarean section (RR 0.93; 95%CI 0.56 to 1.55;
60 women (Analysis 13.6)).
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
In one trial, no significant differences between YCHD and SAMe
were seen for the outcome of meconium-stained liquor (RR 0.86;
95% CI 0.29 to 2.50; 60 women (Analysis 13.7)).
Mean gestational age at birth
Mean gestational age at birth in the YCHD group was 38.1 and
37.4 weeks in the SAMe group. The difference between the two
groups was not significant (MD 0.70 weeks; 95%CI -0.35 to 1.75
(Analysis 13.8).
The following secondary outcomes were not reported: postpartum
haemorrhage, adverse effects of medication, spontaneous preterm
birth, total preterm birth or admission to neonatal unit.
14. Danxiaoling versus yiganling
One trial (58 women) contributed data to this comparison (Shi
2002).
Primary outcomes (maternal)
Pruritus
In one trial, all 58 women, 29 women in each group, noticed im-
provement in pruritus after treatment (MD 1.00; 95% CI 0.94
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to 1.07; 58 women). More women receiving Danxiaoling experi-
enced marked improvement in pruritus in comparison to the Yi-
ganling group and this difference was statistically significant (MD
1.67; 95% CI 1.14 to 2.44; 58 women). See Analysis 14.1.
Primary outcomes (fetal/neonatal)
Stillbirth/neonatal death
There were no stillbirths or neonatal deaths in either group
(Analysis 14.2).
Fetal distress/asphyxial events
Shi 2002 did not report this outcome.
Secondary outcomes (maternal)
Liver function
Shi 2002 found no significant difference in the levels of bile acids
(CGA) (MD -3.83; 95%CI -22.59 to 14.93; 58 women (Analysis
14.3)), or ALT (MD 5.20; 95% CI -36.90 to 47.30; 54 women
(Analysis 14.4)).
Caesarean section
In one trial, no significant differences were seen between theDanx-
iaoling and Yiganling groups for caesarean section (RR 0.60; 95%
CI 0.16 to 2.28; 58 women (Analysis 14.5)).
Secondary outcomes (fetal/neonatal)
Meconium-stained liquor
Significantly lower incidence of meconium-stained liquor was ob-
served in the group receiving Danxioling in comparison to the
group receiving Yiganling (RR 0.40; 95% CI 0.18 to 0.89; 58
women (Analysis 14.6)).
Spontaneous birth at less than 37 weeks
There was no significant difference in the rates of spontaneous
preterm births in the two groups (RR 0.33; 95% CI 0.04 to 3.02;
58 women (Analysis 14.7)).
The following secondary outcomes were not reported: postpartum
haemorrhage, adverse effects of medication, mean gestational age
at birth, total preterm birth or admission to neonatal unit.
15. Early term delivery v expectant management
One trial (62 women) contributed data to this comparison
(PITCH 2012).
There were no stillbirths or neonatal deaths in either group
(Analysis 15.1) and no significant differences in caesarean section
(RR 0.68; 95% CI 0.30 to 1.52; 62 women (Analysis 15.2)), pas-
sage of meconium-stained liquor (RR 0.55; 95% CI 0.15 to 2.01;
63 women (Analysis 15.3)) or admission to neonatal intensive care
unit (RR 0.55; 95% CI 0.05 to 5.76; 63 women (Analysis 15.4)).
D I S C U S S I O N
Summary of main results
Althoughwe found21 trialswith a total of 1197women, in general
the quality of evidence is low.
Only one trial reported a quantified reduction in itching as a
prespecified primary outcome across all women with obstetric
cholestasis. The different approaches to measuring and reporting
pruritus and the very high level of statistical heterogeneity pre-
cluded any aggregation of UDCA versus placebo trials on this out-
come. Individual assessment of these trials for maternal pruritus,
assessed either through a categorical 0-4 scale or on a 100 mm
visual analogue (VAS) scale, demonstrated a greater support for
UDCA compared with placebo and most other treatments in im-
proving pruritus scores. One study reported no significant differ-
ence in pruritus reduction when comparing UDCA with placebo
and dexamethasone, except in the subgroup of women with severe
obstetric cholestasis (bile acids ≥ 40 µmol/L), where a significant
improvement in pruritus was observed with UDCA. UDCA was
also more effective in improving pruritus than either SAMe or
cholestyramine. A combination of UDCA and SAMe was more
effective than SAMe and placebo in improving pruritus. Pruritus
was significantly reduced with Danxiaoling when compared to Yi-
ganling, but the use of these medicines are currently limited to
East Asia. Information on safety and efficacy and further evidence
from well designed randomised controlled trials are needed before
they can be adopted globally. The results from trials comparing
other interventions in regards to pruritus improvement were either
inconsistent or not significant.
Eight trials reported fetal or neonatal deaths, with two deaths re-
ported overall (both in the placebo groups). There were fewer
instances of fetal distress in the UDCA groups compared with
placebo (RR 0.67; 95% CI 0.22 to 2.02; 304 women; I² = 48%
(Analysis 1.5)) but the differencewas not significant. In theUDCA
group, the rates of passage of meconium-stained liquor were lower
and the mean gestational age at birth was higher but neither
reached statistical significance. While the rate of total preterm
births was significantly lower in theUDCA group when compared
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to placebo, there was no significant difference for the outcome of
spontaneous preterm birth between the two groups. This could be
interpreted as the rates of iatrogenic preterm births at less than 37
weeks of gestation being lower in women treated with UDCA, but
evidence from larger trials is required before any robust interpreta-
tion can be attempted. The rates of fetal distress were similar when
UDCA was compared with SAMe, cholestyramine and UDCA +
Salvia. The group receiving combined UDCA + SAMe had fewer
instances of fetal distress/asphyxial events when compared to the
group randomised to UDCA or SAMe monotherapy. The rates
of fetal distress were higher in the group receiving dexamethasone
when compared to UDCA and placebo.
One trial compared early term delivery versus expectant manage-
ment. There were no stillbirths or neonatal deaths in the two
groups. There were no significant differences in the rates of cae-
sarean section, meconium passage or admission to neonatal inten-
sive care unit.
Overall completeness and applicability of
evidence
The 21 studies included in this review are spread thinly over 15
comparisons. In only three comparisons was it possible to include
more than two trials (with seven studies comparing UDCA ver-
sus placebo, four comparing SAMe versus placebo, and four trials
comparing UDCA versus SAMe). In the remaining trials, it was
not possible to answer with adequate levels of reliability how ben-
eficial the relative merits of the interventions considered in this
review are owing to the general paucity of data.
Quality of the evidence
The quality of the studies included in this review ranged from ex-
cellent to poor. Two large studies comparing UDCA with placebo
were of high quality (Glantz 2005; PITCH 2012). Two (Fang
2009; Shi 2002) were quasi-randomised controlled trials and two
trials (Leino 1998; Zhang 2012) were available as conference ab-
stracts only. The methods used for random sequence generation
were described in eight trials (38%), allocation concealment was
judged as adequate in four trials (19%) and there was no blinding
in nine trials (43%). There were no dropouts reported in 10 stud-
ies (48%) and therefore all women were included in the analysis
of those trials.
Due to the varying methods of measuring and reporting pruritus,
pooling of data for this outcome was not possible. Only one trial
reported a quantified reduction in itching as a prespecified primary
outcome across all women with obstetric cholestasis. Eight trials
(40%) used 0-4 scale for pruritus assessment and analysed them as
a continuous outcome, which may not be an appropriate method
of analysis for such a short scale. Dichotomisation of data and re-
analysis was possible in one trial only. One trial did not specify the
methods used for assessing pruritus.
The definition of fetal distress/asphyxial event was clearly prede-
fined in one trial only. The definition of fetal distress/asphyxial
events varied across the studies. Four trials did not report this out-
come and it was unclear in three trials.
Potential biases in the review process
The evidence for this review is derived from studies identified
in a detailed search process. Three studies (Elias 2001; Mazzella
2010; Wang 2003) were identified but Elias 2001 is no longer
on www.controlled-trials.com (where it was originally identified
from) and we could not find any published randomised controlled
trial by this author.Mazzella 2010 was registered onOctober 2010
and is not open for participant recruitment yet and Wang 2003 is
published in Chinese and we were not able to locate this article.
Should any of these studies be published or traced, we will include
them in future updates of this review.
While we endeavoured to use a systematic process for including
and excluding studies in this review and adhered to the criteria de-
fined in our protocol, the final selection is of course open to inter-
pretation or criticism. For further details please see Characteristics
of included studies; Characteristics of excluded studies.
Agreements and disagreements with other
studies or reviews
This previous version of this review Burrows 2001 included just
nine randomised controlled trials with data from 227 women.
In summary, the authors found insufficient evidence to recom-
mend any of the interventions alone or in combination in treat-
ing women with obstetric cholestasis. In this update of the review
there is, in general, slightly stronger support for the comparison
betweenUDCA versus placebo (with the addition of Glantz 2005;
Liu 2006 and PITCH2012), although it is noted that the overview
for this comparison should be treated conservatively until greater
clarity is available from further research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is support for use of UDCA in improving maternal pruritus
in obstetric cholestasis although the size of the benefit is small.
Women should be informed that there is insufficient evidence
to recommend UDCA to improve fetal outcome. There is some
apparent decrease in some measures of fetal/neonatal morbidity
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associated with UDCA, including lower rates of meconium pas-
sage and higher mean gestational age at birth, but we cannot con-
clude this reliably due to the high level of statistical heterogeneity.
Definitive evidence for fetal benefit with any intervention is still
lacking.
There is insufficient evidence to indicate that SAMe, guar gum, ac-
tivated charcoal, dexamethasone, cholestyramine, YCHD, DXLP,
Yiganling alone or in combination are effective in treating women
with cholestasis of pregnancy.
There is insufficient evidence to recommend early term delivery
in obstetric cholestasis.
Implications for research
UDCAand early termdelivery are themostwidely used treatments
for obstetric cholestasis. Further trials of UDCA are justified. Such
trials should be sufficiently large to test its effectiveness in reducing
adverse fetal outcomes, and to confirm its fetal safety. Large trials
of UDCA versus no treatment are feasible, but will probably have
to rely on surrogate fetal outcomes such as admission to intensive
care, and birth asphyxia, which are susceptible to bias. They should
therefore be double blind.
It is unlikely that sufficiently large trials of near term early delivery
are feasible, and there is increasing evidence from trials in other
high risk pregnancies that this type of induction has few maternal
side effects, so further near term induction trials are not a priority.
However, if preterm induction prior to say 37 weeks is considered
to pre-empt stillbirth this should be evaluated in a trial first, before
implementation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Binder 2006
Methods Randomised controlled trial.
Participants 78 women randomised.
Setting: Prague, Czech Republic.
Recruitment: January 1999 to March 2005.
Inclusion criteria: women with singleton pregnancies at < 36 weeks’ gestation with
generalised itching starting in the second half of pregnancy, serum liver enzymes > 1
µkat/L and bile acid levels > 6 µmol/L
Exclusion criteria: hepatitis A, B, C, acute CMV, herpes virus infection, gallbladder
stones
Interventions SAMe (n = 25).
2 x 500 mg/day given by slow infusion for 14 days and subsequently 2 x 500 mg/day
orally until birth (median treatment duration 3 weeks, range 1 to 10)
UDCA (n = 26).
3 x 250 mg/day orally until birth (median treatment duration 4 weeks, range 2 to 8)
SAMe+UDCA (n = 27).
Dosages as above (median treatment duration 3 weeks, range 1 to 12)
All the participants were admitted to prenatal intensive care unit, but were discharged
and followed up in the outpatient clinic in cases of remarkable clinical and biochemical
improvement
A 10-point score was used by the participants to determine itching, where score 1 indi-
cated isolated episodes of pruritus and score 10 indicated a continuous pruritus with im-
pairment of the sleeping rhythm, and described the impact of the mode of treatment on
the severity of itching as ’deterioration’, ’not affected’, ’mild improvement’ and ’marked
improvement’. Blood samples were collected for LFTs and bile acids on alternate days
in the most severe cases and weekly during remission
The fetus was monitored by CTG and ultrasound scans. Amnioscopy was performed
when possible. Corticosteroids were not given for fetal lung maturity
Pregnancy was terminated in case the symptoms endangered the fetus and no later than
1 week if the disease progressed despite intervention. In the case of marked clinical and
biochemical improvement, women were allowed to progress to term
Outcomes Maternal: status of pruritus; biochemical parameters; adverse effects
Fetal/neonatal: perinatal outcomes; adverse effects.
Notes Medications that could affect pruritus, transaminases and bile acid concentrations were
not used
Risk of bias
Bias Authors’ judgement Support for judgement
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Binder 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote “Randomisation into three groups was carried
out by means of sealed envelopes”
No further description of randomisation.
Allocation concealment (selection bias) Unclear risk “The women were divided to treatment group with the
envelope method.” No other details on whether en-
velopes were sequentially numbered, opaque or sealed
Blinding (performance bias and detection
bias)
All outcomes
High risk The route and the duration of interventions were differ-
ent in each of the 3 groups and therefore blinding would
not have been possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Unclear risk Some outcomes were not reported in a way that could
be used in this review (e.g. gestational age at birth not
reported with SDs, preterm birth reported but not spon-
taneous preterm birth)
Other bias Low risk No other additional bias noted
Diaferia 1996
Methods Randomised controlled trial.
Participants 16 women randomised.
Setting: Bari, Italy.
Inclusion criteria: women aged between 20-39 with ICP in the third trimester of
pregnancy, where pruritus appeared after week 29 of pregnancy
Exclusion criteria: hepatitis A, B, C, CMV andHSV; chronic liver disease; urinary tract
infection; gestational diabetes; hypertension
Interventions UDCA (n = 8).
600 mg/day of UDCA in 2 oral doses for 20 days after week 30 of gestation
Placebo (n = 8).
Placebo (vitamin-supradyn) in 2 oral doses for 20 days.
Participants were admitted in the hospital during the duration of the study. No other
drug was used to improve pruritus and LFTs
The severity of prurituswas assessed before randomisation and repeated every 5days using
the following score: 0 = absence of pruritus; 1 = occasional pruritus; 2 = discontinuous
pruritus every day, with prevailing asymptomatic lapses; 3 = discontinuous pruritus with
prevailing symptomatic lapses; 4 = constant pruritus, day and night
Blood samples were collected weekly for assays of liver function and bile acids
Ultrasound examinations and CTGs were performed to assess the fetus
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Diaferia 1996 (Continued)
Outcomes Maternal: pruritus; liver function and bile acid assays; mode of birth; PPH; adverse
effects
Fetal/neonatal: fetal distress; gestation at birth; birthweight; Apgar score at 1 and 5
minutes; adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described only as “randomised”.
Allocation concealment (selection bias) Unclear risk Described only as “randomised”.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind, placebo-controlled” - the investigators
and the participants were blinded to the treatment allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up were reported.
Selective reporting (reporting bias) Unclear risk Perinatal death not reported.
Other bias Low risk No other additional bias noted.
Fang 2009
Methods Quasi-randomised controlled trial.
Participants 128 women randomised.
Setting: First Affiliated Hospital of Xi’an Jiaotong University (Obstetrics Department)
Inclusion criteria:womenwith singleton pregnancy presentingwith antepartum itching
and abnormal ALT and AST which resolved postpartum
Exclusion criteria: antenatal problems such as vomiting, loss of appetite, lethargy or
any medical problems, known liver disease or hepatitis prior to pregnancy
Interventions Salvia+UDCA (N = 72).
Salvia injection IV (10 mL in 10% 500 mL Dextrose) and UDCA 15 mg TDS PO for
14 days
UDCA (N = 56).
UDCA 15 mg TDS PO for 14 days.
Outcomes Maternal: reduction in pruritus score; monitoring of CG, TB, ALT and AST levels
Fetal/neonatal: CS for fetal distress; meconium-stained liquor; Apgar score and birth-
weight
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Fang 2009 (Continued)
Notes Article in Chinese.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised controlled trial. “A total of 128
patients were divided into two groups based on the
date of admission into the First AffiliatedHospital
of Xi’An Jiaotong University.”
Allocation concealment (selection bias) High risk Quasi-randomised controlled trial. “A total of 128
patients were divided into two groups based on the
date of admission into the First AffiliatedHospital
of Xi’An Jiaotong University.”
Blinding (performance bias and detection
bias)
All outcomes
High risk The route of administration of the interven-
tions being compared were different and therefore
blinding would not have been possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk There appear to be no losses to follow-up.
Selective reporting (reporting bias) Unclear risk Results for outcomes described in the abstract and
methods are reported. However, stillbirth, neona-
tal death or preterm birth are not reported
Other bias Unclear risk It is unclear why there are 72 women in the experi-
mental group and 58 women in the control group
Floreani 1996
Methods Randomised controlled trial.
Participants 20 women randomised.
Setting: Padova, Italy.
Inclusion criteria: skin pruritus due to ICP during the last trimester of pregnancy , total
serum bile acids 2 µmol/L and ALT 40 U/L
Exclusion criteria: dermatological or other causes of pruritus; abnormalities unrelated
to pregnancy (acute hepatitis A, hepatitis B and C were excluded)
Interventions UDCA (n = 10).
450 mg/day oral until birth.
SAMe (n = 10).
1000 mg/day IM until birth.
Participants were admitted to the obstetrics ward before 34 weeks’ gestation for strict
fetal monitoring. They were examined by the same hepatologist. The severity of pruritus
was assessed before treatment and subsequently every 3 days using the following score:
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Floreani 1996 (Continued)
0 = absence of pruritus; 1 = occasional pruritus; 2 = discontinuous pruritus every day,
with prevailing relapses at night; 3 = permanent pruritus during day and night
Fasting blood samples were obtained immediately before treatment, every 3 days until
birth and then 5 days later
All fetal monitoring and delivery decisions were made by the treating obstetrician
Outcomes Maternal: status of pruritus; assays of liver function and bile acids; mode of birth
Fetal/neonatal: gestation at birth; birthweight; Apgar score at 5 minutes.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” - no further details given.
Allocation concealment (selection bias) Unclear risk “randomised by closed envelope system”, no other de-
tails on whether envelopes were sequentially numbered,
opaque or sealed
Blinding (performance bias and detection
bias)
All outcomes
High risk It is apparent from the study that blinding was not pos-
sible because the route of administration of the 2 inter-
ventions (oral vs injection) were different
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Unclear risk Liver function outcomes were reported only as graphs.
Other bias Low risk No other additional bias noted.
Frezza 1984
Methods Randomised controlled trial.
Participants 18 women randomised.
Setting: Milan, Italy.
Recruitment: between 1979 to 1982.
Inclusion criteria: women between 28 and 32 weeks of pregnancy with history of
gestational pruritus starting after 19th week of gestation and elevated serum bile acids,
bilirubin and transaminases. Normalisation of biochemical parameters and resolution of
itching after birth
Exclusion criteria: acute hepatitis A, hepatitis B, dermatological diseases.
Interventions SAMe (n = 6).
Daily IV dose of 200 mg of SAMe (as disulphate-p-toluenesulfonate stable salt) dissolved
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Frezza 1984 (Continued)
in 500 mL of saline solution over 4 hours beginning at 8 am for 20 days
SAMe (n = 6).
Daily IV dose of 800 mg of SAMe (as disulphate-p-toluenesulfonate stable salt) dissolved
in 500 mL of saline solution over 4 hours beginning at 8 am for 20 days
Placebo (n = 6).
Daily IV dose of 500 mL of saline solution over 4 hours beginning at 8 am for 20 days
Pruritus was assessed before randomisation and were repeated 10 and 20 days after
treatment. It was graded as: 0, no pruritus; Grade 1+, rare; Grade 2+, occasional; Grade
3+, frequent; Grade 4+, almost continuous
Fasting blood samples were obtained for ALT, AST, ALP, bilirubin and total bile acid
levels before randomisation and at 10-day intervals
Outcomes Maternal: status of pruritus; assays of liver function and bile acids, maternal adverse
events
Fetal/neonatal: Apgar scores.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Quote - “Women were randomly allocated to three
groups of six”. No other details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single blinded. Participants were blinded. The medical
staff were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk Fetal outcomes, mean length of gestation, preterm birth
rates, mode of birth and blood loss at birth were not
reported. Some outcomes were only presented as graphs
Other bias Low risk No other additional bias noted.
Frezza 1990
Methods Randomised placebo-controlled trial- using a pre-established code, single-blinded
Participants 30 women randomised.
Setting: Milan, Italy.
Inclusion criteria: pruritus, with or without jaundice, and elevated levels of serum bile
acids, bilirubin, ALT and AST during the last trimester of pregnancy
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Frezza 1990 (Continued)
Exclusion criteria: acute hepatitis A, hepatitis B, dermatological conditions.
Interventions SAMe (n = 15).
Daily IV dose of 800 mg of SAMe diluted in 500 mL of 5% dextrose. Half of the dosage
was infused in the morning, and half in the afternoon. It was administered up to the day
of birth and was withdrawn 12 hours after birth
Placebo (n = 15).
Daily IV dose of 500 mL of 5% dextrose. Half of the dosage was infused in the morning,
and half in the afternoon. It was administered up to the day of birth and was withdrawn
12 hours after birth
Pruritus was a scored on a 10 cm analogue scale every 3 days up to 24 hours after birth
LFTs were measured before randomisation and 24 hours after birth
Outcomes Maternal: status of pruritus; assays of liver function and bile acid; adverse effects
Fetal/neonatal: preterm birth at < 37 weeks; birthweight < 2500 g.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote - “According to pre-established
code, consecutive patients were ran-
domised to receive either SAMe or
placebo”. It is unclear how this code was
generated
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single-blind. Participants were blinded.
The medical staff were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk Fetal mortality (stillbirth and neonatal
deaths), mean length of gestation, mode
of birth and blood loss at birth were not
reported. Some outcomes were only pre-
sented as graphs
Other bias Low risk No other bias apparent.
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Glantz 2005
Methods Randomised controlled trial.
Participants 130 women randomised.
Setting: 106 antenatal clinics and all 6 departments of obstetrics in the Västra Götaland
region, Sweden
Recruitment: February 1999 - January 2002.
Inclusion criteria: women at < 37 weeks’ gestation with gestational pruritus and fasting
serum bile acid levels > 10 µmol/L
Exclusion criteria: diabetes pre-eclampsia, intrauterine growth restriction, liver disease
(including viral hepatitis), history of manic disorders, bleeding peptic ulcer
Interventions UDCA (n = 47).
1 g/day as a single oral dose, for 3 weeks.
Dexamethasone (n = 36).
12 mg/day as a single oral dose for 1 week, and placebo during weeks 2 and 3
Placebo (n = 47).
Given daily as a single oral dose for 3 weeks.
A 100 mm long VAS was used to score itching: no pruritus at all at 0 mm; worst possible
pruritus at 100 mm
Blood samples were collected at entry for bile acids, ALT and bilirubin. They were
repeated after 2-3 days, after 4-5 days and after 1, 2 and 3 weeks of treatment. If the
pregnancy continued after 3 weeks of treatment, the above biochemical parameters were
measured weekly until birth. CTG monitoring was done each time the samples were
taken
Outcomes Primary outcomes: spontaneous preterm birth (< 37 weeks) in singleton pregnancies,
asphyxial events (operative delivery due to asphyxia, postpartum pH < 7.05 in umbilical
arterial blood or Apgar score < 7 at 5 minutes), and meconium staining of amniotic
fluid, placenta, and membranes
Secondary outcomes: changes in biochemical markers (bile acids, ALT and bilirubin)
, status of pruritus, total prematurity rate, total elective birth rate, maternal blood loss
during vaginal birth
Notes Severe obstetric cholestasis was defined as serum bile acids ≥ 40 µmol/L. Subgroup
analysis was done for this group
Funding: FoU, Västra Götaland.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study drugs were randomised in blocks of 6 (2 each
of UDCA, dexamethasone and placebo). Method of se-
quence generation not specifically described but likely
to be adequate
Allocation concealment (selection bias) Low risk The hospital pharmacy was responsible for randomisa-
tion. Study drugs were provided in tins with a study
code, each containing 6 treatments: 2 each of UDCA,
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Glantz 2005 (Continued)
dexamethasone, and placebo. Staff at the site were in-
structed to hand out the treatments consecutively, start-
ing with the lowest study code number
The lower numbers randomised in the dexamethasone
group may be due to only small numbers of women
being randomised before study drugswere changed,with
a large amount of study medication not being used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Dr Falk Pharma supplied identical looking UDCA,
placebo and empty capsules. The empty capsules were
filled with dexamethasone at the hospital pharmacy
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
80/130 women completed the full 3-week treatment pe-
riod (31 in the UDCA group, 19 in the dexamethasone
group and 30 in the placebo group). 3 women, 1 from
each group, discontinued due to side effects. 1 woman
in each group did not take the medication after being
randomised due to fear of side effects. The remaining 44
women discontinued their treatment because of sponta-
neous or planned birth
Selective reporting (reporting bias) Unclear risk Pruritus and liver function were reported only graphi-
cally as medians (with some P values reported)
Other bias Low risk No other additional bias noted.
Huang 2004
Methods Randomised controlled trial.
Participants 60 women randomised.
Recruitment: July - October 2002.
Inclusion criteria: primigravidae, singleton pregnancies, pruritus in the second half of
pregnancy, raised serum CG (> 10 UNL) and ALT
Exclusion criteria: PIH; gestational diabetes; anaemia; other liver (hepatitis A, B, C, D)
and gallbladder diseases
Interventions YCHD (n = 35).
BD orally for 3 weeks.
SAMe (n = 25).
IV infusion of 2 x 500 mg daily for 3 weeks.
Pruritus, serum bile acids and LFTs were assessed after 3 weeks treatment
Outcomes Maternal: improvement in pruritus; serum CG; ALT; bilirubin; length of gestation;
delivery by CS
Fetal/neonatal: mortality; Apgar score < 7; meconium-stained liquor; preterm birth at
< 37 weeks; birthweight; asphyxial events; umbilical cord artery pH, PO2, PCO2
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Notes Full article in Chinese, abstract published in English.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not mentioned. Unlikely to be blinded because these 2
drugs have different modes of administration
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk All the pre-specified outcomes reported.
Other bias High risk Imbalance in numbers randomised to each group (35
versus 25) which may indicate a failure of proper ran-
domisation
Kaaja 1994
Methods Randomised controlled trial.
Participants 19 women randomised (1 woman entered trial in 2 successive pregnancies)
Setting: Helsinki, Finland.
Inclusion criteria: women with pruritus and abnormalities of liver function.
Exclusion criteria: hepatitis A and B, gallbladder pathology.
Interventions Activated charcoal (n = 10).
Activated charcoal as a water suspension, 50 g 3 times a day for 8 days
vs
No treatment (n = 10).
Normal follow-up of ICP with no charcoal administration.
Participants maintained a daily record of pruritus: 0 = no itching; 1 = mild itching; 2
= moderate itching, does not disturb sleep; 3 = intense itching, disturbs sleep; 4 = very
intense (intolerable) itching, forces participant to scratch continuously
Fasting blood samples were collected for total bile acids and LFTs at the start of the study
and were repeated on day 4 and 8
Outcomes Maternal: status of pruritus; assays of liver function and bile acids
Fetal/neonatal: gestation at delivery, birthweight.
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) High risk Few fetal/neonatal outcomes not reported.
Other bias Low risk No other additional bias noted.
Kondrackiene 2005
Methods Randomised controlled trial.
Participants 84 women randomised.
Setting: Lithuania.
Recruitment: between October 1999 and September 2002.
Inclusion criteria: women at 25 - 39 weeks of gestation with pruritus starting in the
second or third trimester of pregnancy and elevation of at least 1 of the following bio-
chemical markers: ALT > 45 U/L, AST > 40 U/L, fasting serum bile acids > 10 µmol/L
Exclusion criteria: chronic liver disease; viral infections (hep A, B, C, CMV,HSV, EBV)
; skin disease; allergies; symptomatic cholelithiasis
Interventions UDCA (n = 42).
8-10 mg/kg body weight orally daily for 14 days.
Cholestyramine (n = 42).
8 g orally daily for 14 days.
Daily self-assessment of pruritus by the participants using the following score: 0 = no
pruritus; 1 = occasional; 2 = intermittent pruritus everyday with asymptomatic periods
prevailing; 3 = intermittent pruritus everyday with symptomatic periods prevailing; 4 =
constant pruritus day and night
Fasting blood samples were collected at entry and on the day after the completion of
treatment for the analysis of LFTs and bile acid assay
Delivery decisions were made by managing obstetricians independent of the study
Outcomes Primary end point: reduction in the severity of pruritus by more than 50% after 14
days of treatment
Secondary end points: reduction of ALT and serum bile acid levels; mode of birth; drug
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safety, gestation at birth, Apgar score at 1 and 5 minutes, birthweight
Notes Cholestyramine may cause PPH in mother and intracranial haemorrhage in fetus due to
the malabsorption of vitamin K. These outcomes were not analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote - ’All patients gave written informed consent be-
fore inclusion into the study and were randomised to
receive either UDCA or cholestyramine’
No description of random sequence generation.
Allocation concealment (selection bias) Unclear risk “Sealed envelopes.” Unclear as not specified as consecu-
tive and opaque
Blinding (performance bias and detection
bias)
All outcomes
High risk “Open” trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 84 women were included in analyses although 10/42
women in the UDCA group and 4/42 in the cholestyra-
mine group either did not complete the study or were
protocol violations. In the UDCA group, 4 women dis-
continued treatment and 6 women were protocol vio-
lations (apparently 6 women took UDCA before inclu-
sion in the trial). In the cholestyramine group, 3 women
experienced adverse events (nausea and vomiting) and 1
women discontinued treatment
Selective reporting (reporting bias) Unclear risk Most expected outcomes were reported although out-
comes related to bleeding were not reported (see Notes
above)
Other bias Low risk No other additional bias noted.
Leino 1998
Methods Randomised controlled trial.
Participants 18 women with ICP were included in analyses: 10 in the UDCA group and 8 in the
placebo group
Interventions 450 mg of UDCA in 2 doses for 14 days vs placebo.
Outcomes Daily assessment of pruritus, diverse reactions, itching. The following were assessed
at before treatment and at 7 days: fasting serum levels of total bile salts, ALAT, ALP,
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estradiol, progesterone, prolactin, cholesterol, triglycerides, APTT and thrombocytes
Notes Conference abstract. Very limited information.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Very limited information.
Allocation concealment (selection bias) Unclear risk Very limited information.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reported as double-blind but no further information.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very limited information.
Selective reporting (reporting bias) Unclear risk Very limited information. Serum ALP was assessed but
not reported
Other bias Unclear risk Conference abstract. Very limited information.
Liu 2006
Methods Randomised controlled trial.
Participants 68 women randomised.
Setting: Wuhan, China.
Recruitment: June 2001-July 2003.
Inclusion criteria: women at 25 - 37 weeks’ gestation with severe gestational pruritus;
serum total bile acids > 10 µmol/L and raised ALT or conjugated bilirubin
Exclusion criteria: other known causes of liver dysfunction.
Interventions UDCA (n = 34).
300 mg (18 mg/kg body weight) 3 times a day for 2 weeks.
Placebo (n = 34).
Combination of 10% glucose, vitamin C and inosine for 2 weeks. They were kept on a
low-fat diet and bed rest during the period of the study
Outcomes Maternal: pruritus score, mode of birth, adverse effects, LFTs, total bile acids
Pruritus score was self-assessed every 3 days on a VAs: 0 = no pruritus; 1 = occasional; 2
= intermittent pruritus everyday with asymptomatic periods prevailing; 3 = intermittent
pruritus everyday with preponderance of symptomatic periods; 4 = constant pruritus
However results were only reported as a number +- another number. Because it is not
clear if these were means or medians, and if the +- was SD, SE or other measure of
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dispersion, these results are not analysable
Fetal/neonatal: antepartum testing prompting delivery; gestation at birth; passage of
meconium; intrapartum fetal distress; Apgar scores at 1 and 5 minutes; birthweight,
adverse events
Notes Fetal asphyxia was not defined.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participantswere “divided into treatment group and con-
trol group at random”. No further details
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk It is unclear whether the clinicians/investigators and the
participants were blinded to trial allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was no trial flow diagram. The trial was not reg-
istered. Follow-up rates were not reported
Selective reporting (reporting bias) High risk Stillbirths and neonatal deaths were not reported.
Apgar scores, and adverse events were recorded but not
reported
Other bias Low risk No other additional bias noted.
Luo 2008
Methods Randomised controlled trial.
Participants 64 women randomised.
Setting: Affiliated Hospital of Hanzhou Normal University, Hanzhou, China
Recruitment: June 2002-July 2007.
Inclusion criteria: neonatal jaundice and/or maternal? itching, rise in the levels of serum
transaminase and CG
Exclusion criteria: any skin infection, prolonged liver disease, any other illnesses, high
blood pressure, received other forms of treatment for ICP
Interventions Transmetil + UDCA (n = 34).
Transmetil (1 g + 5% Glucose 250 mL IV OD) + UDCA (250 mg Oral pill BD) for 10
days
UDCA (n = 30).
UDCA 250 mg BD for 10 days. Patients took dexamethasone (10 mg OD) for 3 days
before the treatment in both groups
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Outcomes Maternal: scale of itchiness (0-4 Ribalta scale); levels of ALT, AST, total bile acids,
amount of haemoglobin, CS rate
Fetal/neonatal: preterm birth, clearness of amniotic fluid (i.e. number of cases where
the fluid was not clear), Apgar score, birthweight
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomly assigned“ - no further details reported.
Allocation concealment (selection bias) Unclear risk ”randomly assigned“ - no further details reported.
Blinding (performance bias and detection
bias)
All outcomes
High risk The route of administration of interventions in the 2
groups were different and therefore blinding would not
have been possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up or withdrawal in either group.
Selective reporting (reporting bias) Unclear risk Not all expected outcomes reported.
Other bias Low risk According to the translation, “Their traits and charac-
teristics were not significantly different from each other”
Nicastri 1998
Methods Randomised controlled trial.
Participants 32 women randomised.
Setting: Bari, Italy.
Recruitment: March 1995 - July 1996.
Inclusion criteria: participants includedwomen aged 19-37 years, between 30-37weeks’
gestation with history of pruritus after 28 weeks
Interventions UDCA (n = 8).
UDCA in 2 oral doses daily (600 mg/day) for 20 days.
SAMe (n = 8).
SAMe in the stable form of sulphate-P-toluenesulphonate diluted in 500mL5%dextrose
and divided into 2 IV infusions (800 mg/day)
UDCA+SAMe (n = 8).
Combination of UDCA and SAMe in the doses specified above.
Placebo (vitamin) (n = 8).
LFTs and serum total bile acid levels were measured before and at the end of treatment
Pruritus was measured every 3 days up to 24 hours after delivery. Pruritus was scored
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as: 0 = absent pruritus; 1 = occasional pruritus; 2 = intermittent pruritus everyday with
asymptomatic periods prevailing; 3 = intermittent pruritus everyday, with symptomatic
periods prevailing; 4 = constant pruritus
Outcomes Maternal: status of pruritus; assays of liver function and bile acids, side effects of the
treatment
Fetal/neonatal: preterm birth; low birthweight; side effects of the treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random permuted blocks.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded. It is apparent from the study that blinding
was not possible because the route of delivery of the
interventions were different
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up reported.
Selective reporting (reporting bias) High risk Stillbirths and perinatal deaths, mean length of gesta-
tion, mode of birth and blood loss at birth were not re-
ported
Other bias Low risk No other additional bias noted.
Palma 1997
Methods Randomised controlled trial.
Participants 24 women randomised.
Setting: Santiago, Chile.
Recruitment: July 1993 - June 1995.
Inclusion criteria: severe gestational pruritus appearing at < 33 weeks’ gestation and
present daily for at least 2 weeks; fasting total bile salts > 12 µmol/L and ALT or AST >
40 IU/L
Exclusion criteria: chronic liver disorder; symptomatic cholelithiasis; metabolic diseases;
dermatological or neuropsychiatric causes of pruritus; infections requiring antibiotics
Interventions UDCA (n = 8).
1000 mg/day as 3 oral doses until birth.
Placebo (starch) (n = 7).
Orally, until birth.
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Participants were admitted in the hospital. Pruritus was assessed weekly by the same
clinician using the following score: 0 = absence of pruritus; 1 = occasional pruritus; 2
= discontinuous pruritus everyday, prevailing asymptomatic lapses; 3 = discontinuous
pruritus but prevailing asymptomatic lapses everyday; 4 = constant itching, day and
night
Blood samples were collected for LFT and total bile salt levels. They had to be on a
treatment for at least 3 weeks
Outcomes Primary outcome: status of pruritus.
Secondary outcomes: liver function and bile acid assays; mode of birth; PPH; fetal/
neonatal deaths, fetal distress; gestation at birth; birthweight; adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation. Actualmethodof generation
not reported, but judged likely to have been adequate
Allocation concealment (selection bias) Low risk UDCA and placebo capsules were provided by Dr Falk
Pharma in coded boxes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical UDCA and placebo capsules.
Incomplete outcome data (attrition bias)
All outcomes
High risk 9/24 women did not complete the trial and were ex-
cluded from analysis. 8women did not complete 2weeks
of treatment (6 had spontaneous preterm vaginal births
and another 2 women had CS due to signs of fetal dis-
tress). The ninth woman left hospital after 1 week of
treatment
Selective reporting (reporting bias) Unclear risk Insufficient detail.
Other bias Low risk No other additional bias noted.
PITCH 2012
Methods Multicentre, double-blinded, randomised, controlled, factorial design trial
Participants 125 women (111 for UDCA vs placebo comparison plus an additional 14 women in
early vs expectant delivery not in UDCA vs placebo comparison) with ICP (pruritus and
raised maternal serum bile acids) or pruritus and raised alanine transaminase (> 100 IU/
L) recruited after 24 weeks’ gestation
Setting: 9 maternity units in UK.
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Interventions Comparison A:
1. UDCA n = 56 (60 babies). Starting dose 500 mg BD increased in increments of 500
mg per day every 3-14 days if there was no biochemical or clinical improvement until a
maximum of 2 g per day
2. placebo n = 55 (64 babies). Placebo capsules increased according to the same regimen
Comparison B:
1. Early term delivery (induction or delivery commenced between 37 + 0 and 37 + 6 (n
= 30)
2. Expectantmanagement (spontaneous labour awaited until 40weeks orCS as indicated,
usually after 39 weeks’ gestation); n = 33
Outcomes Primary outcomes:
UDCA vs placebo comparison: maternal itching (average of the worst itch in previous
24 hours - 100 mm VAS - between randomisation and delivery)
Timing of delivery comparison: CS.
Secondary outcomes:
Average itch in last 24 hours (VAS); total bile acids, ALT, APT, mode of onset of labour,
mode of birth, indication for delivery, blood loss at birth; gestational age at birth, “baby
outcome”, birthweight, presence of meconium-stained amniotic fluid, arterial cord pH,
venous cord pH, Apgar score at 5 minutes, congenital anomalies, admission to neonatal
unit (and duration), need for ventilation (and duration), convulsions, jaundice, adher-
ence; maternal adverse events.
Notes 48 of the 62 women in the delivery vs expectant management arm were also part of the
part of the UDCA vs placebo arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Low risk Central allocation using a web-based
database.
Blinding (performance bias and detection
bias)
All outcomes
Low risk For the UDCA vs placebo comparison
“investigator, pharmacists and participant
were blind to group allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up in either the drug
or delivery comparisons; however 4 women
in the UDCA group and 3 in the placebo
group discontinued the intervention (3
wanted open-label UDCA and 1 chose to
discontinue after an adverse event in the
UDCA group; 2 and 1 respectively in the
placebo group)
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For the delivery vs expectant management
comparison, none in the delivery groupdis-
continued the intervention and 20 in the
expectant management group discontin-
ued (non-exclusive - 7 fetal/maternal com-
promise 10 maternal request for delivery,
14 obstetrician decision for delivery)
Post randomisation exclusion.
None for UDCA vs placebo comparison.
None for early vs expectant delivery com-
parison.
Selective reporting (reporting bias) Low risk Trial registered. Most expected outcomes
reported.
Other bias Unclear risk The timed delivery comparison was not
blinded to obstetrician, patient or outcome
assessor
Ribalta 1991
Methods Randomised controlled trial.
Participants 20 women randomised.
Setting: Santiago, Chile.
Inclusion criteria: women with ICP, age 21-38 years with pruritus appearing before
week 32 of gestation. Participants had elevated levels of liver function markers
Exclusion criteria: liver and dermatological diseases, acute cholecystitis, urinary tract
infection, diabetes, other chronic diseases
Interventions SAMe (n = 9).
800 mg/day IV administered daily over 3 hours for 20 days.
Placebo (n = 9).
Mannitol IV administered daily over 3 hours for 20 days.
Participants were admitted to the obstetrics ward before 34 weeks’ gestation and were
kept as in-patient until 3-5 days post delivery. They were given a low-fat diet. No other
medications were prescribed to improve pruritus
The severity of prurituswas assessed before treatment and subsequently every 5days using
the following score: 0 = absence of pruritus; 1 = occasional pruritus; 2 = discontinuous
pruritus every day, with prevailing relapses at night; 3 = permanent pruritus during day
and night. They were assessed by the same observer
Fasting blood samples were obtained immediately before treatment, every 5 days until
delivery and then 1-3 days, 1 month and 3 months after delivery
Outcomes Maternal: status of pruritus; assays of liver function and bile acids; mode of birth; adverse
reactions
Fetal/neonatal: gestation at birth; birthweight; Apgar score at 1 and 5 minutes
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Notes Nonumerical datawere reported, results were only presented as graphsmaking it difficult
to extrapolate results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Sequence established at random by the suppliers.”
Allocation concealment (selection bias) Low risk Centralised randomisation. A single lot of identical look-
ing ampoules containing SAMe and mannitol were sup-
plied by BioResearch S.p.A (Milano, Italy). The boxes
were coded using the random sequence generated by the
suppliers
Blinding (performance bias and detection
bias)
All outcomes
Low risk The participants and the investigators were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/20 women did not complete the study; 1 from each
group (1 CS for meconium-stained amniotic fluid and
1 woman unable to tolerate iv infusions)
Selective reporting (reporting bias) High risk Most outcomes were only presented graphically.
Other bias Low risk No other additional bias noted.
Riikonen 2000
Methods Randomised controlled trial.
Participants 39 women randomised.
Setting: Helsinki, Finland.
Inclusion criteria: women with a singleton pregnancy referred due to an elevated serum
bile acid concentration (> 5 mol/L) and/or presence of typical pruritus of ICP, with no
concomitant chronic disease. The participants had to be on treatment for at least 10
days to be included in the analysis
Exclusion criteria: dermatological cause of pruritus; viral hepatitis (hepatitis B and C),
primary liver and gallbladder diseases
1 woman was entered into the study despite the absence of symptoms and biochemical
abnormality. She had developed ICP in 3 previous pregnancies and later developed ICP
Interventions Guar gum (n = 19).
5-15 g day, orally; the dose was increased from 5 to 15 g/day at 3 day intervals, until
birth
Placebo (wheat flour) (n = 20).
Participantswere seen in the outpatient clinic up to37weeks’ gestation andwere admitted
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to hospital at 37 weeks. Fetus was monitored by CTG at every clinic visit and daily at
the ward
The intensity of pruritus was estimated by 1 investigator and participant simultaneously.
The investigator used the following score: 0 = no pruritus; 1 =mild pruritus; 2 =moderate
pruritus disturbing sleep but not requiring antihistamine medication; 3 = severe pruritus
requiring continuous antihistamine medication. The participants used a 10 cm long VAS
Fasting blood samples were collected for the assessment of LFTs and total bile acids from
1-3 days before birth
If pruritus was severe, women were given prometazine hydrochloride 10-30 mg/day
Outcomes Maternal: status of pruritus (assessed by both clinician and woman); assays of liver
function and bile acids; CS for abnormal CTG; adverse effects
Fetal/neonatal: gestation at birth; birthweight.
Notes This study had an additional non-randomised control group of 20 women (additional
to the 39 participating in the randomised trial) to provide a comparison group for the
serum values
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “In-house built computer programme validated accord-
ing to company standard operating procedures.”
Allocation concealment (selection bias) Unclear risk Allocation concealment method not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The investigators and the participants were blinded to
the drug used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 9/39 (23%) women (5 guar gum, 4 placebo) were ex-
cluded from “the intervention analyses” to birth within
10 days of treatment.Not clear which analyses these were
e.g. n’s not given for Table II (liver function results)
Selective reporting (reporting bias) High risk Outcomes such as perinatal death, fetal distress and
spontaneous birth < 37 weeks were not reported
Other bias Low risk No other additional bias noted.
Roncaglia 2004
Methods Randomised controlled trial.
Participants 46 women randomised.
Setting: Monza, Italy.
Recruitment: June 1996 - December 2001.
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Inclusion criteria: women < 36 weeks’ gestation complaining of gestational pruritus
starting in the second or third trimester of pregnancy, persisting to birth and disappearing
after, bile acids > 6 µmol/L or serum transaminases > 41 mg/dL
Exclusion criteria: other medical conditions known to be associated with pruritus
Interventions SAMe (n = 22).
500 mg orally BD until birth.
UDCA (n = 24).
300 mg orally BD until birth.
No other medications apart from the study medications were used to improve pruritus
and LFTs
Prurituswas scored using a semi-quantitative scale of 1-4. 1 =occasional pruritus; 2 =daily
intermittent prurituswith preponderance of asymptomatic periods; 3 =daily intermittent
pruritus with preponderance of symptomatic periods; 4 = persistent pruritus, day and
night
LFTs and bile acid levelswere evaluated every 7-10 days and 1 and 3months post delivery
Non-stress tests and amniotic fluid volume assessment was done twice weekly. A bio-
physical profile was performed if the non-stress test was non-reactive
Outcomes Primary outcome: reduction of serum bile acids concentration.
Secondary outcomes: serum levels of transaminases and bilirubin; status of pruritus;
blood loss; CS; gestation at delivery; rate of preterm delivery; meconium passage at birth;
birthweight < 10th centile; Apgar score < 7 at 5 minutes; umbilical artery pH < 7.10;
admission to the neonatal intensive care unit; adverse effects
Notes Labour was induced at 37 weeks’ gestation or earlier in the presence of abnormal tests
of fetal well being, obstetric complications or severe maternal symptoms unresponsive
to therapy
There were 3 sets of twins (1 set in the UDCA group and 2 sets in the SAMe group);
only 1 twin per set, chosen at random, was included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number tables.
Allocation concealment (selection bias) Unclear risk “Assigned by computer-generated random number ta-
bles.”
Blinding (performance bias and detection
bias)
All outcomes
High risk Reports that there was “no concealment of treatment
allocation” which we interpret as not being blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up - not reported but 1 pruritus score
from each group is missing
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Selective reporting (reporting bias) Unclear risk Some expected outcomes (e.g. perinatal mortality) not
reported
Other bias Low risk No other additional bias noted.
Shi 2002
Methods Quasi-randomised controlled trial.
Participants 58 women randomised.
Recruitment: 1999 - 2000.
Inclusion criteria: women with ICP, not on any relevant treatment.
Exclusion criteria: women with PIH, fatty liver and hepatitis.
Interventions DXLP (n = 29).
9 g thrice daily orally for 7 days.
Yiganling (n = 29).
4 tablets 3 times a day for 7 days.
Outcomes Maternal: status of pruritus, jaundice; serum CGA, TB, ALT, AST, ALP, LDH, lipids
profile; mode of birth
Fetal/neonatal: neonatal mortality; preterm birth at < 37 weeks; meconium-stained
liquor, birthweight
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternation according to hospital admission.
Allocation concealment (selection bias) High risk Alternation according to hospital admission.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were no losses to follow-up.
Selective reporting (reporting bias) Unclear risk Outcomes were reported for 25 (86%) partici-
pants for ALT and AST, 27 (93%) for ALP and
for 21 (72%) women for bilirubin levels out of 29
participants receiving Danxiaoling and for 16 of
29 (55%) participants for bilirubin in the Yigan-
ling group. The reasons for exclusion were unclear
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Other bias Low risk No other additional bias noted.
Zhang 2012
Methods Multicentre randomised controlled trial.
Participants 138 women recruited, among them 18 cases eliminated, data available for 120 women
Setting: 5 centres in Sichuan and Chongqing,China.
Recruitment: July 2009 to March 2011.
Inclusion criteria: ICP patients at 28 to 35 weeks of singleton pregnancy.
Exclusion criteria: not reported.
Interventions Women randomised into 3 groups:
UDCA (n = 41).
250 mg po Qid of UDCA.
SAMe (n = 38).
1000 mg IV Qid of SAMe.
SAMe+UDCA (n = 41).
UDCA & SAMe (dosage not specified).
Outcomes Maternal: pruritus scores; total bile acid; ALT; AST; TB; delivery mode; adverse drug
reactions
Fetal/neonatal: gestational ages; Apgar scores at 1 and 5 minutes; perinatal death
Notes Conference abstract. Very limited information.138 women recruited, among them 18
cases eliminated, data available for 120 women. Numerical results not reported for most
of the outcomes - just quotes whether there were differences between groups and P values
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Data limited - reported as abstract.
Allocation concealment (selection bias) Unclear risk Data limited - reported as abstract.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Data limited - reported as abstract.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 18 cases were eliminated - but not sure at
which stage they were eliminated, i.e. before
or after randomisation
Selective reporting (reporting bias) Unclear risk Data limited - reported as abstract.
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Zhang 2012 (Continued)
Other bias Unclear risk Data limited - reported as abstract.
ALP: alkaline phosphatase
ALT: alanine transferase
APTT: activated partial thromboplastin time
AST: aspartate transaminase
BD: twice daily
CG: cholyglycine
cm: centimetre
CMV: cytomegalovirus
CS: caesarean section
CTG: cardiotocography
DXLP: Danxiaoling Pill
EBV: Epstein Barr virus
g: gram
HSV: herpes simplex virus
ICP: intrahepatic cholestasis of pregnancy
IM: intramuscular
IV: intravenous
kg: kilogram
LDH: lactate dehydrogenase
LFT: liver function test
mg: milligram
mL: millilitre
µmol/L: micromoles per litre
OD: once daily
PCO2: carbon dioxide partial pressure
pH: potential hydrogen
PIH: pregnancy-induced hypertension
PO: per oral
PO2: oxygen partial pressure
PPH: postpartum haemorrhage
QID: four times daily
SAMe: S-adenosylmethionine
SD: standard deviation
SEM: standard error of the mean
TB: total bilirubin
TDS: ter die sumendum (three times daily)
U/L: units per litre
UDCA: ursodeoxycholic acid
VAS: visual analogue scale
vs: versus
YCHD: Yinchenghao decoction
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Elias 2001 This study no longer appears on controlled-trials.com (search date 14 February 2013). We’ve coded it as an excluded
study rather than deleting it, since it was cited in the original version of this review, and to keep a record of why it was
removed
Shi 2006 This is a clinical and experimental study looking at the effect of WLP in treating intrahepatic cholestasis of pregnancy.
In the clinical aspect of the study, women in the control group received a combination of 5% glucose (250 mL),
dexamethasone (5 mg), vitamin C2, compound injection of red sage root, potassium magnesium aspartate (0.3 g) and
Barbital (0.06 g).Women in the test group receivedWLP in addition to the above components. This made the study very
complex as it contained components that may individually affect the outcomes in intrahepatic cholestasis in pregnancy
The experimental part of the study was conducted on rat models
g: gram
mg: milligram
mL: millilitre
WLP: Wuling Pill
Characteristics of studies awaiting assessment [ordered by study ID]
Wang 2003
Methods
Participants
Interventions
Outcomes
Notes Untraceable.
Characteristics of ongoing studies [ordered by study ID]
Mazzella 2010
Trial name or title Ursodeoxycholic Acid And Cholestasis Of Pregnancy (CERTO).
Methods Randomised controlled trial.
Participants 118.
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Mazzella 2010 (Continued)
Interventions Ursodeoxycholic acid
300 mg capsules 20 mg/kg body weight/day divided in 3 administrations per day from enrolment until
delivery
Placebo
300 mg capsules 20 mg/kg body weight/day divided in 3 administrations per day from enrolment until
delivery
Outcomes Primary outcome
Number of participants with preterm delivery (before week 37)
Secondary outcomes
Pruritus on the visual analogue scale, transaminases, bile acids, fetal movement count, number of pregnancies
with cardiotocography suggestive of fetal stress; Apgar score, number of pregnancies with green stained
amniotic fluid
Starting date Estimated study start date: November 2010.
Estimated primary completion date: November 2013.
This study is not yet open for participant recruitment (checked on 14.02.2013)
Contact information Professor Giuseppe Mazzella,
S.Orsola-Malpighi Hospital/University of Bologna
Email: giuseppe.mazzella@unibo.it
Notes ClinicalTrials.gov identifier: NCT01226823.
kg: kilogram
mg: milligram
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D A T A A N D A N A L Y S E S
Comparison 1. UDCA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 1 15 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.72, 2.10]
2 Mean of worst itching scores over
preceding 24 hours between
randomisation and delivery
1 111 Mean Difference (IV, Fixed, 95% CI) -12.90 [-22.59, -3.
21]
3 Mean of average itching scores
over preceding 24 hours
between randomisation and
delivery
1 111 Mean Difference (IV, Fixed, 95% CI) -18.6 [-27.52, -9.68]
4 Stillbirth 3 233 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.03, 2.84]
5 Fetal distress/asphyxial event 5 304 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.22, 2.02]
6 Subgroup analysis - fetal
distress/asphyxial events
1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.15, 3.40]
6.1 Bile acid levels < 40
µmol/L
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.15, 6.90]
6.2 Bile acid levels ≥ 40
µmol/L
1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 6.85]
7 Bile acid reduction, µmol/L 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 At 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 30.4 [23.32, 37.48]
8 ALT, IU/L 2 83 Mean Difference (IV, Random, 95% CI) -109.00 [-182.48, -
39.51]
8.1 At two weeks 1 68 Mean Difference (IV, Random, 95% CI) -90.21 [-101.96, -
78.46]
8.2 At three weeks 1 15 Mean Difference (IV, Random, 95% CI) -175.0 [-294.23, -
55.77]
9 ALT, IU/L 1 16 Mean Difference (IV, Fixed, 95% CI) -50.88 [-75.14, -26.
62]
9.1 At 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) -50.88 [-75.14, -26.
62]
10 ALT reduction, IU/L 1 16 Mean Difference (IV, Fixed, 95% CI) 121.0 [100.93, 141.
07]
10.1 At 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 121.0 [100.93, 141.
07]
11 Caesarean section 4 210 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.82, 1.23]
12 Postpartum haemorrhage 2 127 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.20, 2.98]
13 Adverse effects 3 220 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.66, 2.63]
14 Meconium-stained liquor 3 274 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.24, 1.30]
15 Mean gestational age at birth 3 142 Mean Difference (IV, Random, 95% CI) 2.68 [-0.13, 5.48]
16 Spontaneous birth at less than
37 weeks
2 109 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.41, 2.36]
17 Total preterm birth at less than
37 weeks
2 179 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.28, 0.73]
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18 Admission to neonatal intensive
care unit
1 124 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.18, 1.31]
Comparison 2. SAMe versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirth/neonatal death 1 18 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Bile acid reduction, µmol/L 1 16 Mean Difference (IV, Fixed, 95% CI) 17.5 [12.30, 22.70]
2.1 At 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 17.5 [12.30, 22.70]
3 ALT reduction, IU/L 1 16 Mean Difference (IV, Fixed, 95% CI) 139.6 [119.06, 160.
14]
3.1 At 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 139.6 [119.06, 160.
14]
4 Caesarean section 1 18 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.75, 1.74]
5 Spontaneous birth at less than
37 weeks
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.09, 1.75]
6 Total preterm birth at less than
37 weeks
1 18 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.45, 1.26]
Comparison 3. Guar gum versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Participant assessed 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [0.77, 4.64]
1.2 Clinician assessed 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.46, 3.46]
2 Total bile acids (µmol/L) 1 39 Mean Difference (IV, Fixed, 95% CI) -7.40 [-24.22, 9.42]
3 ALT, U/L 1 39 Mean Difference (IV, Fixed, 95% CI) -37.5 [-137.33, 62.
33]
4 Adverse effects of medication 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.60, 3.29]
5 Mean gestational age at birth 1 39 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.73, 0.93]
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Comparison 4. Activated charcoal versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 1 20 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.55, 147.95]
2 Bile acids after 8 days treatment,
µmol/L
1 20 Mean Difference (IV, Fixed, 95% CI) -45.20 [-74.31, -16.
09]
3 ALT after 8 days treatment, U/L 1 20 Mean Difference (IV, Fixed, 95% CI) 74.60 [-141.33, 290.
53]
4 Mean gestational age at birth 1 20 Mean Difference (IV, Fixed, 95% CI) -1.0 [-2.77, 0.77]
Comparison 5. Dexamethasone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirths 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.02, 10.31]
2 Fetal distress/asphyxial event 1 83 Risk Ratio (M-H, Fixed, 95% CI) 2.61 [0.51, 13.47]
3 Subgroup analysis - fetal
distress/asphyxial event
1 83 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [0.50, 12.33]
3.1 Bile acid levels < 40
µmol/L
1 61 Risk Ratio (M-H, Fixed, 95% CI) 4.32 [0.48, 39.18]
3.2 Bile acid levels ≥ 40
µmol/L
1 22 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.05]
4 Meconium-stained liquor 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Any degree of ICP (all
women)
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.56, 1.78]
4.2 Severe subgroup 1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.36, 1.94]
5 Spontaneous birth at less than
37 weeks
1 83 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.21, 10.90]
5.1 Bile acid levels < 40
µmol/L
1 61 Risk Ratio (M-H, Random, 95% CI) 4.32 [0.95, 19.69]
5.2 Bile acid levels ≥ 40
µmol/L
1 22 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.19, 1.92]
6 Total preterm births at less than
37 weeks
1 83 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.26, 5.10]
6.1 Bile acid levels < 40
µmol/L
1 61 Risk Ratio (M-H, Random, 95% CI) 2.52 [0.82, 7.70]
6.2 Bile acid levels ≥ 40
µmol/L
1 22 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.23, 1.41]
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Comparison 6. UDCA versus SAMe
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Any improvement 3 117 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.89, 1.61]
1.2 Marked improvement 1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [1.00, 2.98]
1.3 Complete resolution 1 20 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.41, 120.16]
1.4 Complete resolution or
marked improvement
2 71 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [1.15, 3.41]
2 Fetal distress/asphyxial events 3 117 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.25, 3.58]
3 Bile acids, µmol/L 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 After 3-4 weeks treatment 1 51 Mean Difference (IV, Fixed, 95% CI) -27.0 [-43.67, -10.
33]
3.2 Reduction after 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 12.90 [4.36, 21.44]
4 ALT, µkat/L 1 51 Mean Difference (IV, Fixed, 95% CI) -2.2 [-3.55, -0.85]
4.1 After 3-4 weeks treatment 1 51 Mean Difference (IV, Fixed, 95% CI) -2.2 [-3.55, -0.85]
5 Caesarean section 3 117 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.52, 1.58]
6 Meconium-stained liquor 2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.17, 1.27]
7 Mean gestational age at birth 2 66 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.84, 0.76]
8 Spontaneus birth at less than 37
weeks
2 62 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.22, 1.59]
9 Total preterm birth at less than
37 weeks
2 71 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.33, 1.54]
10 Admission to neonatal intensive
care unit
2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.21, 1.27]
Comparison 7. UDCA versus dexamethasone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fetal distress/asphyxial events 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.08, 1.45]
1.1 Bile acid levels < 40
µmol/L
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.80]
1.2 Bile acid levels ≥ 40
µmol/L
1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 6.85]
2 Adverse effects of medication 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.05, 11.83]
3 Meconium-stained liquor 1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.60, 1.87]
4 Spontaneous birth at less than
37 weeks
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.29, 1.59]
5 Total preterm birth at less than
37 weeks
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.44, 1.71]
5.1 Bile acid levels < 40
µmol/L
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.23, 1.60]
5.2 Bile acid levels ≥ 40
µmol/L
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.52, 3.61]
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Comparison 8. UDCA versus cholestyramine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus score (> 50% reduction
after 14 days treatment)
1 84 Risk Ratio (M-H, Fixed, 95% CI) 3.5 [1.81, 6.77]
2 Fetal distress/asphyxial event 1 84 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.47]
3 Bile acids, µmol/L 1 84 Mean Difference (IV, Fixed, 95% CI) -1.80 [-13.10, 9.50]
4 ALT, U/L 1 84 Mean Difference (IV, Fixed, 95% CI) -144.2 [-186.63, -
101.77]
5 Caesarean section 1 84 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.65, 8.42]
6 Adverse effects of medication 1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.65]
7 Mean gestational age at birth 1 84 Mean Difference (IV, Fixed, 95% CI) -1.30 [-1.99, -0.61]
8 Total preterm birth at less than
37 weeks
1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.15, 2.35]
Comparison 9. UDCA + SAMe versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bile acid reduction at 20 days,
µmol/L
1 16 Mean Difference (IV, Fixed, 95% CI) 41.70 [35.57, 47.83]
Comparison 10. UDCA + SAMe versus SAMe
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Any improvement 1 52 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.99, 2.03]
1.2 Marked improvement 1 52 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.09, 3.14]
2 Stillbirths/neonatal deaths 2 131 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fetal distress/asphyxial event 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.03, 2.78]
4 Bile acids, µmol/L 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 After 3-4 weeks treatment 1 52 Mean Difference (IV, Fixed, 95% CI) -25.0 [-40.16, -9.84]
4.2 Reduction at 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 24.20 [16.43, 31.97]
5 ALT, µkatl/L 1 52 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.59, -1.21]
5.1 After 3-4 weeks treatment 1 52 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.59, -1.21]
6 Caesarean section 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.08, 1.74]
7 Postpartum haemorrhage 1 52 Mean Difference (IV, Fixed, 95% CI) 1.0 [-76.75, 78.75]
8 Meconium-stained liquor 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.09, 2.31]
9 Spontaneous birth at less than
37 weeks
1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.56]
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10 Total preterm birth at less than
37 weeks
1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.18, 1.59]
11 Admission to neonatal intensive
care unit
1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.09, 2.31]
Comparison 11. UDCA + SAMe versus UDCA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Any improvement 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.83, 1.35]
1.2 Marked improvement 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.76, 1.50]
2 Stillbirths/neonatal deaths 2 135 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fetal distress/asphyxial event 1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.05, 4.99]
4 Bile acids, µmol/L 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 After 3-4 weeks treatment 1 53 Mean Difference (IV, Fixed, 95% CI) 2.0 [-11.71, 15.71]
4.2 Reduction at 20 days 1 16 Mean Difference (IV, Fixed, 95% CI) 11.30 [2.16, 20.44]
5 ALT, µkatl/L 1 52 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.59, -1.21]
5.1 After 3-4 weeks treatment 1 52 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.59, -1.21]
6 Reduction in ALT (IU/L) after
treatment
1 64 Mean Difference (IV, Fixed, 95% CI) 1.28 [1.15, 1.41]
7 Caesarean section 2 116 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.35, 1.02]
8 Meconium-stained liquor 1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.12, 3.54]
9 Spontaneous birth at less than
37 weeks
1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.06, 4.47]
10 Total preterm births at less than
37 weeks
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.29, 1.62]
11 Admission to neonatal intensive
care unit
1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.12, 3.54]
Comparison 12. UDCA + Salvia versus UDCA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in pruritus from
moderate/severe to mild (0-4
scale)
1 128 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.87, 1.26]
2 Caesarean section for fetal
distress
1 128 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.45, 1.89]
3 Reduction in ALT (IU/L) after
treatment
1 128 Mean Difference (IV, Fixed, 95% CI) -14.90 [-24.42, -5.
38]
4 Meconium-stained liquor 1 128 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.38, 1.98]
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Comparison 13. YCHD versus SAMe
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Degree of pruritus after
treatment
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.77, 1.29]
1.1 Marked improvement 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.77, 1.29]
2 Stillbirths/neonatal deaths 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fetal distress/asphyxial event 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.29, 2.50]
4 Bile salt (CGA) levels 1 60 Mean Difference (IV, Fixed, 95% CI) -1.5 [-6.12, 3.12]
5 ALT 1 60 Mean Difference (IV, Fixed, 95% CI) 3.40 [-12.37, 19.17]
6 Caesarean section 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.56, 1.55]
7 Meconium-stained liquor 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.29, 2.50]
8 Mean gestational age at birth 1 60 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.35, 1.75]
Comparison 14. Danxiaoling versus Yiganling
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pruritus 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Any improvement after
treatment
1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.94, 1.07]
1.2 Marked improvement
after treatment
1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.14, 2.44]
2 Stillbirths/neonatal deaths 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Bile acid levels (CGA) 1 58 Mean Difference (IV, Fixed, 95% CI) -3.83 [-22.59, 14.
93]
4 ALT 1 54 Mean Difference (IV, Fixed, 95% CI) 5.20 [-36.90, 47.30]
5 Caesarean section 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.16, 2.28]
6 Meconium-stained liquor 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.18, 0.89]
7 Spontaneous birth at less than
37 weeks
1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.02]
Comparison 15. Early term delivery v expectant management
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirths/neonatal deaths 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Caesarean section 1 62 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.30, 1.52]
3 Meconium-stained liquor 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.15, 2.01]
4 Admission to neonatal intensive
care unit
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.05, 5.76]
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Analysis 1.1. Comparison 1 UDCA versus placebo, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 1 Pruritus improvement
Study or subgroup Favours UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Palma 1997 7/8 5/7 100.0 % 1.23 [ 0.72, 2.10 ]
Total (95% CI) 8 7 100.0 % 1.23 [ 0.72, 2.10 ]
Total events: 7 (Favours UDCA), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours UDCA
Analysis 1.2. Comparison 1 UDCA versus placebo, Outcome 2 Mean of worst itching scores over preceding
24 hours between randomisation and delivery.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 2 Mean of worst itching scores over preceding 24 hours between randomisation and delivery
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PITCH 2012 56 49 (24.8) 55 61.9 (27.2) 100.0 % -12.90 [ -22.59, -3.21 ]
Total (95% CI) 56 55 100.0 % -12.90 [ -22.59, -3.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours UDCA Favours Placebo
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Analysis 1.3. Comparison 1 UDCA versus placebo, Outcome 3 Mean of average itching scores over
preceding 24 hours between randomisation and delivery.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 3 Mean of average itching scores over preceding 24 hours between randomisation and delivery
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PITCH 2012 56 32.8 (22.4) 55 51.4 (25.4) 100.0 % -18.60 [ -27.52, -9.68 ]
Total (95% CI) 56 55 100.0 % -18.60 [ -27.52, -9.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.4. Comparison 1 UDCA versus placebo, Outcome 4 Stillbirth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 4 Stillbirth
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 0/47 1/47 48.6 % 0.33 [ 0.01, 7.98 ]
Palma 1997 0/8 1/7 51.4 % 0.30 [ 0.01, 6.29 ]
PITCH 2012 0/60 0/64 Not estimable
Total (95% CI) 115 118 100.0 % 0.31 [ 0.03, 2.84 ]
Total events: 0 (UDCA), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 UDCA versus placebo, Outcome 5 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 5 Fetal distress/asphyxial event
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Diaferia 1996 0/8 4/8 11.6 % 0.11 [ 0.01, 1.78 ]
Glantz 2005 2/47 2/47 18.8 % 1.00 [ 0.15, 6.81 ]
Liu 2006 2/34 9/34 24.7 % 0.22 [ 0.05, 0.95 ]
Palma 1997 2/8 2/7 21.7 % 0.88 [ 0.16, 4.68 ]
PITCH 2012 6/56 2/55 23.3 % 2.95 [ 0.62, 13.97 ]
Total (95% CI) 153 151 100.0 % 0.67 [ 0.22, 2.02 ]
Total events: 12 (UDCA), 19 (Placebo)
Heterogeneity: Tau2 = 0.74; Chi2 = 7.62, df = 4 (P = 0.11); I2 =48%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 UDCA versus placebo, Outcome 6 Subgroup analysis - fetal distress/asphyxial
events.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 6 Subgroup analysis - fetal distress/asphyxial events
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bile acid levels < 40 mol/L
Glantz 2005 2/35 2/36 55.8 % 1.03 [ 0.15, 6.90 ]
Subtotal (95% CI) 35 36 55.8 % 1.03 [ 0.15, 6.90 ]
Total events: 2 (UDCA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 0/12 1/11 44.2 % 0.31 [ 0.01, 6.85 ]
Subtotal (95% CI) 12 11 44.2 % 0.31 [ 0.01, 6.85 ]
Total events: 0 (UDCA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 47 47 100.0 % 0.71 [ 0.15, 3.40 ]
Total events: 2 (UDCA), 3 (Placebo)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 1.7. Comparison 1 UDCA versus placebo, Outcome 7 Bile acid reduction, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 7 Bile acid reduction, mol/L
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 20 days
Nicastri 1998 8 33 (10) 8 2.6 (2.1) 100.0 % 30.40 [ 23.32, 37.48 ]
Subtotal (95% CI) 8 8 100.0 % 30.40 [ 23.32, 37.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.41 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Placebo Favours UDCA
74Interventions for treating cholestasis in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 UDCA versus placebo, Outcome 8 ALT, IU/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 8 ALT, IU/L
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 At two weeks
Liu 2006 34 80.14 (16.43) 34 170.35 (30.86) 75.5 % -90.21 [ -101.96, -78.46 ]
Subtotal (95% CI) 34 34 75.5 % -90.21 [ -101.96, -78.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.05 (P < 0.00001)
2 At three weeks
Palma 1997 8 54 (50) 7 229 (154) 24.5 % -175.00 [ -294.23, -55.77 ]
Subtotal (95% CI) 8 7 24.5 % -175.00 [ -294.23, -55.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
Total (95% CI) 42 41 100.0 % -111.00 [ -182.48, -39.51 ]
Heterogeneity: Tau2 = 1726.45; Chi2 = 1.92, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 3.04 (P = 0.0023)
Test for subgroup differences: Chi2 = 1.92, df = 1 (P = 0.17), I2 =48%
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Analysis 1.9. Comparison 1 UDCA versus placebo, Outcome 9 ALT, IU/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 9 ALT, IU/L
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 20 days
Diaferia 1996 8 40.87 (13.2) 8 91.75 (32.43) 100.0 % -50.88 [ -75.14, -26.62 ]
Total (95% CI) 8 8 100.0 % -50.88 [ -75.14, -26.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000040)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 UDCA versus placebo, Outcome 10 ALT reduction, IU/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 10 ALT reduction, IU/L
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 20 days
Nicastri 1998 8 131.1 (19.3) 8 10.1 (21.6) 100.0 % 121.00 [ 100.93, 141.07 ]
Total (95% CI) 8 8 100.0 % 121.00 [ 100.93, 141.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 UDCA versus placebo, Outcome 11 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 11 Caesarean section
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Diaferia 1996 2/8 4/8 6.7 % 0.50 [ 0.13, 2.00 ]
Liu 2006 32/34 31/34 52.1 % 1.03 [ 0.90, 1.18 ]
Palma 1997 5/8 4/7 7.2 % 1.09 [ 0.47, 2.52 ]
PITCH 2012 21/56 20/55 33.9 % 1.03 [ 0.63, 1.68 ]
Total (95% CI) 106 104 100.0 % 1.00 [ 0.82, 1.23 ]
Total events: 60 (UDCA), 59 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 UDCA versus placebo, Outcome 12 Postpartum haemorrhage.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 12 Postpartum haemorrhage
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Diaferia 1996 0/8 2/8 55.3 % 0.20 [ 0.01, 3.61 ]
PITCH 2012 3/56 2/55 44.7 % 1.47 [ 0.26, 8.48 ]
Total (95% CI) 64 63 100.0 % 0.77 [ 0.20, 2.98 ]
Total events: 3 (UDCA), 4 (Placebo)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 UDCA versus placebo, Outcome 13 Adverse effects.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 13 Adverse effects
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 1/47 1/47 8.6 % 1.00 [ 0.06, 15.52 ]
Palma 1997 1/8 0/7 4.6 % 2.67 [ 0.13, 56.63 ]
PITCH 2012 13/56 10/55 86.8 % 1.28 [ 0.61, 2.66 ]
Total (95% CI) 111 109 100.0 % 1.32 [ 0.66, 2.63 ]
Total events: 15 (UDCA), 11 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 UDCA versus placebo, Outcome 14 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 14 Meconium-stained liquor
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Glantz 2005 18/47 17/47 41.6 % 1.06 [ 0.63, 1.79 ]
Liu 2006 4/34 12/34 28.4 % 0.33 [ 0.12, 0.93 ]
PITCH 2012 5/56 13/56 30.0 % 0.38 [ 0.15, 1.01 ]
Total (95% CI) 137 137 100.0 % 0.56 [ 0.24, 1.30 ]
Total events: 27 (UDCA), 42 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 6.13, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 UDCA versus placebo, Outcome 15 Mean gestational age at birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 15 Mean gestational age at birth
Study or subgroup UDCA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diaferia 1996 8 38 (0.4) 8 34 (0.7) 41.8 % 4.00 [ 3.44, 4.56 ]
Palma 1997 8 37.8 (0.9) 7 33.8 (7.1) 16.9 % 4.00 [ -1.30, 9.30 ]
PITCH 2012 56 37.6 (1.9) 55 36.8 (2) 41.3 % 0.80 [ 0.07, 1.53 ]
Total (95% CI) 72 70 100.0 % 2.68 [ -0.13, 5.48 ]
Heterogeneity: Tau2 = 4.81; Chi2 = 47.07, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 UDCA versus placebo, Outcome 16 Spontaneous birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 16 Spontaneous birth at less than 37 weeks
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 8/47 7/47 81.5 % 1.14 [ 0.45, 2.90 ]
Palma 1997 0/8 1/7 18.5 % 0.30 [ 0.01, 6.29 ]
Total (95% CI) 55 54 100.0 % 0.99 [ 0.41, 2.36 ]
Total events: 8 (UDCA), 8 (Placebo)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 UDCA versus placebo, Outcome 17 Total preterm birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 17 Total preterm birth at less than 37 weeks
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liu 2006 4/34 13/34 33.1 % 0.31 [ 0.11, 0.85 ]
PITCH 2012 14/56 26/55 66.9 % 0.53 [ 0.31, 0.90 ]
Total (95% CI) 90 89 100.0 % 0.46 [ 0.28, 0.73 ]
Total events: 18 (UDCA), 39 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 UDCA versus placebo, Outcome 18 Admission to neonatal intensive care unit.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 1 UDCA versus placebo
Outcome: 18 Admission to neonatal intensive care unit
Study or subgroup UDCA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PITCH 2012 5/60 11/64 100.0 % 0.48 [ 0.18, 1.31 ]
Total (95% CI) 60 64 100.0 % 0.48 [ 0.18, 1.31 ]
Total events: 5 (UDCA), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 SAMe versus placebo, Outcome 1 Stillbirth/neonatal death.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 1 Stillbirth/neonatal death
Study or subgroup SAMe placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ribalta 1991 0/9 0/9 Not estimable
Total (95% CI) 9 9 Not estimable
Total events: 0 (SAMe), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 SAMe versus placebo, Outcome 2 Bile acid reduction, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 2 Bile acid reduction, mol/L
Study or subgroup SAMe placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 20 days
Nicastri 1998 8 20.1 (7.2) 8 2.6 (2.1) 100.0 % 17.50 [ 12.30, 22.70 ]
Total (95% CI) 8 8 100.0 % 17.50 [ 12.30, 22.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 SAMe versus placebo, Outcome 3 ALT reduction, IU/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 3 ALT reduction, IU/L
Study or subgroup SAMe placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 20 days
Nicastri 1998 8 149.7 (20.3) 8 10.1 (21.6) 100.0 % 139.60 [ 119.06, 160.14 ]
Total (95% CI) 8 8 100.0 % 139.60 [ 119.06, 160.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 SAMe versus placebo, Outcome 4 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 4 Caesarean section
Study or subgroup SAMe placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ribalta 1991 8/9 7/9 100.0 % 1.14 [ 0.75, 1.74 ]
Total (95% CI) 9 9 100.0 % 1.14 [ 0.75, 1.74 ]
Total events: 8 (SAMe), 7 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 SAMe versus placebo, Outcome 5 Spontaneous birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 5 Spontaneous birth at less than 37 weeks
Study or subgroup SAMe Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frezza 1990 2/15 5/15 100.0 % 0.40 [ 0.09, 1.75 ]
Total (95% CI) 15 15 100.0 % 0.40 [ 0.09, 1.75 ]
Total events: 2 (SAMe), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 SAMe versus placebo, Outcome 6 Total preterm birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 2 SAMe versus placebo
Outcome: 6 Total preterm birth at less than 37 weeks
Study or subgroup SAMe Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ribalta 1991 6/9 8/9 100.0 % 0.75 [ 0.45, 1.26 ]
Total (95% CI) 9 9 100.0 % 0.75 [ 0.45, 1.26 ]
Total events: 6 (SAMe), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Guar gum versus placebo, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 3 Guar gum versus placebo
Outcome: 1 Pruritus improvement
Study or subgroup guar gum placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participant assessed
Riikonen 2000 9/19 5/20 100.0 % 1.89 [ 0.77, 4.64 ]
Subtotal (95% CI) 19 20 100.0 % 1.89 [ 0.77, 4.64 ]
Total events: 9 (guar gum), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Clinician assessed
Riikonen 2000 6/19 5/20 100.0 % 1.26 [ 0.46, 3.46 ]
Subtotal (95% CI) 19 20 100.0 % 1.26 [ 0.46, 3.46 ]
Total events: 6 (guar gum), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
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Analysis 3.2. Comparison 3 Guar gum versus placebo, Outcome 2 Total bile acids (µmol/L).
Review: Interventions for treating cholestasis in pregnancy
Comparison: 3 Guar gum versus placebo
Outcome: 2 Total bile acids ( mol/L)
Study or subgroup Guar gum placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riikonen 2000 19 19.6 (24.41) 20 27 (29.07) 100.0 % -7.40 [ -24.22, 9.42 ]
Total (95% CI) 19 20 100.0 % -7.40 [ -24.22, 9.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Guar gum versus placebo, Outcome 3 ALT, U/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 3 Guar gum versus placebo
Outcome: 3 ALT, U/L
Study or subgroup guar gum placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riikonen 2000 19 156 (189.61) 20 193.5 (118.51) 100.0 % -37.50 [ -137.33, 62.33 ]
Total (95% CI) 19 20 100.0 % -37.50 [ -137.33, 62.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Guar gum versus placebo, Outcome 4 Adverse effects of medication.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 3 Guar gum versus placebo
Outcome: 4 Adverse effects of medication
Study or subgroup Guar gum placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Riikonen 2000 8/19 6/20 100.0 % 1.40 [ 0.60, 3.29 ]
Total (95% CI) 19 20 100.0 % 1.40 [ 0.60, 3.29 ]
Total events: 8 (Guar gum), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Guar gum versus placebo, Outcome 5 Mean gestational age at birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 3 Guar gum versus placebo
Outcome: 5 Mean gestational age at birth
Study or subgroup Guar gum placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riikonen 2000 19 38.4 (1.31) 20 38.3 (1.34) 100.0 % 0.10 [ -0.73, 0.93 ]
Total (95% CI) 19 20 100.0 % 0.10 [ -0.73, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Activated charcoal versus no treatment, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 4 Activated charcoal versus no treatment
Outcome: 1 Pruritus improvement
Study or subgroup Activated charcoal No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaaja 1994 4/10 0/10 100.0 % 9.00 [ 0.55, 147.95 ]
Total (95% CI) 10 10 100.0 % 9.00 [ 0.55, 147.95 ]
Total events: 4 (Activated charcoal), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Activated charcoal versus no treatment, Outcome 2 Bile acids after 8 days
treatment, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 4 Activated charcoal versus no treatment
Outcome: 2 Bile acids after 8 days treatment, mol/L
Study or subgroup Activated charcoal No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaaja 1994 10 33.9 (25.1) 10 79.1 (39.7) 100.0 % -45.20 [ -74.31, -16.09 ]
Total (95% CI) 10 10 100.0 % -45.20 [ -74.31, -16.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Activated charcoal versus no treatment, Outcome 3 ALT after 8 days
treatment, U/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 4 Activated charcoal versus no treatment
Outcome: 3 ALT after 8 days treatment, U/L
Study or subgroup Activated charcoal No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaaja 1994 10 314.3 (270.3) 10 239.7 (219.8) 100.0 % 74.60 [ -141.33, 290.53 ]
Total (95% CI) 10 10 100.0 % 74.60 [ -141.33, 290.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Activated charcoal versus no treatment, Outcome 4 Mean gestational age at
birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 4 Activated charcoal versus no treatment
Outcome: 4 Mean gestational age at birth
Study or subgroup Activated charcoal No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaaja 1994 10 35.4 (1.7) 10 36.4 (2.3) 100.0 % -1.00 [ -2.77, 0.77 ]
Total (95% CI) 10 10 100.0 % -1.00 [ -2.77, 0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Dexamethasone versus placebo, Outcome 1 Stillbirths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 1 Stillbirths
Study or subgroup Dexamethasone Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 0/36 1/47 100.0 % 0.43 [ 0.02, 10.31 ]
Total (95% CI) 36 47 100.0 % 0.43 [ 0.02, 10.31 ]
Total events: 0 (Dexamethasone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Dexamethasone versus placebo, Outcome 2 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 2 Fetal distress/asphyxial event
Study or subgroup Dexamethasone placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 4/36 2/47 100.0 % 2.61 [ 0.51, 13.47 ]
Total (95% CI) 36 47 100.0 % 2.61 [ 0.51, 13.47 ]
Total events: 4 (Dexamethasone), 2 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Dexamethasone versus placebo, Outcome 3 Subgroup analysis - fetal
distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 3 Subgroup analysis - fetal distress/asphyxial event
Study or subgroup Dexamethasone Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bile acid levels < 40 mol/L
Glantz 2005 3/25 1/36 45.0 % 4.32 [ 0.48, 39.18 ]
Subtotal (95% CI) 25 36 45.0 % 4.32 [ 0.48, 39.18 ]
Total events: 3 (Dexamethasone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 1/11 1/11 55.0 % 1.00 [ 0.07, 14.05 ]
Subtotal (95% CI) 11 11 55.0 % 1.00 [ 0.07, 14.05 ]
Total events: 1 (Dexamethasone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 36 47 100.0 % 2.50 [ 0.50, 12.33 ]
Total events: 4 (Dexamethasone), 2 (Placebo)
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.40), I2 =0.0%
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Analysis 5.4. Comparison 5 Dexamethasone versus placebo, Outcome 4 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 4 Meconium-stained liquor
Study or subgroup Dexamethasone placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any degree of ICP (all women)
Glantz 2005 13/36 17/47 100.0 % 1.00 [ 0.56, 1.78 ]
Subtotal (95% CI) 36 47 100.0 % 1.00 [ 0.56, 1.78 ]
Total events: 13 (Dexamethasone), 17 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 1.0)
2 Severe subgroup
Glantz 2005 5/11 6/11 100.0 % 0.83 [ 0.36, 1.94 ]
Subtotal (95% CI) 11 11 100.0 % 0.83 [ 0.36, 1.94 ]
Total events: 5 (Dexamethasone), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 5.5. Comparison 5 Dexamethasone versus placebo, Outcome 5 Spontaneous birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 5 Spontaneous birth at less than 37 weeks
Study or subgroup Dexamethasone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bile acid levels < 40 mol/L
Glantz 2005 6/25 2/36 47.0 % 4.32 [ 0.95, 19.69 ]
Subtotal (95% CI) 25 36 47.0 % 4.32 [ 0.95, 19.69 ]
Total events: 6 (Dexamethasone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 3/11 5/11 53.0 % 0.60 [ 0.19, 1.92 ]
Subtotal (95% CI) 11 11 53.0 % 0.60 [ 0.19, 1.92 ]
Total events: 3 (Dexamethasone), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 36 47 100.0 % 1.52 [ 0.21, 10.90 ]
Total events: 9 (Dexamethasone), 7 (Placebo)
Heterogeneity: Tau2 = 1.56; Chi2 = 4.28, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 4.10, df = 1 (P = 0.04), I2 =76%
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Analysis 5.6. Comparison 5 Dexamethasone versus placebo, Outcome 6 Total preterm births at less than
37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 5 Dexamethasone versus placebo
Outcome: 6 Total preterm births at less than 37 weeks
Study or subgroup Dexamethasone Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bile acid levels < 40 mol/L
Glantz 2005 7/25 4/36 47.5 % 2.52 [ 0.82, 7.70 ]
Subtotal (95% CI) 25 36 47.5 % 2.52 [ 0.82, 7.70 ]
Total events: 7 (Dexamethasone), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 4/11 7/11 52.5 % 0.57 [ 0.23, 1.41 ]
Subtotal (95% CI) 11 11 52.5 % 0.57 [ 0.23, 1.41 ]
Total events: 4 (Dexamethasone), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 36 47 100.0 % 1.16 [ 0.26, 5.10 ]
Total events: 11 (Dexamethasone), 11 (Placebo)
Heterogeneity: Tau2 = 0.88; Chi2 = 4.29, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 4.11, df = 1 (P = 0.04), I2 =76%
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Analysis 6.1. Comparison 6 UDCA versus SAMe, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 1 Pruritus improvement
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any improvement
Binder 2006 21/26 15/25 49.6 % 1.35 [ 0.93, 1.95 ]
Floreani 1996 3/10 2/10 6.5 % 1.50 [ 0.32, 7.14 ]
Roncaglia 2004 14/24 13/22 44.0 % 0.99 [ 0.61, 1.60 ]
Subtotal (95% CI) 60 57 100.0 % 1.20 [ 0.89, 1.61 ]
Total events: 38 (UDCA), 30 (SAMe)
Heterogeneity: Chi2 = 1.07, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Marked improvement
Binder 2006 18/26 10/25 100.0 % 1.73 [ 1.00, 2.98 ]
Subtotal (95% CI) 26 25 100.0 % 1.73 [ 1.00, 2.98 ]
Total events: 18 (UDCA), 10 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
3 Complete resolution
Floreani 1996 3/10 0/10 100.0 % 7.00 [ 0.41, 120.16 ]
Subtotal (95% CI) 10 10 100.0 % 7.00 [ 0.41, 120.16 ]
Total events: 3 (UDCA), 0 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
4 Complete resolution or marked improvement
Binder 2006 18/26 10/25 95.3 % 1.73 [ 1.00, 2.98 ]
Floreani 1996 3/10 0/10 4.7 % 7.00 [ 0.41, 120.16 ]
Subtotal (95% CI) 36 35 100.0 % 1.98 [ 1.15, 3.41 ]
Total events: 21 (UDCA), 10 (SAMe)
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 4.38, df = 3 (P = 0.22), I2 =32%
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Analysis 6.2. Comparison 6 UDCA versus SAMe, Outcome 2 Fetal distress/asphyxial events.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 2 Fetal distress/asphyxial events
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/26 3/25 74.6 % 0.64 [ 0.12, 3.52 ]
Floreani 1996 0/10 0/10 Not estimable
Roncaglia 2004 2/24 1/22 25.4 % 1.83 [ 0.18, 18.84 ]
Total (95% CI) 60 57 100.0 % 0.94 [ 0.25, 3.58 ]
Total events: 4 (UDCA), 4 (SAMe)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 UDCA versus SAMe, Outcome 3 Bile acids, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 3 Bile acids, mol/L
Study or subgroup UDCA SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 26 18 (28.25) 25 45 (32.25) 100.0 % -27.00 [ -43.67, -10.33 ]
Subtotal (95% CI) 26 25 100.0 % -27.00 [ -43.67, -10.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
2 Reduction after 20 days
Nicastri 1998 8 33 (10) 8 20.1 (7.2) 100.0 % 12.90 [ 4.36, 21.44 ]
Subtotal (95% CI) 8 8 100.0 % 12.90 [ 4.36, 21.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.0031)
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Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 4 ALT, kat/L
Study or subgroup UDCA SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 26 1.7 (2.22) 25 3.9 (2.68) 100.0 % -2.20 [ -3.55, -0.85 ]
Total (95% CI) 26 25 100.0 % -2.20 [ -3.55, -0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 UDCA versus SAMe, Outcome 5 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 5 Caesarean section
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 4/26 5/25 31.3 % 0.77 [ 0.23, 2.54 ]
Floreani 1996 6/10 7/10 43.0 % 0.86 [ 0.45, 1.64 ]
Roncaglia 2004 5/24 4/22 25.7 % 1.15 [ 0.35, 3.73 ]
Total (95% CI) 60 57 100.0 % 0.90 [ 0.52, 1.58 ]
Total events: 15 (UDCA), 16 (SAMe)
Heterogeneity: Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 UDCA versus SAMe, Outcome 6 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 6 Meconium-stained liquor
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 3/26 5/25 49.4 % 0.58 [ 0.15, 2.16 ]
Roncaglia 2004 2/24 5/22 50.6 % 0.37 [ 0.08, 1.70 ]
Total (95% CI) 50 47 100.0 % 0.47 [ 0.17, 1.27 ]
Total events: 5 (UDCA), 10 (SAMe)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
UDCA SAMe
Analysis 6.7. Comparison 6 UDCA versus SAMe, Outcome 7 Mean gestational age at birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 7 Mean gestational age at birth
Study or subgroup UDCA SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Floreani 1996 10 36 (1.82) 10 36.8 (1.93) 23.6 % -0.80 [ -2.44, 0.84 ]
Roncaglia 2004 24 36.4 (1.3) 22 36.2 (1.8) 76.4 % 0.20 [ -0.71, 1.11 ]
Total (95% CI) 34 32 100.0 % -0.04 [ -0.84, 0.76 ]
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 UDCA versus SAMe, Outcome 8 Spontaneus birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 8 Spontaneus birth at less than 37 weeks
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nicastri 1998 2/8 3/8 36.5 % 0.67 [ 0.15, 2.98 ]
Roncaglia 2004 3/24 5/22 63.5 % 0.55 [ 0.15, 2.04 ]
Total (95% CI) 32 30 100.0 % 0.59 [ 0.22, 1.59 ]
Total events: 5 (UDCA), 8 (SAMe)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 UDCA versus SAMe, Outcome 9 Total preterm birth at less than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 9 Total preterm birth at less than 37 weeks
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 4/26 7/25 64.1 % 0.55 [ 0.18, 1.65 ]
Floreani 1996 4/10 4/10 35.9 % 1.00 [ 0.34, 2.93 ]
Total (95% CI) 36 35 100.0 % 0.71 [ 0.33, 1.54 ]
Total events: 8 (UDCA), 11 (SAMe)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 UDCA versus SAMe, Outcome 10 Admission to neonatal intensive care unit.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 6 UDCA versus SAMe
Outcome: 10 Admission to neonatal intensive care unit
Study or subgroup UDCA SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 3/26 4/25 35.8 % 0.72 [ 0.18, 2.90 ]
Roncaglia 2004 3/24 7/22 64.2 % 0.39 [ 0.12, 1.33 ]
Total (95% CI) 50 47 100.0 % 0.51 [ 0.21, 1.27 ]
Total events: 6 (UDCA), 11 (SAMe)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 UDCA versus dexamethasone, Outcome 1 Fetal distress/asphyxial events.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 7 UDCA versus dexamethasone
Outcome: 1 Fetal distress/asphyxial events
Study or subgroup UDCA Dexamethasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bile acid levels < 40 mol/L
Glantz 2005 2/35 4/25 74.9 % 0.36 [ 0.07, 1.80 ]
Subtotal (95% CI) 35 25 74.9 % 0.36 [ 0.07, 1.80 ]
Total events: 2 (UDCA), 4 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 0/12 1/11 25.1 % 0.31 [ 0.01, 6.85 ]
Subtotal (95% CI) 12 11 25.1 % 0.31 [ 0.01, 6.85 ]
Total events: 0 (UDCA), 1 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 47 36 100.0 % 0.34 [ 0.08, 1.45 ]
Total events: 2 (UDCA), 5 (Dexamethasone)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 7.2. Comparison 7 UDCA versus dexamethasone, Outcome 2 Adverse effects of medication.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 7 UDCA versus dexamethasone
Outcome: 2 Adverse effects of medication
Study or subgroup UDCA Dexamethasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 1/47 1/36 100.0 % 0.77 [ 0.05, 11.83 ]
Total (95% CI) 47 36 100.0 % 0.77 [ 0.05, 11.83 ]
Total events: 1 (UDCA), 1 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 UDCA versus dexamethasone, Outcome 3 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 7 UDCA versus dexamethasone
Outcome: 3 Meconium-stained liquor
Study or subgroup UDCA Dexamethasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 18/47 13/36 100.0 % 1.06 [ 0.60, 1.87 ]
Total (95% CI) 47 36 100.0 % 1.06 [ 0.60, 1.87 ]
Total events: 18 (UDCA), 13 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 UDCA versus dexamethasone, Outcome 4 Spontaneous birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 7 UDCA versus dexamethasone
Outcome: 4 Spontaneous birth at less than 37 weeks
Study or subgroup UDCA Dexamethasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Glantz 2005 8/47 9/36 100.0 % 0.68 [ 0.29, 1.59 ]
Total (95% CI) 47 36 100.0 % 0.68 [ 0.29, 1.59 ]
Total events: 8 (UDCA), 9 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours UDCA Favours dexamethasone
105Interventions for treating cholestasis in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.5. Comparison 7 UDCA versus dexamethasone, Outcome 5 Total preterm birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 7 UDCA versus dexamethasone
Outcome: 5 Total preterm birth at less than 37 weeks
Study or subgroup UDCA Dexamethasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bile acid levels < 40 mol/L
Glantz 2005 6/35 7/25 66.2 % 0.61 [ 0.23, 1.60 ]
Subtotal (95% CI) 35 25 66.2 % 0.61 [ 0.23, 1.60 ]
Total events: 6 (UDCA), 7 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 Bile acid levels ≥ 40 mol/L
Glantz 2005 6/12 4/11 33.8 % 1.38 [ 0.52, 3.61 ]
Subtotal (95% CI) 12 11 33.8 % 1.38 [ 0.52, 3.61 ]
Total events: 6 (UDCA), 4 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Total (95% CI) 47 36 100.0 % 0.87 [ 0.44, 1.71 ]
Total events: 12 (UDCA), 11 (Dexamethasone)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 1.35, df = 1 (P = 0.24), I2 =26%
0.02 0.1 1 10 50
Favours UDCA Favours Dexamethasone
106Interventions for treating cholestasis in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.1. Comparison 8 UDCA versus cholestyramine, Outcome 1 Pruritus score (> 50% reduction
after 14 days treatment).
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 1 Pruritus score (> 50% reduction after 14 days treatment)
Study or subgroup UDCA Cholestyramine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondrackiene 2005 28/42 8/42 100.0 % 3.50 [ 1.81, 6.77 ]
Total (95% CI) 42 42 100.0 % 3.50 [ 1.81, 6.77 ]
Total events: 28 (UDCA), 8 (Cholestyramine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00020)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Cholestyramine Favours UDCA
Analysis 8.2. Comparison 8 UDCA versus cholestyramine, Outcome 2 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 2 Fetal distress/asphyxial event
Study or subgroup UDCA cholestyramine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondrackiene 2005 1/42 1/42 100.0 % 1.00 [ 0.06, 15.47 ]
Total (95% CI) 42 42 100.0 % 1.00 [ 0.06, 15.47 ]
Total events: 1 (UDCA), 1 (cholestyramine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 UDCA versus cholestyramine, Outcome 3 Bile acids, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 3 Bile acids, mol/L
Study or subgroup UDCA cholestyramine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kondrackiene 2005 42 24.4 (29.2) 42 26.2 (23.3) 100.0 % -1.80 [ -13.10, 9.50 ]
Total (95% CI) 42 42 100.0 % -1.80 [ -13.10, 9.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 UDCA versus cholestyramine, Outcome 4 ALT, U/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 4 ALT, U/L
Study or subgroup UDCA cholestyramine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kondrackiene 2005 42 78.2 (57.4) 42 222.4 (128) 100.0 % -144.20 [ -186.63, -101.77 ]
Total (95% CI) 42 42 100.0 % -144.20 [ -186.63, -101.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 UDCA versus cholestyramine, Outcome 5 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 5 Caesarean section
Study or subgroup UDCA Cholestyramine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondrackiene 2005 7/42 3/42 100.0 % 2.33 [ 0.65, 8.42 ]
Total (95% CI) 42 42 100.0 % 2.33 [ 0.65, 8.42 ]
Total events: 7 (UDCA), 3 (Cholestyramine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 UDCA versus cholestyramine, Outcome 6 Adverse effects of medication.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 6 Adverse effects of medication
Study or subgroup UDCA Cholestyramine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondrackiene 2005 0/42 12/42 100.0 % 0.04 [ 0.00, 0.65 ]
Total (95% CI) 42 42 100.0 % 0.04 [ 0.00, 0.65 ]
Total events: 0 (UDCA), 12 (Cholestyramine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 UDCA versus cholestyramine, Outcome 7 Mean gestational age at birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 7 Mean gestational age at birth
Study or subgroup UDCA Cholestyramine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kondrackiene 2005 42 37.4 (1.5) 42 38.7 (1.7) 100.0 % -1.30 [ -1.99, -0.61 ]
Total (95% CI) 42 42 100.0 % -1.30 [ -1.99, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 UDCA versus cholestyramine, Outcome 8 Total preterm birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 8 UDCA versus cholestyramine
Outcome: 8 Total preterm birth at less than 37 weeks
Study or subgroup UDCA Cholestyramine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondrackiene 2005 3/42 5/42 100.0 % 0.60 [ 0.15, 2.35 ]
Total (95% CI) 42 42 100.0 % 0.60 [ 0.15, 2.35 ]
Total events: 3 (UDCA), 5 (Cholestyramine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 UDCA + SAMe versus placebo, Outcome 1 Bile acid reduction at 20 days,
µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 9 UDCA + SAMe versus placebo
Outcome: 1 Bile acid reduction at 20 days, mol/L
Study or subgroup UDCA+SAMe Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nicastri 1998 8 44.3 (8.6) 8 2.6 (2.1) 100.0 % 41.70 [ 35.57, 47.83 ]
Total (95% CI) 8 8 100.0 % 41.70 [ 35.57, 47.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 UDCA + SAMe versus SAMe, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 1 Pruritus improvement
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any improvement
Binder 2006 23/27 15/25 100.0 % 1.42 [ 0.99, 2.03 ]
Subtotal (95% CI) 27 25 100.0 % 1.42 [ 0.99, 2.03 ]
Total events: 23 (UDCA + SAMe), 15 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 Marked improvement
Binder 2006 20/27 10/25 100.0 % 1.85 [ 1.09, 3.14 ]
Subtotal (95% CI) 27 25 100.0 % 1.85 [ 1.09, 3.14 ]
Total events: 20 (UDCA + SAMe), 10 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 10.2. Comparison 10 UDCA + SAMe versus SAMe, Outcome 2 Stillbirths/neonatal deaths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 2 Stillbirths/neonatal deaths
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 0/27 0/25 Not estimable
Zhang 2012 0/41 0/38 Not estimable
Total (95% CI) 68 63 Not estimable
Total events: 0 (UDCA + SAMe), 0 (SAMe)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 UDCA + SAMe versus SAMe, Outcome 3 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 3 Fetal distress/asphyxial event
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 1/27 3/25 100.0 % 0.31 [ 0.03, 2.78 ]
Total (95% CI) 27 25 100.0 % 0.31 [ 0.03, 2.78 ]
Total events: 1 (UDCA + SAMe), 3 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 UDCA + SAMe versus SAMe, Outcome 4 Bile acids, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 4 Bile acids, mol/L
Study or subgroup UDCA + SAMe SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 27 20 (22.18) 25 45 (32.25) 100.0 % -25.00 [ -40.16, -9.84 ]
Subtotal (95% CI) 27 25 100.0 % -25.00 [ -40.16, -9.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0012)
2 Reduction at 20 days
Nicastri 1998 8 44.3 (8.6) 8 20.1 (7.2) 100.0 % 24.20 [ 16.43, 31.97 ]
Subtotal (95% CI) 8 8 100.0 % 24.20 [ 16.43, 31.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.10 (P < 0.00001)
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Analysis 10.5. Comparison 10 UDCA + SAMe versus SAMe, Outcome 5 ALT, µkatl/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 5 ALT, katl/L
Study or subgroup UDCA + SAMe SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 27 1.5 (1.46) 25 3.9 (2.68) 100.0 % -2.40 [ -3.59, -1.21 ]
Total (95% CI) 27 25 100.0 % -2.40 [ -3.59, -1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000073)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 UDCA + SAMe versus SAMe, Outcome 6 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 6 Caesarean section
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 5/25 100.0 % 0.37 [ 0.08, 1.74 ]
Total (95% CI) 27 25 100.0 % 0.37 [ 0.08, 1.74 ]
Total events: 2 (UDCA + SAMe), 5 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 UDCA + SAMe versus SAMe, Outcome 7 Postpartum haemorrhage.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 7 Postpartum haemorrhage
Study or subgroup UDCA + SAMe SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Binder 2006 27 296 (151) 25 295 (135) 100.0 % 1.00 [ -76.75, 78.75 ]
Total (95% CI) 27 25 100.0 % 1.00 [ -76.75, 78.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 10.8. Comparison 10 UDCA + SAMe versus SAMe, Outcome 8 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 8 Meconium-stained liquor
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 4/25 100.0 % 0.46 [ 0.09, 2.31 ]
Total (95% CI) 27 25 100.0 % 0.46 [ 0.09, 2.31 ]
Total events: 2 (UDCA + SAMe), 4 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 10.9. Comparison 10 UDCA + SAMe versus SAMe, Outcome 9 Spontaneous birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 9 Spontaneous birth at less than 37 weeks
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nicastri 1998 1/8 3/8 100.0 % 0.33 [ 0.04, 2.56 ]
Total (95% CI) 8 8 100.0 % 0.33 [ 0.04, 2.56 ]
Total events: 1 (UDCA + SAMe), 3 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 10.10. Comparison 10 UDCA + SAMe versus SAMe, Outcome 10 Total preterm birth at less than
37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 10 Total preterm birth at less than 37 weeks
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 4/27 7/25 100.0 % 0.53 [ 0.18, 1.59 ]
Total (95% CI) 27 25 100.0 % 0.53 [ 0.18, 1.59 ]
Total events: 4 (UDCA + SAMe), 7 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 10.11. Comparison 10 UDCA + SAMe versus SAMe, Outcome 11 Admission to neonatal intensive
care unit.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 10 UDCA + SAMe versus SAMe
Outcome: 11 Admission to neonatal intensive care unit
Study or subgroup UDCA + SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 4/25 100.0 % 0.46 [ 0.09, 2.31 ]
Total (95% CI) 27 25 100.0 % 0.46 [ 0.09, 2.31 ]
Total events: 2 (UDCA + SAMe), 4 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 UDCA + SAMe versus UDCA, Outcome 1 Pruritus improvement.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 1 Pruritus improvement
Study or subgroup UDCA + SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any improvement
Binder 2006 23/27 21/26 100.0 % 1.05 [ 0.83, 1.35 ]
Subtotal (95% CI) 27 26 100.0 % 1.05 [ 0.83, 1.35 ]
Total events: 23 (UDCA + SAMe), 21 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Marked improvement
Binder 2006 20/27 18/26 100.0 % 1.07 [ 0.76, 1.50 ]
Subtotal (95% CI) 27 26 100.0 % 1.07 [ 0.76, 1.50 ]
Total events: 20 (UDCA + SAMe), 18 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 11.2. Comparison 11 UDCA + SAMe versus UDCA, Outcome 2 Stillbirths/neonatal deaths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 2 Stillbirths/neonatal deaths
Study or subgroup UDCA + SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 0/27 0/26 Not estimable
Zhang 2012 0/41 0/41 Not estimable
Total (95% CI) 68 67 Not estimable
Total events: 0 (UDCA + SAMe), 0 (UDCA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 UDCA + SAMe versus UDCA, Outcome 3 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 3 Fetal distress/asphyxial event
Study or subgroup UDCA + SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 1/27 2/26 100.0 % 0.48 [ 0.05, 4.99 ]
Total (95% CI) 27 26 100.0 % 0.48 [ 0.05, 4.99 ]
Total events: 1 (UDCA + SAMe), 2 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 UDCA + SAMe versus UDCA, Outcome 4 Bile acids, µmol/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 4 Bile acids, mol/L
Study or subgroup UDCA + SAMe UDCA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 27 20 (22.18) 26 18 (28.25) 100.0 % 2.00 [ -11.71, 15.71 ]
Subtotal (95% CI) 27 26 100.0 % 2.00 [ -11.71, 15.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
2 Reduction at 20 days
Nicastri 1998 8 44.3 (8.6) 8 33 (10) 100.0 % 11.30 [ 2.16, 20.44 ]
Subtotal (95% CI) 8 8 100.0 % 11.30 [ 2.16, 20.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.015)
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Analysis 11.5. Comparison 11 UDCA + SAMe versus UDCA, Outcome 5 ALT, µkatl/L.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 5 ALT, katl/L
Study or subgroup UDCA + SAMe UDCA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 After 3-4 weeks treatment
Binder 2006 27 1.5 (1.46) 25 3.9 (2.68) 100.0 % -2.40 [ -3.59, -1.21 ]
Total (95% CI) 27 25 100.0 % -2.40 [ -3.59, -1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000073)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 UDCA + SAMe versus UDCA, Outcome 6 Reduction in ALT (IU/L) after
treatment.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 6 Reduction in ALT (IU/L) after treatment
Study or subgroup UDCA+SAMe UDCA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Luo 2008 34 2.1 (0.31) 30 0.82 (0.21) 100.0 % 1.28 [ 1.15, 1.41 ]
Total (95% CI) 34 30 100.0 % 1.28 [ 1.15, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 19.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 UDCA + SAMe versus UDCA, Outcome 7 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 7 Caesarean section
Study or subgroup UDCA + SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 5/25 23.4 % 0.37 [ 0.08, 1.74 ]
Luo 2008 12/34 16/30 76.6 % 0.66 [ 0.38, 1.16 ]
Total (95% CI) 61 55 100.0 % 0.59 [ 0.35, 1.02 ]
Total events: 14 (UDCA + SAMe), 21 (UDCA)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 11.8. Comparison 11 UDCA + SAMe versus UDCA, Outcome 8 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 8 Meconium-stained liquor
Study or subgroup
Favours
UDCA +
SAMe SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 3/26 100.0 % 0.64 [ 0.12, 3.54 ]
Total (95% CI) 27 26 100.0 % 0.64 [ 0.12, 3.54 ]
Total events: 2 (Favours UDCA + SAMe), 3 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 11.9. Comparison 11 UDCA + SAMe versus UDCA, Outcome 9 Spontaneous birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 9 Spontaneous birth at less than 37 weeks
Study or subgroup
Favours
UDCA +
SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nicastri 1998 1/8 2/8 100.0 % 0.50 [ 0.06, 4.47 ]
Total (95% CI) 8 8 100.0 % 0.50 [ 0.06, 4.47 ]
Total events: 1 (Favours UDCA + SAMe), 2 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 11.10. Comparison 11 UDCA + SAMe versus UDCA, Outcome 10 Total preterm births at less
than 37 weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 10 Total preterm births at less than 37 weeks
Study or subgroup UDCA+SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Luo 2008 7/34 9/30 100.0 % 0.69 [ 0.29, 1.62 ]
Total (95% CI) 34 30 100.0 % 0.69 [ 0.29, 1.62 ]
Total events: 7 (UDCA+SAMe), 9 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 11.11. Comparison 11 UDCA + SAMe versus UDCA, Outcome 11 Admission to neonatal intensive
care unit.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 11 UDCA + SAMe versus UDCA
Outcome: 11 Admission to neonatal intensive care unit
Study or subgroup UDCA + SAMe UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Binder 2006 2/27 3/26 100.0 % 0.64 [ 0.12, 3.54 ]
Total (95% CI) 27 26 100.0 % 0.64 [ 0.12, 3.54 ]
Total events: 2 (UDCA + SAMe), 3 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours UDCA + SAMe Favours UDCA
Analysis 12.1. Comparison 12 UDCA + Salvia versus UDCA, Outcome 1 Reduction in pruritus from
moderate/severe to mild (0-4 scale).
Review: Interventions for treating cholestasis in pregnancy
Comparison: 12 UDCA + Salvia versus UDCA
Outcome: 1 Reduction in pruritus from moderate/severe to mild (0-4 scale)
Study or subgroup UDCA + Salvia UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fang 2009 58/72 43/56 100.0 % 1.05 [ 0.87, 1.26 ]
Total (95% CI) 72 56 100.0 % 1.05 [ 0.87, 1.26 ]
Total events: 58 (UDCA + Salvia), 43 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Salvia + UDCA Favours UDCA
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Analysis 12.2. Comparison 12 UDCA + Salvia versus UDCA, Outcome 2 Caesarean section for fetal distress.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 12 UDCA + Salvia versus UDCA
Outcome: 2 Caesarean section for fetal distress
Study or subgroup UDCA + Salvia UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fang 2009 13/72 11/56 100.0 % 0.92 [ 0.45, 1.89 ]
Total (95% CI) 72 56 100.0 % 0.92 [ 0.45, 1.89 ]
Total events: 13 (UDCA + Salvia), 11 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Salvia + UDCA Favours UDCA
Analysis 12.3. Comparison 12 UDCA + Salvia versus UDCA, Outcome 3 Reduction in ALT (IU/L) after
treatment.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 12 UDCA + Salvia versus UDCA
Outcome: 3 Reduction in ALT (IU/L) after treatment
Study or subgroup UDCA + Salvia UDCA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fang 2009 72 78.7 (25.3) 56 93.6 (28.7) 100.0 % -14.90 [ -24.42, -5.38 ]
Total (95% CI) 72 56 100.0 % -14.90 [ -24.42, -5.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Salvia + UDCA Favours UDCA
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Analysis 12.4. Comparison 12 UDCA + Salvia versus UDCA, Outcome 4 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 12 UDCA + Salvia versus UDCA
Outcome: 4 Meconium-stained liquor
Study or subgroup UDCA + Salvia UDCA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fang 2009 10/72 9/56 100.0 % 0.86 [ 0.38, 1.98 ]
Total (95% CI) 72 56 100.0 % 0.86 [ 0.38, 1.98 ]
Total events: 10 (UDCA + Salvia), 9 (UDCA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Salvia + UDCA Favours UDCA
Analysis 13.1. Comparison 13 YCHD versus SAMe, Outcome 1 Degree of pruritus after treatment.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 1 Degree of pruritus after treatment
Study or subgroup YCHD SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Marked improvement
Huang 2004 28/35 20/25 100.0 % 1.00 [ 0.77, 1.29 ]
Total (95% CI) 35 25 100.0 % 1.00 [ 0.77, 1.29 ]
Total events: 28 (YCHD), 20 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours YCHD Favours SAMe
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Analysis 13.2. Comparison 13 YCHD versus SAMe, Outcome 2 Stillbirths/neonatal deaths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 2 Stillbirths/neonatal deaths
Study or subgroup YCHD SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huang 2004 0/35 0/25 Not estimable
Total (95% CI) 35 25 Not estimable
Total events: 0 (YCHD), 0 (SAMe)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours YCHD Favours SAMe
Analysis 13.3. Comparison 13 YCHD versus SAMe, Outcome 3 Fetal distress/asphyxial event.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 3 Fetal distress/asphyxial event
Study or subgroup YCHD SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huang 2004 6/35 5/25 100.0 % 0.86 [ 0.29, 2.50 ]
Total (95% CI) 35 25 100.0 % 0.86 [ 0.29, 2.50 ]
Total events: 6 (YCHD), 5 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours YCHD Favours SAMe
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Analysis 13.4. Comparison 13 YCHD versus SAMe, Outcome 4 Bile salt (CGA) levels.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 4 Bile salt (CGA) levels
Study or subgroup YCHD SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huang 2004 35 21.6 (9.8) 25 23.1 (8.4) 100.0 % -1.50 [ -6.12, 3.12 ]
Total (95% CI) 35 25 100.0 % -1.50 [ -6.12, 3.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours YCHD Favours SAMe
Analysis 13.5. Comparison 13 YCHD versus SAMe, Outcome 5 ALT.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 5 ALT
Study or subgroup YCHD SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huang 2004 35 92.1 (32.5) 25 88.7 (29.4) 100.0 % 3.40 [ -12.37, 19.17 ]
Total (95% CI) 35 25 100.0 % 3.40 [ -12.37, 19.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours YCHD Favours SAMe
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Analysis 13.6. Comparison 13 YCHD versus SAMe, Outcome 6 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 6 Caesarean section
Study or subgroup YCHD SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huang 2004 17/35 13/25 100.0 % 0.93 [ 0.56, 1.55 ]
Total (95% CI) 35 25 100.0 % 0.93 [ 0.56, 1.55 ]
Total events: 17 (YCHD), 13 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours YCHD Favours SAMe
Analysis 13.7. Comparison 13 YCHD versus SAMe, Outcome 7 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 7 Meconium-stained liquor
Study or subgroup YCHD SAMe Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huang 2004 6/35 5/25 100.0 % 0.86 [ 0.29, 2.50 ]
Total (95% CI) 35 25 100.0 % 0.86 [ 0.29, 2.50 ]
Total events: 6 (YCHD), 5 (SAMe)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours YCHD Favours SAMe
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Analysis 13.8. Comparison 13 YCHD versus SAMe, Outcome 8 Mean gestational age at birth.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 13 YCHD versus SAMe
Outcome: 8 Mean gestational age at birth
Study or subgroup YCHD SAMe
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huang 2004 35 38.1 (1.6) 25 37.4 (2.3) 100.0 % 0.70 [ -0.35, 1.75 ]
Total (95% CI) 35 25 100.0 % 0.70 [ -0.35, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours YCHD Favours SAMe
Analysis 14.1. Comparison 14 Danxiaoling versus Yiganling, Outcome 1 Pruritus.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 1 Pruritus
Study or subgroup Danxiaoling Yiganling Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any improvement after treatment
Shi 2002 29/29 29/29 100.0 % 1.00 [ 0.94, 1.07 ]
Subtotal (95% CI) 29 29 100.0 % 1.00 [ 0.94, 1.07 ]
Total events: 29 (Danxiaoling), 29 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Marked improvement after treatment
Shi 2002 25/29 15/29 100.0 % 1.67 [ 1.14, 2.44 ]
Subtotal (95% CI) 29 29 100.0 % 1.67 [ 1.14, 2.44 ]
Total events: 25 (Danxiaoling), 15 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0085)
0.5 0.7 1 1.5 2
Favours Yiganling Favours Danxiaoling
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Analysis 14.2. Comparison 14 Danxiaoling versus Yiganling, Outcome 2 Stillbirths/neonatal deaths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 2 Stillbirths/neonatal deaths
Study or subgroup Danxiaoling Yiganling Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shi 2002 0/29 0/29 Not estimable
Total (95% CI) 29 29 Not estimable
Total events: 0 (Danxiaoling), 0 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Danxiaoling Favours Yiganling
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Analysis 14.3. Comparison 14 Danxiaoling versus Yiganling, Outcome 3 Bile acid levels (CGA).
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 3 Bile acid levels (CGA)
Study or subgroup Danxiaoling Yiganling
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shi 2002 29 34.03 (36.98) 29 37.86 (35.92) 100.0 % -3.83 [ -22.59, 14.93 ]
Total (95% CI) 29 29 100.0 % -3.83 [ -22.59, 14.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Danxiaoling Favours Yiganling
Analysis 14.4. Comparison 14 Danxiaoling versus Yiganling, Outcome 4 ALT.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 4 ALT
Study or subgroup Danxiaoling Yiganling
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shi 2002 25 94.1 (77.3) 29 88.9 (80.3) 100.0 % 5.20 [ -36.90, 47.30 ]
Total (95% CI) 25 29 100.0 % 5.20 [ -36.90, 47.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Danxiaoling Favours Yiganling
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Analysis 14.5. Comparison 14 Danxiaoling versus Yiganling, Outcome 5 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 5 Caesarean section
Study or subgroup Danxiaoling Yiganling Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shi 2002 3/29 5/29 100.0 % 0.60 [ 0.16, 2.28 ]
Total (95% CI) 29 29 100.0 % 0.60 [ 0.16, 2.28 ]
Total events: 3 (Danxiaoling), 5 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Danxiaoling Favours Yiganling
Analysis 14.6. Comparison 14 Danxiaoling versus Yiganling, Outcome 6 Meconium-stained liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 6 Meconium-stained liquor
Study or subgroup Danxiaoling Yiganling Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shi 2002 6/29 15/29 100.0 % 0.40 [ 0.18, 0.89 ]
Total (95% CI) 29 29 100.0 % 0.40 [ 0.18, 0.89 ]
Total events: 6 (Danxiaoling), 15 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Danxiaoling Favours Yiganling
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Analysis 14.7. Comparison 14 Danxiaoling versus Yiganling, Outcome 7 Spontaneous birth at less than 37
weeks.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 14 Danxiaoling versus Yiganling
Outcome: 7 Spontaneous birth at less than 37 weeks
Study or subgroup Danxiaoling Yiganling Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shi 2002 1/29 3/29 100.0 % 0.33 [ 0.04, 3.02 ]
Total (95% CI) 29 29 100.0 % 0.33 [ 0.04, 3.02 ]
Total events: 1 (Danxiaoling), 3 (Yiganling)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Danxiaoling Favours Yiganling
Analysis 15.1. Comparison 15 Early term delivery v expectant management, Outcome 1
Stillbirths/neonatal deaths.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 15 Early term delivery v expectant management
Outcome: 1 Stillbirths/neonatal deaths
Study or subgroup Early term delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PITCH 2012 0/30 0/33 Not estimable
Total (95% CI) 30 33 Not estimable
Total events: 0 (Early term delivery), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early term del. Favours expectant del.
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Analysis 15.2. Comparison 15 Early term delivery v expectant management, Outcome 2 Caesarean section.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 15 Early term delivery v expectant management
Outcome: 2 Caesarean section
Study or subgroup Early term delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PITCH 2012 7/30 11/32 100.0 % 0.68 [ 0.30, 1.52 ]
Total (95% CI) 30 32 100.0 % 0.68 [ 0.30, 1.52 ]
Total events: 7 (Early term delivery), 11 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early term del. Favours expectant del.
Analysis 15.3. Comparison 15 Early term delivery v expectant management, Outcome 3 Meconium-stained
liquor.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 15 Early term delivery v expectant management
Outcome: 3 Meconium-stained liquor
Study or subgroup Early term delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PITCH 2012 3/30 6/33 100.0 % 0.55 [ 0.15, 2.01 ]
Total (95% CI) 30 33 100.0 % 0.55 [ 0.15, 2.01 ]
Total events: 3 (Early term delivery), 6 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early term del. Favours expectant del.
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Analysis 15.4. Comparison 15 Early term delivery v expectant management, Outcome 4 Admission to
neonatal intensive care unit.
Review: Interventions for treating cholestasis in pregnancy
Comparison: 15 Early term delivery v expectant management
Outcome: 4 Admission to neonatal intensive care unit
Study or subgroup Early term delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PITCH 2012 1/30 2/33 100.0 % 0.55 [ 0.05, 5.76 ]
Total (95% CI) 30 33 100.0 % 0.55 [ 0.05, 5.76 ]
Total events: 1 (Early term delivery), 2 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early term del. Favours expectant del.
A P P E N D I C E S
Appendix 1. Methods used to assess trials included in previous versions of this review
Data collection and analysis
Three reviewers (R Burrows, O Clavisi, E Burrows) independently searched for, assessed and selected trials for inclusion in this review.
The decision to include trials was made without knowledge of authors, institutional affiliations, journal of publication and results. Any
disagreements about inclusion of studies were resolved through discussion.
Two reviewers (O Clavisi, E Burrows) independently appraised included trials for their methodological quality using the validity criteria
for intervention studies developed by Sackett et al (Sackett 2000). Individual appraisals were then compared and agreement reached.
The validity criteria used are:
1. adequate method of randomisation (e.g. random number tables);
2. concealment of allocation (e.g. opaque envelopes);
3. blinding of study participants, caregivers and assessors;
4. inclusion of all randomised patients in the analysis of results;
5. adequate follow-up of study participants (> 80%);
6. study patients have similar prognostic factors at the start of the trial;
7. study patients treated equally during the trial.
If any of this information was unavailable in the publication, we contacted the authors. However, no additional information was
obtained.
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F E E D B A C K
Gludd, July 2007
Summary
Could you explain why you chose to exclude trials published in abstract form only. Due to publication bias, trials are more likely to be
published if they report statistically significant results. Excluding abstracts may therefore lead to an overestimate of treatment effects.
(Summary of comment from Lise Lotte Gluud, July 2007)
Reply
This review has been recently updated by a new review team and we have now included a randomised controlled trial published in
abstract form (Leino 1998). However, it was not reported in a way that enabled the results to be included in RevMan 2012 and so is
included in the text of the UCDA versus placebo results.
Contributors
Feedback: Lise Lotte Gluud
Reply to feedback: Vinita Gurung, Philippa Middleton, and Jim G Thornton
WH A T ’ S N E W
Last assessed as up-to-date: 20 February 2013.
Date Event Description
6 May 2014 Amended Michael Stokes added on the byline as an author and his contribution specified
H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 4, 2001
Date Event Description
1 March 2013 New citation required and conclusions have changed In this update, there is now support for a modest ben-
eficial effect of ursodeoxycholic acid (UDCA) on pru-
ritus, in the UDCA versus placebo comparison
20 February 2013 New search has been performed Search updated. Twelve studies have been included
(Binder 2006; Fang 2009; Glantz 2005; Huang 2004;
Kondrackiene 2005; Leino 1998; Liu 2006; Luo 2008;
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(Continued)
Roncaglia 2004; Shi 2002; PITCH 2012; Zhang
2012).
A new team of review authors prepared this review
update.
The methods have also been updated.
6 June 2011 Feedback has been incorporated The authors have replied to the feedback by Gludd
from July 2007. See Feedback.
30 November 2009 Amended Search updated. Nineteen reports added to Studies
awaiting classification.
30 October 2008 Amended Converted to new review format.
13 November 2007 Feedback has been incorporated Feedback added.
C O N T R I B U T I O N S O F A U T H O R S
Michael Stokes wrote the initial version of the background, with help from Philippa Middleton. Michael Stokes, Vinita Gurung and
Philippa Middleton independently identified and scanned the reports of identified studies and assessed risk of bias in the included
trials. Vinita Gurung, Philippa Middleton and Stephen Milan wrote the review. Bill Hague supplied content expertise and reviewed
review drafts. Jim Thornton checked the accuracy of data entry, reviewed the draft review and provided editorial support.
D E C L A R A T I O N S O F I N T E R E S T
Jim Thornton and Vinita Gurung are the authors of PITCH 2012. Assessment, data extraction and data entry for this trial was
conducted by Philippa Middleton and Stephen Milan.
S O U R C E S O F S U P P O R T
Internal sources
• Discipline of Obstetrics and Gynaecology, The University of Adelaide, Australia.
• Department of Health and Ageing, Australia.
• Department of Obstetrics and Gynaecology, University of Nottingham, UK.
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External sources
• National Institute for Health Research, UK.
NIHR Programme of centrally-managed pregnancy and childbirth systematic reviews of priority to the NHS and users of the NHS:
10/4001/02
• Australian Department of Health and Ageing, Australia.
• National Health and Medical Research Council, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Glantz 2005 performed a subgroup analysis of changes in pruritus and laboratory parameters in women with bile acid levels greater
than or equal to 40 µmol/L at inclusion. We have included this in the update. We have also included data relating to meconium-stained
liquor and caesarean section.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Charcoal [therapeutic use]; Cholagogues and Choleretics [therapeutic use]; Cholestasis [complications; ∗therapy]; Cholestyramine
Resin [therapeutic use]; Drugs, Chinese Herbal [therapeutic use]; Galactans [therapeutic use]; Mannans [therapeutic use]; Plant Gums;
Pregnancy Complications [∗therapy]; Pruritus [etiology; ∗therapy]; Randomized Controlled Trials as Topic; S-Adenosylmethionine
[therapeutic use]; Ursodeoxycholic Acid [therapeutic use]
MeSH check words
Female; Humans; Pregnancy
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